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ABSTRACT 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease affecting multiple organ systems. 
Neuropsychiatric (NP) manifestations are a major cause of morbidity and mortality in patients with 
SLE. The prevalence of NPSLE ranges widely reflecting variable diagnostic criteria and differences 
in selection of patients for study. The pathogenesis of NPSLE is still unclear. This study was done 
to describe the prevalence of NP syndromes in a Finnish population of patients with SLE and 
classify them according to the American College of Rheumatology (ACR) nomenclature and case 
definitions for NPSLE; to assess the validity of the ACR nomenclature system; to evaluate whether 
serum matrix metalloproteinase-9 (MMP-9) levels are associated with NP manifestations and to 
evaluate the volumetric brain magnetic resonance imaging (MRI) findings in SLE patients. 
 
The study group consisted of 46 SLE patients and an equal amount of matched controls. A complete 
medical history was obtained from all and a clinical neurological examination was performed by the 
same neurologist. All past and present NP syndromes were listed and classified according to the 
ACR nomenclature and case definitions. Individual disease activity and an accumulated NP 
abnormality were assessed by using standardized scores. A cumulative lifetime dose of 
glucucorticoids was derived from the medical records. Laboratory tests including anticardiolipin 
antibodies and a quantification of immunoreactive MMP-9 were done for all. A battery of 
standardized neuropsychological tests and a clinical interview by the psychologist were performed 
in order to detect a possible cognitive deficit, depression or anxiety disorder. Cerebral MRI was 
done for all study subjects. Volumetric measures of cerebral atrophy as well as T1- and T2-
weighted lesions were obtained.  
  
At least one NP syndrome was identified in 91% of SLE patients in this population-based study. 
Cognitive dysfunction was the most frequent single manifestation followed by headache and mood 
disorder. When mild NP syndromes (mild cognitive deficit, headache, mild depression, anxiety and 
polyneuropathy with normal ENMG findings) were excluded, the prevalence of NPSLE dropped to 
46%. 
 
All NPSLE syndromes were more frequent among SLE patients than controls. However, most 
syndromes were also found among controls, which resulted in low specificity. To improve the 
criteria we constructed revised criteria based on objective findings only. We entirely excluded mild 
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NP syndromes and with this modification, the proportion of controls fulfilling at least 1 of the 
criteria was substantially lower (7% versus 54%). 
 
No significant difference was found in serum MMP-9 levels between the overall group of SLE 
patients and controls. However, patients with at least one NP manifestation had significantly higher 
MMP-9 concentrations than SLE patients without NP syndromes. Among SLE patients, those with 
cognitive deficits had significantly higher MMP-9 concentrations than did those with normal 
cognitive function. Furthermore, serum MMP-9 levels correlated positively with the volumes of T1- 
and T2-weighted lesions in the brain MRI. 
 
Compared with controls, SLE patients had increased volumes of both T1- and T2-weighted lesions 
and increased cerebral atrophy in brain MRI. Cerebral atrophy was associated with cognitive 
dysfunction, epileptic seizures and cerebrovascular disease; T1-weighted lesions with epileptic 
seizures and T2-weighted lesions with cognitive dysfunction. A positive correlation was found 
between a cumulative dose of glucocorticoids and cerebral atrophy in SLE patients. 
 
As a summary, the prevalence of NPSLE in a population-based sample of SLE patients was 91% by 
using ACR nomenclature and case definitions, and 46% when our revised criteria based on 
neurologic injury and exclucion of mild NP syndromes, was used. ACR criteria for NPSLE were 
not able to differentiate SLE patients from controls. In cerebral MRI, brain atrophy, cerebrovascular 
and demyelinating lesions were more common in patients with SLE than in general population, and 
associated with certain NP manifestations. Elevated levels of serum MMP-9 in patients with SLE 
may indicate NP involvement, especially cognitive dysfunction. 
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TIIVISTELMÄ 
 
Systeeminen lupus erythematosus (SLE) on useisiin elinjärjestelmiin vaikuttava 
autoimmuunisairaus.  Neuropsykiatriset (NP) ilmenemismuodot ovat suuri sairastavuuden ja 
kuolleisuuden syy SLE:ssä. NPSLE:n prevalenssi vaihtelee suuresti riippuen tutkimuksessa 
käytetyistä diagnostisista kriteereistä ja potilasvalinnasta. NPLSE:n patogeneesi on tuntematon. 
 
Tämän tutkimuksen tarkoituksena oli selvittää NP ilmenemismuotojen prevalenssia suomalaisilla 
SLE-potilailla väestöpohjaisessa otannassa ja luokitella syndroomat American College of 
Rheumatologyn (ACR) laatiman NPSLE:n luokittelujärjestelmän pohjalta; arvioida ACR:n 
luokittelujärjestelmän validiteettia; selvittää, onko seerumin matriksin metalloproteinaasi-9:llä 
(MMP-9) yhteys NP ilmenemismuotoihin ja tutkia aivojen magneettikuvalöydöksiä (MK) SLE-
potilailla. 
 
Tutkimusryhmä koostui 46 SLE-potilaasta ja yhtä monesta vakioidusta verrokkihenkilöstä. Heidän 
sairaushistoriansa selvitettiin ja sama neurologi teki kaikille kliinisen neurologisen tutkimuksen. 
Kaikki aiemmat ja nykyiset NP-syndroomat luetteloitiin ja luokiteltiin ACR:n luokittelujärjestelmän 
perusteella. Sairauden aktiviteetti ja kumulatiivinen NP vaurioaste määritettiin standardoiduilla 
asteikoilla. Elinikäinen glukokortikoidien kokonaisannos laskettiin sairauskertomustietojen 
perusteella. Kaikilta tutkimukseen osallistujilta otettiin laboratoriokokeita sisältäen 
immunoreaktiivisen MMP-9:n määrityksen. Mahdollisen kognitiivisen eli tiedonkäsittelyn häiriön, 
depression ja ahdistuneisuuden toteamiseksi tehtiin neuropsykologinen tutkimus ja psykologin 
suorittama kliininen haastattelu. Kaikille tutkittaville tehtiin aivojen MK, jonka perusteella 
määritettiin aivoatrofian sekä T1- ja T2-signaalimuutosten tilavuudet. 
 
Tässä väestöpohjaisessa tutkimuksessa ainakin yksi NP-syndrooma todettiin 91 %:lla SLE-
potilaista. Kognitiivinen häiriö oli yleisin yksittäinen syndrooma; seuraavina tulivat päänsärky ja 
mielialahäiriö. Kun lievät NP-syndroomat (lievä kognitiivinen häiriö, päänsärky, lievä depressio, 
ahdistuneisuus ja polyneuropatia ilman ENMG-vahvistusta) poissuljettiin, NPSLE:n prevalenssi 
laski 46 %:iin. 
 
Kaikkia NP-syndroomia esiintyi SLE-potilailla enemmän kuin verrokeilla. Kuitenkin useimpia 
syndroomia oli todettavissa myös verrokeilla, minkä vuoksi luokittelun spesifisyys on heikko. 
Kehittääksemme kriteeristöä loimme korjatun version pohjautuen objektiivisiin löydöksiin. 
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Poissulkemalla lievät NP-syndroomat vain 7 %:lla kontrolleista oli todettavissa NP manifestaatio 
(vrt. 54 %:lla käyttäen alkuperäistä kriteeristöä). 
 
Seerumin MMP-9-pitoisuuksissa ei ollut eroa SLE-potilaiden ja verrokeiden välillä. Kuitenkin 
potilasryhmän niillä potilailla, joilla oli ainakin yksi NP-syndrooma, MMP-9-pitoisuudet olivat 
merkittävästi korkeampia kuin niillä, joilla ei ollut NP-syndroomaa. Samoin SLE-potilailla, joilla 
oli todettavissa kognitiivisia häiriöitä, MMP-9-pitoisuudet olivat korkeammat kuin SLE-potilailla, 
joiden kognitiivinen tilanne oli normaali. Lisäksi seerumin MMP-9-pitoisuudet korreloivat 
positiivisesti aivojen T1- ja T2-signaalimuutosten tilavuuksiin. 
 
Verrokkeihin verrattuna SLE-potilaiden aivojen MK:ssa oli todettavissa suuremmat T1- ja T2-
signaalimuutosten sekä atrofian tilavuudet. Aivoatrofia oli yhteydessä kognitiiviseen häiriöön, 
epileptisiin kohtauksiin ja aivoverenkiertohäiriöihin; T1-muutokset epileptisiin kohtauksiin ja T2-
muutokset kognitiiviseen häiriöön. SLE-potilaiden kumulatiivinen kortisoniannos korreloi 
positiivisesti aivoatrofian määrään. 
 
Yhteenvetona, NPSLE:n prevalenssi populaatiopohjaisessa aineistossa SLE-potilaita oli 91 % 
käyttäen ACR:n luokittelujärjestelmää ja 46 % käyttäen korjattua kriteeristöämme, jossa 
poissuljettiin lievät NP-syndroomat ilman neurologista vauriota. Kognititiivinen häiriö oli yleisin 
NP-manifestaatio. ACR:n kriteeristö ei erotellut potilaita verrokeista. Aivojen MK:ssa atrofia, 
aivoverenkiertohäiriöt ja demyelinaatiomuutokset olivat yleisempiä SLE-potilailla kuin verrokeilla 
ja liittyivät tiettyihin NP-manifestaatioihin. Kohonneet MMP-9-pitoisuudet SLE-potilailla saattavat 
liittyä NP sairastavuuteen, erityisesti kognitiiviseen häiriöön. 
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INTRODUCTION 
 
SLE is a chronic idiopathic autoimmune disorder with a broad spectrum of clinical and 
immunologic manifestations affecting multiple organ systems. A challenging problem in SLE is the 
diagnosis and management of NP involvement. According to the definition of NPSLE, this 
condition includes neurologic syndromes of the central, peripheral, and autonomic nervous system 
and the psychiatric syndromes observed in patients with SLE (ACR 1999). NPSLE may present 
with serious manifestations (eg. acute confusional state, seizure disorder, and stroke), but more 
subtle deficits as mild cognitive dysfunction have also been recognized (Van Dam AP 1991, 
Carbotte et al 1986, Hermosillo-Romo & Brey 2002). The prevalence of NPSLE has ranged widely 
reflecting variable diagnostic criteria and differences in selection of patients for study (McCune & 
Golbus 1988; Hanly & Liang 1997).  A former definition for NPSLE in the 1982 revised American 
College of Rheumatology (ACR) criteria for SLE has been inadequate including only two elements, 
psychosis and seizure. The ACR has developed in 1999 a standardized nomenclature system, 
providing case definitions for 19 NP syndromes seen in SLE and recommendations for laboratory 
and imaging tests (ACR 1999). 
 
The pathogenesis of NPSLE is still unclear, but it appears to be multifactorial and may involve 
autoantibody production, microangiopathy, intrathecal production of proinflammatory cytokines 
and atherosclerosis. The integrity of the blood-brain-barrier seems to be very important in SLE-
related neuropathology. A microvasculopathy appears to be the most common microscopic brain 
finding in SLE (Brey 2007).  
 
 
In general, the diagnosis of NPSLE is difficult, because no single laboratory marker or imaging 
modality serves as a gold standard, and the diagnosis is primarily clinical (Kovacs et al 1993). The 
assessment of patients is based on clinical neurologic and rheumatologic evaluation, 
immunoserological testing, brain imaging, and psychiatric and neuropsychological assessment. An 
important consideration is whether the particular clinical syndrome is caused by SLE-mediated 
organ dysfunction, a secondary phenomenon related to infection, metabolic abnormalities or 
medication side effects, or even by an unrelated condition (Muscal & Brey 2010). 
 
Imaging studies are important in the management of NPSLE patients (Huizinga et al 2001; Peterson 
et al 2005; Castellino et al 2008). Despite many different types of brain MRI changes described in 
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NPSLE, no consistent pattern of abnormality has been associated with the condition (Kozora et al 
1996; Tanabe & Weiner 1997). MRI abnormalities such as cortical stroke, global atrophy, non-
spesific foci of increased signal in both grey and white matter on T2-weighted images, cerebral 
venous thrombosis, or intracranial calcifications are not specific for NPSLE (Tanabe & Weiner 
1997). 
 
MMPs are a family of endoproteinases that can degrade a variety of extracellular matrix 
components (Lijnen 2001). Increased activity of MMPs has been implicated in numerous disease 
processes, including malignancies, cardiovascular disease, and autoimmune disease such as 
multiple sclerosis and rheumatoid arthritis (Ahrens et al 1996; Goezl et al 1996; Lee et al 1999). 
The role of MMPs in the pathogenesis of NPSLE is not clear. 
 
The aims of this study were to describe the prevalence of NP syndromes in a Finnish population of 
SLE patients; assess the validity of the ACR nomenclature and case definitions; investigate whether 
there is any association between brain atrophy and signal lesions and NP manifestations in SLE; 
and to evaluate whether serum MMP-9 levels are associated with NP manifestations or cerebral 
MRI abnormalities in SLE patients. 
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REVIEW OF THE LITERATURE 
 
 
1. Definition and classification of SLE 
 
SLE is a chronic relapsing-remitting autoimmune disease characterized by a wide variety of clinical 
manifestations. The disease occurs primarily in young women and ranges in severity from a mild 
disease with rash and arthritis to a illness with renal failure and profound nervous system 
disturbances (Pisetsky 1997). The classification of SLE is based on 11 criteria proposed by the 
American College of Rheumatology (ACR) and later revised (Tan et al 1982; Hochberg 1997) 
(Table 1). 
 
2. Epidemiology of SLE 
 
SLE is a worldwide disease. The incidence peaks between the ages of 15 and 40 years, with a mean 
age of onset in women of 32 years, and men, of 40 years (Pisetsky 1997). SLE affects multiple 
organ systems in women 9 times more frequently than men (Muscal et al 2010). Incidence and 
prevalence rates vary a lot in the world depending on genetic and possibly environmental factors. 
SLE is more common in African-Americans, African-Caribbeans, and Asians, than in Caucasians. 
Several recent studies have suggested that the incidence of SLE is increasing. However, 
identification of milder SLE, or earlier diagnosis of SLE could explain an apparent increase (Moss 
et al 2002; Petri 2002). International studies have reported prevalences of 4-250/100 000; in Finland 
the reported prevalence is 28/100 000 (Helve T 1985). 
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Table 1. 
American Rheumatism Association (ARA) 1997 Revised Criteria for the Classification of 
Systemic Lupus erythematosus 
___________________________________________________________________________ 
Criterion   Definition  
___________________________________________________________________________ 
1. Malar rash  Fixed erythema, flat or raised, over the malar eminences, tending to  
  spare the nasolabial folds 
   
2. Discoid rash  Erythematous raised patches with adherent keratotic scaling and   
  follicular plugging; atrophic scarring may occur in older lesions 
 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patients history  
  or physician observation 
 
4. Oral ulcers  Oral or nasopharyngeal ulceration, usually painless, observed by a  
  physician 
 
5. Arthritis  Nonerosive arthritis involving two or more peripheral joints,   
  characterized by tenderness, swelling, or effusion 
 
6. Serositis  a) Pleuritis – convincing history of pleuritic pain or rub heard by a  
  physician or evidence of pleural effusion 
   OR 
  b) Pericarditis 
 
7. Renal disorder a) Persistent proteinuria greater than 0.5 per day or greater than 3+ if quantification not 
performed 
  OR 
 b) Cellular casts 
 
8. Neurologic disorder a) Seizures – in the absence of offending drugs or known metabolic derangements: e.g., 
uremia, ketoacidosis, or electrolyte imbalance 
  OR 
 b) Psychosis – in the absence of offending drugs or known metabolic derangements: 
e.g., uremia, ketoacidosis, or electrolyte imbalance 
 
9. Hematologic disorder a) Hemolytic anemia 
   OR 
  b) Leukopenia – less than 4000/mm total on two or more occasions 
   OR 
  c) Lymphopenia – less than 1500/mm on two or more occasions 
   OR 
d) Thrombocytopenia – less than 100 000/mm in the absence of   offending drugs 
 
10. Immunologic disorder a) Anti-DNA: antibody to native DNA in abnormal titer 
   OR 
  b) Anti-Sm: presence of antibody to Sm nuclear antigen 
   OR 
  c) Positive finding of antiphopsholipid antibodies 
 
11. Antinuclear antibody An abnormal titer of antinuclear antibody at any time and in the absence of drugs 
known to be associated with “drug-induced lupus syndrome” 
 
________________________________________________________________________________ 
The classification is based on 11 criteria. SLE can be diagnosed when 4 or more of the 11 criteria 
are present, serially or simultaneously, during any interval of observation. 
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3. Clinical manifestations of SLE 
 
 
General features of SLE include fatigue, fever, malaise and weight loss (Pisetsky 1997). Fatigue 
occurs in virtually all patients. Low-grade fever is common, it may reflect active disease or 
infection. Weight loss occurs in about 60% of patients (Schur 1996). 
 
Arthritis and/or arthralgia affect 85% to 90% of patients during the course of their illness. Arthritis 
predominantly affects the small joints of the hands, wrists, and knees and can be deforming, 
although it does not produce joint erosion (Pisetsky 1997). 
 
The skin is involved in most SLE patients. A wide variety of skin manifestations include butterfly 
rash, discoid rash, livedo reticularis, photosensitivity, mucous membrane lesions, alopecia and 
vasculitic skin lesions (Schur 1996). 
 
Clinically evident pericarditis occurs in about 25% of patients (Rothfield 1996). Asymptomatic 
valvular lesions are detected by ECHO in 25% of patients, but Libman-Sacks endocarditis is now 
rarely seen. Occasionally it can be associated with antiphopsholipid syndrome (APS) (Pettersson et 
al 2005). The lung is involved in about 50% of SLE patients, with pleuritis being the most 
commonly noted manifestation (Schur 1996). 
 
Renal disease is a frequent manifestation of SLE and develops in about 50%-75% of patients (Schur 
1996; Pisetsky 1997). The spectrum of renal involvement is broad. Only a minority of patients 
develop clinical renal disease, but most patients have some histologic abnormalities of the kidneys. 
The basic lesion is glomerulonephritis (GN). Renal biopsy is important in assessment of the 
nephritis pattern and the reversibility of the lesion. The 1982 World Health Organization grading 
system is currently used, with Class 1 indicating a normal kidney, Class 2 mesangial GN, Class 3 
focal segmental proliferative GN, Class 4 diffuse proliferative GN, Class 5 membranous GN and 
Class 6 chronic sclerosing GN. The higher the grade, the more severe is the renal involvement 
(Burnett et al 2005). 
 
Muscle pain is a frequent complaint and accompanied on occasion by muscle wasting and 
weakness. True myositis is uncommon in SLE (Schur 1996). 
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One or more hematological abnormalities are present in nearly all SLE patients with active disease 
(Rothfield 1996). They may reflect the nonspecific effects of inflammation on bone marrow 
function as well as the binding of specific antibodies to blood cell elements. Generalized 
lymphadenopathy is very common, especially with active disease. Anti-phospholipid antibodies 
(APL) can be found in 20-35% of patients with SLE (Pisetsky 1997).  
 
SLE may involve virtually any ocular structure. The most common ocular manifestation is 
xerostomia (Rosenbaum et al 1996). 
 
Gastrointestinal symptoms are common in SLE. Complaints include dyspepsia, nausea, vomiting 
and abdominal pain. Etiologies include bowel vasculitis, diffuse peritonitis, pancreatitis, 
inflammatory bowel disease or the use of medications (Schur 1996). 
 
The typical course of SLE is one of flares and remissions, sometimes with many months or years 
between periods of clinical activity. The measurement of disease activity includes monitoring 
certain laboratory tests and clinical features. A number of valid and reliable indices, including the 
SLAM (Systemic Lupus Activity Measure), SLEDAI (Systemic Lupus Erythematosus Disease 
Activity Index), LAI (Lupus Activity Index), BILAG (British Isles Lupus Activity Group) and 
ECLAM (European Consensus Lupus Activity Measure) are available for measuring disease 
activity in SLE and a damage index composed of variables related to irreversible organ injury from 
SLE and complications of therapy has been developed (Systemic Lupus International Collaborating 
Clinics / ACR; SLICC/ACR) (Vitali et al 1992; Gladman 1994; Caponi et al 1995).  
 
The survival of patients with SLE has improved over the past four decades from <50% five year 
survival before 1955 to >90% five year survival in recent studies. The leading cause of death in 
patients with SLE is infection, which may be due to a complication of either active disease and/or 
its treatment. Other major causes of death are pulmonary, renal or CNS failure and premature 
coronary artery disease (Boumpas et al 1995; Schur 1996; Doria et al 2006). In a recent study 
patients with SLE had a death rate four times that of the general population. The most common 
cause of death was malignancy followed by infection and vascular disease. Early deaths were more 
often due to renal disease, whereas late deaths tended to be caused by atherosclerosis (Moss et al 
2010). 
 
Neuropsychiatric (NP) manifestations of SLE will be discussed later. 
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4. Pathogenesis of SLE 
 
The aetiology of SLE is not known. As with most autoimmune diseases, multiple factors likely 
effect it. These factors include genetic predisposition, hormonal factors and environmental stimuli 
(Rosenbaum et al 1996). 
 
 
4.1 Genetic susceptibility 
 
SLE shows a strong familial aggregation, with a much higher frequency among first degree 
relatives of patients. The concordance of the disease in identical twins is approximately 25-50% and 
that in dizygotic twins around 5% suggesting that genetic factors play an important role in the 
predisposition of the disease. In a small proportion of patients a single gene may be responsible, but 
for most of patients multiple genes may be involved. During the past few years, linkage analyses 
using SLE multiplex families have provided many chromosomal regions for further exploration of 
susceptibility genes. It is estimated that at least four susceptibility genes are needed for the 
development of the disease. Population studies reveal that the susceptibility to SLE involves human 
leucocyte antigen (HLA) class II gene polymorphisms. An association of HLA DR2 and DR3 with 
SLE is a common finding in patients with different ethnicities, with a relative risk for the 
development of disease of approximately two to five. However, most cases of SLE are sporadic 
without identifiable genetic predisposing factors, suggesting that multiple environmental or yet 
unknown factors may also be responsible (Mok & Lau 2001; Sawalha & Harley 2004; Tsao 2004). 
 
 
4.2 Role of hormones 
 
A role of endogenous sex hormones in disease predisposition has been shown. SLE is 
predominantly a female disease. First flare of SLE before puberty and after menopause is 
uncommon. Abnormal oestrogen metabolism has been demonstrated in patients with SLE of both 
sexes and women with SLE also have low plasma androgens. Flares of SLE are well known to 
occur during periods of rapid hormonal changes. There is also evidence that endogenous oestrogen 
concentrations may influence disease activity and prognosis of the disease. Prolactin has been found 
to be an immunostimulatory hormone and hyperprolactinemia has been demonstrated in a 
proportion of patients with SLE of both sexes. Hormones may not have a direct causative role in 
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SLE, but a milieu consisting of different hormones may create an endogenous environment for 
susceptible individuals to develop the disease (Mok & Lau 2001). 
 
 
4.3 Environmental triggers 
 
Although genetic factors and the hormonal milieu may create a predisposition towards SLE, the 
initiation of the disease probably results from several environmental triggers and exogenous factors. 
Environmental triggers that may be relevant in the pathogenesis of SLE are chemical and physical 
factors, like drugs (including procainamide, hydralazine, isoniazid, quinidine, methyl DOPA and 
chlorpromazine), tobacco smoke, hair dyes, aromatic amines, hydrazines and UV light. Some 
dietary factors, like high intake of saturated fats have been suspected to precipitate SLE. Infectious 
agents such as viruses might theoretically initiate or cause a flare in SLE by activating B cells, 
damaging tissues to release autoantigens, and triggering the disease by molecular mimicry. Thus, 
there is little evidence to support that one infectious agent causes SLE. Viruses suspected to be 
involved in pathogenesis of SLE are Epstein-Barr virus, cytomegalovirus, parvovirus B19 and the 
retroviruses. Hormones and environmental oestrogens have been linked to autoimmune disorders. 
Hormonal replacement therapy and oral contraceptive pills have been associated with a small 
increase in the risk of SLE development (Mongey et al 1996; Mok & Lau 2001, Manson & Isenberg 
2003). 
 
 
4.4 Immunopathology 
 
Multiple immunologic abnormalities are important for the development and clinical expression of 
SLE (Anolik & Sanz 2004). The basic pathological features are that of inflammation and blood 
vessel abnormalities, which include vasculopathy, vasculitis, and immune complex deposition (Mok 
& Lau 2001). The fundamental disturbance appears to be a dysfunction of immune system, with a 
loss of self-tolerance caused by alterations in B-cell functions. The disease is characterized by 
autoantibody production and immune-complex-mediated end-organ damage; both of them reflect 
the failure of immune tolerance (Burnett et al 2005; Tieng et al 2007). 
 
The central immunological disturbance in patients with SLE is autoantibody production by B cells 
that normally should be inactive or tolerant and unable to produce antibodies against themselves. 
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There is evidence that depending on genetic background and specific environmental insults, the 
disease may be induced by a breakdown of B-cell tolerance leading to the generation of pathogenic 
antibodies (Anolik & Sanz 2004). Antibodies are directed against several self molecules found in 
the nucleus, cytoplasm, and cell surface. In addition to be used in diagnosis of SLE, various 
autoantibodies may predict the disease manifestations and be helpful in monitoring the disease 
activity and response to treatment (Sawalha & Harley 2004).  
 
Antinuclear antibodies (ANA) are most characteristic and present in more than 95% of patients, 
making the ANA test most sensitive test for SLE (Manson & Isenberg 2003; Mok & Lau 2001; 
Sawalha & Harley 2004). However, ANA are not specific, because they can be detected in a variety 
of autoimmune, rheumatic, and infectious conditions; and even in normal individuals. The absence 
of ANA makes the diagnosis of SLE less likely, although still possible. The recent demonstration 
that patients with SLE may express ANA several years before the onset of clinical disease suggests 
that the breakdown of B-cell tolerance occurs very early in SLE and may precede or even trigger 
other immune malfunctions (Anolik & Sanz 2004; Sawalha & Harley 2004; Doria et al 2008). The 
antibodies with the highest specificity for the diagnosis of SLE are those directed toward dsDNA 
(Anti-dsDNA) (Mok & Lau 2001; Manson & Isenberg 2003). Anti-dsDNA is not particularly 
sensitive because it may be transiently present and found in only 50% to 60% of SLE patients at 
some point in their disease course. Anti-Sm antibodies are also unique to patients with SLE. The 
Sm antigen is designated as a small nuclear ribonucleoprotein (snRNP) (Sawalha et al 2004, Mok et 
al 2005). The most remarkable feature of anti-dsDNA antibodies is their association with 
glomerulonephritis. Raised anti-dsDNA antibody titres have been found in active lupus nephritis. 
Anti-dsDNA antibodies show preferential deposition in the kidneys, suggesting that DNA-anti-
DNA antibody immune complexes are the main mediators of inflammation. The pathogenesis of 
manifestations other than glomerulonephritis is less well understood, although immune complex 
deposition with activation of complement at relevant sites is a probable mechanism. Anti-dsDNA 
antibody titers and disease activity frequently vary over time but anti Sm antibody titres remain 
usually constant. In addition to these antibodies, a variety of other autoantibodies are often detected. 
The antigens targeted may be associated with patient ethnicity or particular disease manifestations 
(Manson & Isenberg 2003) (Table 2).  
 
The mechanisms by which B cells may influence SLE are diverse and include in addition to 
autoantibody-dependent functions also autoantibody–independent ones. B cells act as antigen-
presenting cells and provide costimulatory signals necessary for T-cell activation, differentiation, 
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and expansion. B-cells also respond to or secrete cytokines such as interleukin (IL)-10,IL-6, tumor 
necrosis factor (TNF)-alfa and interferon (IFN)-alfa. Furthermore, they link innate and acquired 
immunity by Toll-like receptors and affect follicular dendritic cell differentiation. Alterations in one 
or more B-cell functions can lead to a breach of tolerance and to the development of autoimmune 
disease (Anolik & Sanz 2004; Tieng 2008).  
 
Abnormalities in T cell function are also evident in patients with SLE. The number of activated T 
cells has been found to be increased in peripheral blood in SLE patients. The activated T cells are 
able to stimulate the B cells to produce autoantibodies (Mok & Lau 2001; Hoffman 2004; Kyttaris 
et al 2004). The propagation of self-directed B-cell clones may also be assisted by an inappropriate 
lack of T-cell suppression (Manson & Isenberg 2003). 
 
Cytokines are low-molecular-weight proteins which act as the chemical modulators of the immune 
system. Cytokine profiles in patients with SLE have been studied extensively. Interleukin-10 (Il-10) 
is secreted by T-helper cells, and stimulates B-cell proliferation and antibody production. The 
serum concentrations of IL-10 are significantly higher in SLE patients than in controls. There is an 
increasing body of research to suggest that this cytokine may be central to the overproduction of 
antibody seen in SLE (Mok & Lau 2001; Manson & Isenberg 2003). Tumour necrosis factor α 
(TNFα) has also been investigated, and there is some evidence suggesting that it may be protective 
against SLE (Manson & Isenberg 2003). 
 
The clearing of immune complexes by phagocytic cells is defective in patients with SLE and this 
has been considered to be an important pathogenetic mechanism in SLE. Complement is involved 
in the clearance of immune complexes. Genetic complement deficiencies have been found in SLE 
patients and complement consumption, with falling serum concentrations, often mirrors disease 
activity (Mok & Lau 2001; Manson & Isenberg 2003). 
 
The understanding of autoimmune diseases has increased since the Toll-like receptors (TLRs) have 
been identified as possible key players in autoimmune pathophysiology. These receptors are 
transmembrane proteins that are expressed in various immune cells such as B-cells, macrophages 
and specific types of T-cells. They recognize a variety of structures derived from viruses, bacteria 
and fungi, so called pathogen-associated molecular patterns (PAMPs) and also endogenous danger 
signals named alarmins, leading to subsequent initiation of relevant immune responses, rapid and 
effective control of infection. In addition TLRs may be involved in the induction of chronic 
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inflammation and autoimmune reactions. Endogenous ligand such as RNA and DNA can activate 
TLRs under certain conditions and induce a typical autoimmune reaction. The resulting cytokine 
production after TLR activation may trigger and continue the autoimmune process (Hurst et al 
2008; Pöllänen et al 2009). 
 
Flares of SLE are accompanied by a diffuse vasculopathy in which the endothelium is activated. 
Adhesion molecules, expressed on vascular endothelium and circulating leucocytes, regulate the 
processes by which leucocytes bind to and migrate through endothelium, and mediate a number of 
central cellular interactions in inflammatory responses. Vascular cell adhesion molecule-1 (VCAM-
I) upregulation has been reported in patients with active SLE in several studies (Merrill et al 2005). 
 
 
 
 
Table 2. Common antinuclear antibodies in SLE (Sawalha & Harley 2004). 
__________________________________________________________________________ 
Autoantibody Frequency (%) Autoantigen 
___________________________________________________________________________ 
Anti-dsDNA  50-60  DNA double helix 
Anti-Sm  10-25  Spliceosomal snRNP 
Anti-Ro (SS-A) 25-40  60-kDa or 52-kDa proteins 
Anti-La (SS-B) 10-15  48-kDa proteins 
Anti-Ribosomal P 15  Ribosomal phosphoproteins P0, P1, P2 
Anti-nRNP  23-40  Spliceosomal snRNP 
Anti-Histone  50-70  H1, H2A, H2B, H3, H4, H5 
Anti-Ku  20-40  p70/80 proteins 
___________________________________________________________________________ 
dsDNA, double-stranded DNA; Sm, Smith; snRNP, small nuclear ribonucleoprotein; nRNP, 
nuclear ribonucleoprotein 
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4.5 Apoptosis 
 
Evidence is accumulating that implicates apoptosis, programmed cell death, as a mechanism by 
which SLE may be provoked and propagated. Precipitating factors such as UV light, infections and 
drugs may cause increased apoptosis. This can result in increased exposure of target antigens and 
production of antibodies. Under normal circumstances, apoptotic cells are engulfed by macrophages 
in the early phase of apoptotic cell death without inducing inflammation or the immune response. 
Recent studies have shown that the clearance of apoptotic cells in patients with SLE is impaired. 
The reasons are not clear. It could be the result of defects of early complement proteins, such as C2, 
C4, or C1q. Patients with homozygous deficiencies in these complement components develop a 
severe lupus-like disease early in life (Mok & Lau 2001; Manson & Isenberg 2003). High 
concentrations of plasma membrane-derived vesicles also known as microparticles have also been 
suspected. They are small membrane-bound vesicles which are able to reduce phagocytosis of 
apoptotic cells. In SLE, there have been measured raised levels of microparticles (Antwi-Baffour et 
al 2010). 
 
 
5. Definition and classification of neuropsychiatric SLE (NPSLE) 
 
 
NPSLE includes the neurologic syndromes of the central, peripheral, and autonomic nervous system 
observed in patients with SLE. It is estimated that two thirds of NP manifestations in SLE are not 
directly related to active NPSLE (primary NPSLE) but instead are a consequence of secondary 
causes such as drugs, infections, and hypertensive and metabolic complications (secondary 
NPSLE). The NP symptoms vary in their clinical expression from focal to diffuse manifestations 
(Kovacs et al 1993). They can also be divided to major symptoms, including eg. cerebrovascular 
events, seizures and psychosis; and minor symptoms eg. headaches, mood swings and cognitive 
complaints (Denburg et al 1993). There is no single diagnostic test sensitive and spesific for 
NPSLE. The assessment of individual patients is based on clinical neurological and rheumatological 
evaluation, immunoserological testing, brain imaging, and psychiatric and neuropsychological 
assessment (Brey 2007). NPSLE syndromes can occur as a single event, or multiple events at any 
time during the course of the disease, even during periods in which no disease activity is detected 
outside the nervous system. Approximately 28% to 40% of the NPSLE manifestations develop 
before the onset of SLE, or at the time of diagnosis, and 63% within the first year after diagnosis 
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(Brey 2007; Burnett et al 2005). NPSLE has been reported to be a prognostic factor for a poor long-
term outcome in SLE. In a recent study, the occurrence of NP events in newly diagnosed patients 
was associated with reduced quality of life and increased organ damage (Hanly et al 2007). The 
mortality rate in NPSLE has varied from 7% to 40% depending on the particular manifestation, and 
NP involvement constitutes the second most common cause of death in SLE after renal failure 
(Kovacs et al 1993; Sibbitt et al 1999) 
 
Central nervous system involvement in SLE was first described by Kaposi in 1872; recurrent stupor 
and coma were noted in two of his original patients with SLE (Feinglass et al 1976; Ellis & Verity 
1979). The systemic nature of the illness was first emphasized by Osler; among the 29 patients 
whom he described between 1895 and 1903, there were two with neurologic or psychiatric 
manifestations. One of these cases presented with delirium and the other with five or six episodes of 
aphasia and hemiplegia (Feinglass et al 1976; Futrell et al 1989). The clinical spectrum of NP 
manifestations in SLE was clarified by Harvey et al and Dubois et al. In Harvey`s monograph in 
1954, 37% of 105 patients with SLE developed nervous system involvement. Dubois reported a 
large serie, 520 SLE patients with CNS involvement occuring in 25%; NP abnormalities were a 
frequent cause of death (Harvey et al 195; Dubois & Tuffanelli 1964).   
 
Since those decades, NP manifestations in SLE have been a subject of several studies. Johnson and 
Richardson reported a 75% incidence of CNS involvement in a retrospective autopsy series (Small 
et al 1977). Estes and Christian followed the progress of 150 patients with SLE for up to 8 years; 
59% developed a neurologic disease. Feinglass et al evaluated retrospectively 140 hospitalized 
patients with SLE; NP features were found in 51% of them. In both of these studies, psychiatric 
disorders and epileptic seizures were the most frequent manifestations (Estes & Christian 1971; 
Feinglass et al 1976) In general, the reported prevalence of NP manifestations in SLE in the last 
century has varied widely, from 14% to 75%, though most clinical studies agreed that NP 
involvement occurs in approximately 50% of SLE patients (Estes & Christian 1971; Feinglass et al 
1976; Gibson & Myers 1976; Grigor et al 1977; Tan et al 1978; Abel et al 1980). 
 
The most important explanation for the variability in the prevalence of NPSLE is that the definition 
and nomenclature of NPSLE has not been standardized (ACR 1999). Different investigators have 
used markedly different terminology, making cross-study comparisons and conclusions difficult 
(Sibbitt et al 1999). It has been even claimed, that the literature describing NP syndromes is a 
phenomenological nightmare (Calabrese et al 1995). Neurologic and psychiatric manifestations 
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have been termed CNS vasculitis, CNS lupus, neurolupus, neuropsychiatric lupus, or lupus 
cerebritis. In older studies, the diagnosis of NPSLE has been made on the basis of major NP 
involvement. Since then there has been increasing awareness also of minor manifestations, 
especially of cognitive impairment due largely to the application of standardized 
neuropsychological assessment techniques. A former definition for NPSLE in the 1997 revised 
ACR criteria for SLE is inadequate because only two elements, psychosis and seizures, were 
included (Table 1).  
 
In 1999, ACR developed a standardized nomenclature system providing case definitions for the NP 
syndromes of SLE to facilitate and enhance patient classification and reporting requirements in 
clinical research. The committee consisted of 35 international members representing rheumatology, 
neurology, psychiatry, neuropsychiatry and haematology. It developed 19 NPSLE case definitions 
with diagnostic criteria, exclusions, associations and ascertainment, as well as reporting standards 
(Table 3.). Recommendations were also included for minimum laboratory evaluation and imaging 
techniques. ACR eliminated the term lupus cerebritis because true cerebral vasculitis is rarely found 
in SLE despite its popular use as a clinical diagnosis. Similarly, because both psychiatric and 
peripheral nervous system disorders may be present, the term CNS lupus was considered 
inappropriate. The term NPSLE was recommended to describe the wide range of psychiatric and 
neurologic syndromes in SLE (ACR 1999). 
 
Published experience with the ACR nomenclature and case definitions 
 
Studies using the ACR case definitions have detected the presence of 14 to 17 of the 19 syndromes 
and reported a fairly consistent prevalence of the following syndromes: headache (39%-61%), 
seizures (8%-18%), cerebrovascular disease (2%-8%), psychosis (3%-5%), cranial neuropathy 
(1.5%-2.1%) and movement disorder (1%). The range in the prevalence of cognitive dysfunction 
was much wider, with studies using systematic assessment of cognitive function finding a higher 
prevalence (75%-80%) than studies that evaluated patients using sensitive instruments only if 
clinically indicated (5.4%). Accordingly, mood disorders were found from 12.4 % to 69%-74% of 
patients depending whether sensitive psychiatric assessments were used or not (Muscal & Brey 
2010).  
 
In the San Antonio Lupus Study of Neuropsychiatric disease, 128 unselected subjects with SLE 
were evaluated and one or more NPSLE syndromes were found in 80% of these patients The most 
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common manifestations were headaches in 57%, major depressive-like episodes in 28%, anxiety 
disorder in 24% and mood disorder with depressive features in 19% (Brey et al 2002). In another 
study using ACR case definitions the prevalence of NPSLE was 72%. Cognitive dysfunction in 
52% of patients was followed by mood disorders (27%), cerebrovascular disease (24%) and 
headache (21%) (Afeltra et al 2003). A retrospective application of the ACR case definitions on 527 
SLE patients classified 39 patients with seizures, 28 with psychosis, 20 with polyneuropathy, 15 
with acute confusional state and 13 with cerebrovascular disease (Costallat et al 2001). In another 
retrospective study, 185 out of 323 consecutive patients with SLE had NP manifestations according 
to ACR case definitions (Sanna et al 2003). In a recent international inception cohort study, 28% of 
SLE patients experienced at least 1 NP event around the time of diagnosis of SLE, of which only a 
minority were attributed to SLE (Hanly et al 2007). 
 
In an international multicentre study, 1206 patients with SLE were evaluated prospectively with a 
mean follow-up of 23 months. 40.3% of patients had at least one NP event, which weas attributed to 
SLE in 13-24% of patients. The most common events were headache (47%), mood disorders (17%) 
and seizures (8%). Formal neuropsychological assessments were not performed on all patients and 
neuroimaging studies were done only if clinically indicated (Hanly et al 2010). 
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Table 3. The neuropsychiatric syndromes in SLE according to the American College of 
Rheumatology nomenclature and case definitions (ACR Ad Hoc Committee on neuropsychiatric 
Lupus Nomenclature 1999). 
 
 
________________________________________________________________________________ 
Central nervous system   Peripheral nervous system  
  
 
Aseptic meningitis Acute inflammatory demyelinating 
polyradiculoneuropathy 
Cerebrovascular disease     
Demyelinating syndrome   Autonomic disorder 
Headache    Mononeuropathy, single/multiplex  
Movement disorder (chorea)  Myasthenia gravis 
Myelopathy    Neuropathy, cranial 
Seizure disorders   Plexopathy 
Acute confusional state   Polyneuropathy 
Anxiety disorder 
Cognitive dysfunction 
Mood disorder 
Psychosis 
___________________________________________________________________________ 
   
 
 
 
 
 
 
 
 
 
 
29 
 
6. Clinical features of NPSLE 
 
6.1 Central nervous system 
 
6.1.1. Aseptic meningitis 
 
The term aseptic meningitis is used for a meningeal syndrome of non-infectious origin with some 
degree of nuchal rigidity and pleocytosis in the cerebrospinal fluid (CSF). Aseptic meningitis is one 
of the least common manifestations of NPSLE. It can be the initial symptom of SLE and may occur 
early in the course of illness. Aseptic meningitis in SLE is probably heterogeneous in origin and due 
to vasculitis in some cases. The deposition of immune complexes in the choroid plexus has been 
suspected in pathogenesis. When making a diagnosis of aseptic meningitis as a part of active SLE, 
nonsteroidal anti-inflammatory drugs (NSAID) as a potential cause must be excluded. Aseptic 
meningitis as a side effect of NSAID is probably more common in SLE patients than in others 
(Kovacs et al 1993; Ostensen & Villiger 2001; Jennekens & Kater 2002). 
 
 According to the ACR case definitions, acute or subacute onset of headache with photophobia, 
neck stiffness, and fever; signs of meningeal irritation; and abnormal CSF should be observed to 
make a diagnosis of aseptic meningitis (ACR 1999). 
 
 
6.1.2. Cerebrovascular disease 
 
Stroke occurs in patients with SLE via a variety of mechanisms, including cardiogenic embolus, 
large-vessel occlusion or stenosis, small-vessel ischemia, and intracranial hemorrhage. It is not 
known how often stroke in SLE is due to cerebral venous thrombosis. Stroke due to vasculitis is 
probably rare. Ischaemic stroke in SLE is attributed at least in part to circulating antiphospholipid 
antibodies and premature atherosclerosis (Jennekens & Kater 2002).  
 
Stroke is among the CNS diagnoses in all large series of patients with SLE (Estes & Christian 1971; 
Feinglass et al 1976; Tan et al 1978, Abel 1980; How et al 1985; Futrell et al 1989; Sibley et al 
1992). The estimated frequency of strokes and transient ischemic attacks (TIA) among SLE patients 
ranges from 3% to 19% (Estes & Christian 1971; Feinglass et al 1976; Gibson & Myers 1976; 
Grigor et al 1978; How et al 1985; Futrell & Millikan 1989). Futrell and Millikan reviewed 105 
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patients with SLE and found that the majority of patients had their first cerebrovascular accident 
within the first 5 years of illness and the mean age at the time of stroke was 40 years (Futrell & 
Millikan 1989). SLE patients with a history of cerebral infarct or TIA are at a high risk for recurrent 
cerebral ischemia, the risk may be over 50% (Kovacs et al 1993). 
 
The ACR case definitions suggests the following diagnostic criteria for cerebrovascular disease: 
stroke syndrome, TIA, chronic multifocal disease, subarachnoid and intracranial hemorrhage and 
sinus thrombosis; supporting radioimaging study must be included and antiphospholipid antibodies 
(APL) recorded (ACR 1999). In newer studies using ACR case definitions the prevalence of 
cerebrovascular disease has varied from 2% to 24% (Brey et al 2002; Sanna et al 2002; Afeltra et al 
2003; Hanly et al 2004) 
 
 
 
6.1.3. Demyelinating syndrome 
 
The term “lupoid sclerosis” has been used to describe SLE patients with complex neurologic 
deficits similar to those seen in multiple sclerosis (MS). This particular syndrome might represent a 
concordance or overlap of two autoimmune conditions. It often refers to relapsing myelopathy or 
optic neuropathy in patients whose laboratory abnormalities support the diagnosis of SLE. (ACR 
1999; Jennekens & Kater 2002; Hanly et al 2005).  In CSF oligoclonal bands may exist and 
multifocal white matter bright spots may be seen on magnetic resonance imaging (MRI) studies. A 
Finnish epidemiologic survey found three instances of both MS and SLE occuring in the same 
patients (Kinnunen et al 1993). To facilitate further research, the ACR case definitions recommend 
the term demyelinating syndrome to be used instead of lupoid sclerosis (ACR 1999). 
 
 
6.1.4. Headache 
 
Head pain or headache is a common symptom both in SLE patients and in the normal population; 
whether there is a unique syndrome attributable to SLE is debated (Liang & Karlson 1984; ACR 
1999, Hanly et al 2005). A large number of studies have reported the prevalence of headache in 
SLE ranging from 30% to 65% (Mitsikostas et al 2004). Isenberg et al published the first controlled 
trial on this subject. They found that migraine with aura was more prevalent in SLE patients than in 
31 
 
controls, suggesting that migrainous phenomena may be a feature of SLE (Isenberg et al 1982). The 
incidence of migraine was prospectively studied in 90 patients and controls by Markus & 
Hopkinson; a history of migraine in SLE patient group (34%) was approximately twice as common 
as in controls. An association between migraine and SLE disease activity was found, too (Markus & 
Hopkinson 1992). In another study, the overall prevalence of headache, tension-type headache, and 
migraine was similar among patients and controls (Fernandez-Nebro et al 1999). 
 
In two recent controlled studies the prevalence of headache in SLE has been investigated. In the 
first one, migraine was significantly more prevalent among SLE patients than in patients with 
rheumatoid arthritis (RA), and related with SLE activity and organ damage measured by SLICC 
(Appenzeller & Costallat 2004). In another study, headaches were also more prevalent in SLE 
patients than in RA patients, but no particular primary headache type reached significant difference 
between the two groups. The scores for SLE activity or damage, function disability and quality of 
life were similar between SLE headache suffers and SLE headache-free patients (Weder-Cisneros et 
al 2004). Both studies agreed that Raynaud`s phenomenon is associated either with migraine or 
headache in general in SLE patients. 
 
Although there is a serious doubt about relationship between headache and SLE, all the following 
entities are included in the ACR case definitions: migraine without aura, migraine with aura, tension 
headache, cluster headache, headache from intracranial hypertension and intractable, nonspecific 
headache (ACR 1999). 
 
 
6.1.5. Movement disorder (chorea) 
 
Although a number of movement disorders have been reported in patients with SLE, the ACR case 
definitions accepted only chorea, which is the most common of these disorders (ACR 1999). It is 
recognized in less than 2% of cases and tends to appear early in the course of illness and resolve 
regardless of treatment (Kovacs et al 1993). It may be unilateral or generalized and is often 
accompanied by other focal neurologic signs or by changes in mental status. APLs are present in 
many SLE patients with chorea. The imaging features and histopathological studies point to 
abnormalities of the basal ganglia, but it is not yet clear whether chorea is due to vascular insult or 
to antibody-induced neuronal dysfunction (Jennekens & Kater 2002).  
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6.1.6. Myelopathy 
 
Spinal cord disease is a rare but well-described complication in SLE. Transverse myelitis occurs in 
under 1% of patients with SLE and is characterized by the development of paraplegia, associated 
with back pain and sensory loss. It is usually seen in late course of the illness and carries a poor 
prognosis. Vasculitis is a prominent feature of the spinal cord on post-mortem. There has been an 
association with APL suggesting that the symptom might result from a coagulopathy or that 
antibodies cross-react with spinal cord phopsholipids.  At least 25% of patients with myelopathy 
develop optic neuropathy, usually bilateral (Devic`syndrome). Secondary causes of myelopathy in 
SLE include an epidural or paraspinal abscess, epidural or subdural hematoma, disc herniation, and 
intramedullary or extramedullary tumor (Kovacs et al 1993; Liang et al 1994; Brey 2000; Jennekens 
& Kater 2002). 
 
 
6.1.7. Seizure disorders 
 
 
Seizures are part of the revised ACR classification criteria for SLE. They have been reported in 8% 
to 35% of patients with SLE, although fatal status epilepticus is rare. Seizures are usually 
generalized, but focal seizures have also been reported (McCune et al 1988; Kovacs et al 1993;     
Brey et al 2002, Sanna et al 2002). They may antedate a diagnosis of SLE by years or be the first 
manifestation of the disease (Liang & Karlson 1996). APLs have been reported with increased 
frequency in SLE patients with epilepsy. The aetiology of seizures may be an APL-associated 
cerebral infarction (Brey 2000). In a study of 519 patients, 60 (11.7%) patients with epileptic 
seizures were identified and all seven patients who presented recurrent seizures had 
antiphospholipid syndrome (Appenzeller et al 2004). The differential diagnosis of seizures in SLE 
patients includes pre-existing seizure disorders unrelated to SLE or seizures secondary to other 
manifestations of SLE, such as uremia, hypertension, stroke or infection (Kovacs et al 1993; Ranua 
2005).  
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6.1.8. Acute confusional state 
 
In the literature, the term organic brain syndrome is commonly used to define disturbed mental 
functioning with delirium, emotional inadequacy, impaired memory or concentration, incoherent 
speech, and increased or decreased psychomotor activity in the absence of any secundary causes 
(Kovacs et al 1993). The incidence of organic brain syndrome has varied between 2-35% (Estes & 
Christian 1971; Grigor et al 1978; How et al 1985; van Dam 1991). The disturbances typically 
develop over hours to days and tend to fluctuate during the course of the day (ACR 1999). 
Metabolic abnormalities such as hypoxia and electrolyte abnormalities should be sought after and 
corrected and CNS infection and hypertensive encephalopathy should be excluded (Liang & 
Karlson 1996; Hanly et al 2005). 
 
The term “acute confusional state” is equivalent to the term “delirium”, and according to the ACR 
nomenclature it should be used instead of the term “organic brain syndrome”. Diagnostic criteria for 
this statement are disturbance of consciousness or level of arousal and acute or subacute change in 
cognition and/or a change in behavior, mood, or affect. If only cognitive deficits are present, and 
not the other features, the syndrome should be diagnosed as “cognitive dysfunction” (ACR 1999).  
 
 
6.1.9. Anxiety disorder, mood disorder and psychosis 
 
In older literature, reported frequencies of psychiatric symptoms have varied between 3 and 82%. 
Variations might be caused by the way data were collected, by in- or exclusion of mild or functional 
complaints as symptoms of NPSLE and by the profession of the investigator; psychiatrists and 
psychologists tended to report more psychiatric disease if compared to other physicians (Estes & 
Christian 1971; Feinglass et al 1976; Gibson & Myers 1976; Grigor et al 1978; How et al 1985; van 
Dam 1994).  
 
A case of SLE psychosis may present with paranoia and visual and auditory hallucinations. 
Recovery is complete but relapses are common (Sibley et al 1992). The incidence of psychosis in 
SLE is not easy to estimate reliably because the literature often fails to distinguish psychosis from 
acute confusional state and because the distinction from corticosteroid psychosis is difficult 
(Jennekens & Kater 2002).   
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Psychiatric manifestations often occur in the absence of SLE disease activity, are more likely to 
occur in patients with past NPSLE episodes, and can be exacerbated by recent stressful life events 
in patients with clinically mild disease activity. The debate in the literature is whether psychiatric 
features are a reflection of active disease or a simply a consequence of emotional stresses that 
accompany a chronic, painful, and sometimes debilitating disease (Hay 1992; Hermosillo-Romo et 
al 2002). In some studies noted association between antiribosomal P protein antibodies and 
psychosis and APL and depression supports an organic basis for this presentation (Bonfa et al 1987; 
Arnett et al 1996; Hermosillo-Romo et al 2002). Despite the controversy over milder psychiatric 
complaints being features of NPSLE anxiety disorder, mood disorder and psychosis are involved in 
the ACR case definitions (ACR 1999). 
 
  
6.1.10. Cognitive dysfunction 
 
The prevalence of cognitive abnormalities in SLE patients has varied widely from 21-66% most 
probably due to differences in patient selection and case-definition. Very different sets of 
neuropsychological tests have been used and different criteria for defining impairment have been 
adopted. In these studies, consecutive clinical samples are composed of very different proportions 
of active, inactive, and never NPSLE patients (Carbotte et al 1986; Denburg et al 1993; Hanly et al 
1998; Denburg et al 2003). Many patients with SLE have a host of comorbidities (eg psychiatric) 
and other potentially confounding factors (Hermosillo-Romo et al 2002). However, the important 
consistent finding in these studies has been that cognitive impairment is significantly more frequent 
in SLE patients than in matched samples of healthy subjects or other patients with systemic disease. 
In addition, throughout the studies, subclinical cognitive impairment has been detected. Even in the 
absence of overt NP symptoms, a sizable proportion of SLE patients have been shown to have 
significant cognitive problems. Although a stable feature of CNS involvement in many patients 
with SLE, cognitive dysfunction fluctuates over time, transiently approaching the dementia severity 
range in a small number of patients. (Denburg et al 1993; Carbotte et al 1995; Hanly et al 1998; 
Hermosillo-Romo et al 2002; Denburg et al 2003). No pattern of cognitive dysfunction has emerged 
to be spesific for SLE, but most studies have reported deficits in attention and concentration, 
decreased psychomotor speed, mild verbal memory problems, decreased verbal fluency, and 
executive dysfunction (Denburg et al 1993; Hanly et al 1998). Studies using ACR case definitions 
have detected the total range of cognitive disorders to be between 52%-78% when cognitive 
function is tested in every patient by neuropsychological instruments. Remarkably lower prevalence 
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rates (5%-11%) have been found in  studies that evaluated patients using sensitive instruments only 
if clinically indicated (Brey et al 2002;  Sanna et al 2002; Afeltra et al 2003; Hanly et al 2007).  
 
Cognitive impairment in SLE patients is assumed to reflect CNS dysfunction. Two possible causes 
of cognitive disorder have been suggested; small-vessel vasculopathy and an antibody-mediated 
effect on neuronal functioning (Denburg et al 1993; Denburg et al 2003; Hanly 2004). In a cross-
sectional assessment of cognitive and APL status in 118 consecutive adult SLE patients, LA-
positivity was associated with an almost two-fold increased risk of cognitive impairment (Denburg 
et al 2003). Denburg has also reported associations of neuronal antibodies and lymphocytotoxic 
antibodies with cognitive functioning (Denburg et al 1987; Denburg et al 2003). Several studies 
have examined the association between cognitive dysfunction and other clinical features. Most 
studies have found no association between disease activity and cognitive disordes. The presence of 
other overt NP manifestations at any time in the disease course or at the time of neuropsychological 
testing is frequently linked with impaired cognitive performance. Comorbid psychiatric disorders 
can be found in up to 40% of patients with SLE who have cognitive dysfunction and changes in 
psychiatric disorders have been shown to parallel changes in cognitive function. Hippocampal 
atrophy has shown to be a negative prognostic factor to cognitive dysfunction and a progression of 
atrophy a predictor of progressive cognitive impairment. Controversy exists about the role of 
corticosteroid use beyond the cognitive dysfunction, most cross-sectional studies report no 
association between cognitive dysfunction and the use or dose of corticosteroid. An association 
between cognitive dysfunction and various chemotherapeutic drugs in several cancer populations 
has been found. Similarly, alkylating agents, such as cyclophospamide may have an effect on 
cognitive function in SLE patients (Denburg et al 1993; Ginsburg et al 1992; Hay et al 1992; Fisk et 
al 1993; Carbotte et al 1995; Hanly et al 1998; Hermosillo-Romo et al 2002; Hanly et al 2005; 
Appenzeller et al 2006). 
 
Cognitive impairment is most reliably detected and monitored by neuropsychological examination. 
The use of standardized tests for screening cognitive function such as the Mini-Mental State 
Examination is limited with substantial rates of false-negative findings. According to the ACR 
nomenclature, the diagnostic criteria for cognitive dysfunction require documentation by 
neuropsychological testing (documented impairment in one or more of the cognitive domains: 
simple attention, complex attention, memory, visual-spatial processing, language, 
reasoning/problem solving, psychomotor speed and executive functions); and a significant decline 
from a former level of functioning (ACR 1999).  
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6.2 Peripheral nervous system 
 
 
Manifestations resulted from peripheral nervous system (PNS) involvement have not been 
extensively investigated in SLE. The reported frequencies of abnormalities in PNS have mostly 
varied between 2% and 27%, but when evaluated using clinical electromyography and nerve 
conduction velocity studies, clinical and subclinical peripheral nerve abnormalities are detected in 
up to 47% of unselected SLE patients (Estes & Christian 1971; Feinglass et al 1976, Gibson & 
Myers 1976; Grigor et al 1978; Omdal et al 1988; Hermosillo-Romo et al 2002). A mild, symmetric 
distal sensory or sensomotor neuropathy is the most common peripheral neuropathy in SLE. 
Usually, the neuropathic process is modestly progressive over time, but it may fluctuate and is not 
necessarily irreversible (Goransson et al 2006). In most patients, biopsy and electrodiagnostic 
findings would be consistent with vasculitic neuropathy (Rosenbaum et al 1996). Peripheral 
neuropathy has been linked to cutaneous vasculitis and renal failure. It may be an important 
prognostic factor for mortality in SLE (Hermosillo-Romo et al 2002).  
 
Some patients with SLE have neuropathic symptoms despite normal results of clinical evaluation 
and nerve conduction studies. Since small nerve fibers convey perceptions of warmth and burning 
pain (C fibers) and cold and sharp pain (A alfa fibers), a pure small-diameter nerve fiber neuropathy 
may be responsible for this. The optimal method for proving the diagnosis of small fiber neuropathy 
is not established; measurement of warmth-detection thresholds or heat-pain thresholds and 
quantitative estimation of epidermal nerve fibers have been used. (Omdal et al 2002; Goransson et 
al 2006) 
 
Acute ascending paralysis (the Guillan-Barre syndrome) has reported to occur in less than 1% of 
patients; chronic inflammatory demyelinating polyneuropathy has also been linked to SLE.  
 
Mononeuritis multiplex in SLE is quite rare and almost always accompanied by evidence of active 
disease in other organs, although occasionally it may be the presenting feature of the disease 
(Martinez-Taboada et al 1996). 
 
Carpal tunnel syndrome may be the most common peripheral nerve complication of SLE. 
 
37 
 
Cranial nerve syndromes have been reported in 3-16% of SLE patients in several large series (Estes 
& Christian 1971; Feinglass et al 1976; Gibson & Myers 1976; Grigor et al 1978). Most often 
described neuropathies have related to the function of the eye (Kovacs et al 1993). Optic neuropathy 
occurs in about 1% of patients, in some cases associated with myelopathy but often without such an 
association. No particular clinical pattern predominates; visual loss, pain and visual field defects 
may appear. Vascular origin; small vessel disease or vasculitis, have been suggested as an ethiology 
for optic neuropathy in SLE. Other cranial nerve disorders seen in SLE include trigeminal neuralgia 
and facial neuropathy (Rosenbaum et al 1996, Jennekens & Kater 2002). 
 
Myasthenia gravis is an autoimmune disorder mediated by antibodies to acetylcholine receptors. It 
may occur with other disease of immunologic origin and has been diagnosed in patients with SLE 
but is rare (Rosenbaum et al 1996; ACR 1999). 
 
 
 
7. Pathogenesis of NPSLE 
 
The origin of NP manifestations in SLE has remained unresolved, but some progress has been 
noted. NPSLE is a heterogeneous disorder and it is unlikely that a single mechanism will account 
for the diversity of features seen (Kovacs et al 1993; Trysberg & Tarkowski 2004; Brey 2007). 
APL-mediated ischemia, microthrombosis and noninflammatory vasculopathy, local production of 
cytokines leading to neuronal cytotoxicity, and direct interaction of autoantibodies with 
autoantigens on neuronal cell membranes, leading to interference with neurotransmission, loss of 
neuronal plasticity, and neuronal cell death may be involved in the pathogenesis (Hermosillo-Romo 
et al 2002; Senecal & Raymond 2004; Trysberg & Tarkowski 2004). It is becoming clearer that the 
integrity of the blood-brain-barrier is very important in SLE-related neuropathology. It is possible 
that the magnitude and degree of dysfunction of the blood-brain-barrier in concert with the type and 
level of autoantibodies may be the determining factor regarding their pathogenicity in the brain 
(Brey 2007; Muscal & Brey 2010). In general, inflammatory disorders are no longer considered to 
be the main cause of damage, instead current knowledge holds ischaemia to be the main reason for 
NP manifestations (Hermosillo-Romo et al 2002; Jennekens & Kater 2002; Trysberg & Tarkowski 
2004).  
 
38 
 
One way to categorize the mechanisms of clinical injury is to distinguish immunologic effects 
directly affecting nervous system cells (neurons, glial cells, ependyma) from secondary ischemic 
effects caused by immune-mediated injury on vascular tissue. Table 4 summarizes the 
immunopathogenic mechanisms of NPSLE (Moore & Lisak 1995). 
 
 
 
Table 4. Immunopathogenesis of NPSLE (Moore & Lisak 1995). 
 
Primary Immune-mediated direct effects 
  Immune complexes 
  Autoantibodies 
  Cytokines 
  Activated lymhocytes 
 
 Immune-mediated indirect effects 
  Vasculopathy 
  Coagulopathy 
  Emboli from cardiac disease 
  Hematologic disturbances 
 
Secondary Infectious 
 Metabolic 
 Toxic 
 
 
 
 
7.1. Direct immune-mediated effects 
 
Immune-mediated direct effects result from the action of antibodies, cytokines, or immune 
complexes on neurons or, possibly, glia. Typically these effects are acute or subacute in onset 
(Moore & Lisak 1995).  
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7.1.1. Autoantibodies 
 
Although autoantibodies have long been considered as primary suspects, their role in pathogenesis 
of has not been established (Senecal & Raymond 2004; Brey 2007). The evidence based on human 
studies of the importance of them is largely circumstantial, and includes a temporal relationship 
between autoantibodies and NP manifestations, their presence in both CSF and serum, and their 
detection in neuronal tissues of some patients succumbing to NP manifestation (Hanly 1998).  
 
The integrity of the blood-brain barrier seems to be very important in SLE-related neuropathology. 
An abnormal endothelial-white blood cell interaction, allowing proteins or cells to access to the 
CNS, may be a mechanism whereby autoantibody-mediated CNS effects can occur. This can be 
stimulated by proinflammatory cytokines or certain autoantibodies (Brey 2007). Direct interaction 
of autoantibodies with autoantigens on neuronal cell membranes may lead to interference with 
neurotransmission, loss of neuronal plasticity, and neuronal cell death (Senecal & Raymond 2004). 
 
Table 5 lists most common autoantibodies reported in NPSLE and associated clinical manifestations 
(Senecal & Raymond 2004; Brey 2007). 
 
Antiphospholipid antibodies (APLs) are a heterogenous group of circulating autoantibodies directed 
against negatively charged phopholipids and protein co-factors. There are at least two distinct 
groups of APLs; type I occur in patients with infections, type II are frequently found in patients 
with autoimmune disease. These antibodies are implicated in the pathogenesis of the thrombotic 
events that characterize the antiphospholipid syndrome (APS). The hallmarks of APS are arterial 
thrombosis, recurrent fetal loss and thrombocytopenia. A serum co-factor, beta 2 glucoprotein I has 
been identified as a requirement for in vitro APL antibody binding to phopsholipid and it seems to 
be the true antigenic target of type II APL (Hanly 1998).  
 
APLs have been reported to be present in 20-55% of SLE patients (Jennekens & Kater 2002). In a 
review of over 1000 SLE patients, NP manifestations occurred in 38% of patients with lupus 
anticoagulant compared to 21% of patients without these APL. In addition to prothrombotic effects 
(below), APLs may exert direct damage to brain tissue. In several studies APLs have been 
associated with both cerebrovascular disease and cognitive dysfunction in people with SLE and 
they have also been reported in NPSLE patients with cranial neuropathy, seizures, chorea, headache 
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and myelopathy (Toubi et al 1995; Hanly 1998; Hanly 1999; Brey 2000; Jennekens & Kater 2002; 
Denburg et al 2003; Sanna et al 2003; Herranz; Trysberg & Tarkowski 2004; Brey 2007).  
 
Much attention has been directed toward antineuronal antibodies with specificity toward antigens 
on neurons or brain tissue. Positive correlations have been found between antineuronal antibodies 
and NPSLE. In particular, diffuse NP manifestations; acute confusional state, psychosis and 
seizures; have been associated with antineuronal antibodies (How et al 1985; van Dam 1991; 
Kovacs et al 1993). One hypothesis is that antineuronal antibodies bind to neuronal membranes and 
cause a transient alteration of cell function without cell death or inflammation; this would account 
for reversibility of symptoms (Moore & Lisak 1995). 
 
Anti-ribosomal P antibodies have been investigated in NPSLE since Bonfa et al 1987 first reported 
a strong association of them with lupus psychosis. This result was supported by Arnett et al, who 
found also an association with organic depression. In some patients, psychiatric symptoms seemed 
to vary in parallel with anti-ribosomal P titers (Bonfa et al 1987; Arnett et al 1996). Not all 
psychotic patients with SLE have high anti-ribosomal P titers and some studies have also refuted 
the association between psychiatric symptoms and anti-ribosomal P antibodies, (Moore & Lisak 
1995; Gerli et al 2002). Recently a meta-analysis of 1537 patients with SLE found anti-ribosomal P 
antibodies to be present in one-third of patients with NPSLE as well as in 15-25% of lupus patients 
without NP manifestations (Kassara et al 2006).  
 
Recently, the potential role of anti-glutamate receptor antibodies in cognitive dysfunction and 
psychiatric disease in patients with SLE has been considered. N-methyl-D-aspartate (NMDA) 
receptors NR2a and NR2b bind the neurotransmitter glutamate and are present on neurons 
throughout the forebrain. Hippocampus has the highest density of NMDA receptors. In addition to 
their putative role in learning and memory, these receptors display altered expression in major 
psychosis and if engaged by receptor antagonists cause hallucinations and paranoia (Hanly et al 
2005). A subset of lupus anti-DNA antibodies has been found to cross-react with the NR2 glutamate 
receptor in patients with SLE (DeGiorgio et al 2001). In contrast to previous antineuronal 
antibodies described in SLE, the anti-NR2 glutamate receptor antibodies appear to have a functional 
consequence leading to neuronal injury in a manner similar to that seen in excitatory amino-acid 
toxicity (Hanly et al 2005). It has been suggested that they might be involved in damage of the 
amygdala in human SLE (Arinuma et al 2008) It has been found a correlation between anti-NR2 
antibodies with deficits of memory and learning, depression, psychopathic deviate, schizophrenia 
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and hypomania (Omdal et al 2005). Most studies report that anti-glutamate receptor antibodies are 
seen in 25% to 30% of patients with SLE but their association with NP manifestations is 
controversial. A recent study suggests that these antibodies are associated with cognitive 
dysfunction and hippocampal apoptosis only in the presence of blood-brain barrier disruption 
(Kowal C et al 2006; Brey 2007). Furthermore, elevated levels of anti-NR2 antibodies in CSF but 
not in serum have been found to associate with diffuse NPSLE (Arinuma et al 2008). 
 
 
 
Table 5. Human autoantibodies associated with NPSLE (Senecal & Raymond 2004, Brey 2007). 
 
Antigenic specificities  Associated clinical manifestations 
Neural tissue-spesific autoantibodies 
  Anti-neurofilament antibodies Diffuse CNS presentation 
  Anti-glial fibrillary acidic protein Organic/major type NP manifestation 
  Anti-microtubule-associated Various NP manifestations 
  protein 2 (MAP-2) 
 
Non-neural tissue-specific autoantibodies 
  Anti-dsDNA antibodies cross-reactive  Progressive cognitive decline (single patient) 
  with neuronal receptors in the CNS 
  Antiphospholipid antibodies Focal neurologic deficits (strokes, seizures, transverse 
myelopathy), deterioration in cognitive function 
  Antilymphocyte antibodies cross- Encephalopathies, seizures, visuospatial deficits 
  reactive with brain antigens 
  Antiribosomal P protein antibodies Controversial association with psychosis and severe 
depression 
  Antiganglioside Controversial association with NPSLE, stronger 
association with peripheral neuropathy 
 Anti-glutamate receptor antibodies Controversial association with cognitive dysfunction and 
 psychiatric disease 
 
 
 
42 
 
7.1.2. Immune complex 
 
Immune complex-mediated tissue injury is a hallmark of SLE, well established in the pathogenesis 
of renal and cutaneus disease. Immune complexes can activate endothelium, resulting in increased 
adhesion of leucocytes and enhanced thrombus formation. Much of the interest in immune 
complexes and neurologic function has developed from the observations that immune complexes 
appear in CSF, are deposited in the choroid plexus, and can alter the blood-brain barrier when 
injected to experimental animals. However, evidence for immune complex-triggered inflammation 
in the CNS is scanty. In brain vessels restrictive tight junctions can prevent the perivascular 
accumulation of immune complexes. There are immune complex depositions in the choroid plexus 
also in patients without NP manifestations. Furthermore, neurologic abnormalities are usually not 
associated with evidence of active elevation of circulating immune complexes (Moore & Lisak 
1995, Abbott et al 2006, Senecal & Raymond 2004). 
 
 
7.1.3. Cytokines 
 
 
 
Cytokines, small proteins produced by lymphocytes, macrophages, and other cells, are prominent in 
the pathogenesis of neurologic disease. They cause biologic effects in cells with receptors for that 
particular cytokine. Both physiologic and pathologic effects on neurologic function may result 
(Moore & Lisak 1995). Among other effects, cytokines are capable of inducing production of 
proteolytic enzymes, metalloproteinases, with ability to destroy brain parenchyma.  
 
Several studies have shown that the level of interleukin-6 (IL-6) in CSF is elevated in patients with 
NPSLE. Also elevated levels of IL-6 mRNA in the hippocampus and cerebral cortex have been 
found in autopsies on patients with NPSLE (Efthimiou et al 2009). Il-6 serves as an important 
growth factor for activated B cells. Increased production of other cytokines such as Il-1, 
transforming growth factor-B, Il-8, interleukin-10, and interferon-G have also been reported in CSF 
of patients with NPSLE (Trysberg & Tarkowski 2004).  
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7.1.4. Activated lymphocytes 
 
Activated lymphocytes may have a pathogenic effort on brain tissue in SLE. Activated 
immunocompetent cells can penetrate the blood-brain barrier, lodge in the brain, and secrete 
cytokines, leukotrienes, and prostaglandines. B cells may be the source of intrathecal synthesis of Ig 
(Moore & Lisak 1995). 
 
 
7.2. Indirect immune-mediated effects 
 
Immune-mediated indirect neurologic effects typically result from the action of autoantibodies, 
cytokines, immune complexes, or activated lymphocytes on the vasculature. Neurologic effects 
result from tissue ischemia. Neurologic abnormalities develop when a critical degree of local 
disease or a series of sub-clinical events in abnormal blood vessel occur (Moore & Lisak 1995). 
 
 
7.2.1. Vasculopathy 
 
Vasculopathy refers to structural abnormalities of the blood vessel wall; in NPSLE these changes 
occur primarily in small but sometimes in medium-sized, vessels (Moore & Lisak 1995). In 
histopathological studies in NPSLE patients, small-vessel angiopathy, leading to microinfarcts, is 
the predominant structural abnormality (Johnson & Richardson 1968; Hanly et al 1992; Trysberg & 
Tarkowski 2004). Changes in the walls of affected vessels include proliferation of intimal cells, 
increase in fibrous tissue, and mucoid hyperplasia or hyalinization (Jennekens & Kater 2002). 
Characteristic histopathological features of true vasculitis with a brisk infiltrate of inflammatory 
cells within the vessel wall is infrequent, it has been documented in only 7% to 15% of NPSLE 
autopsy cases (Trysberg & Tarkowski 2004). No clinical syndrome of central nervous system has 
been associated with cerebral vessel spasm (Jennekens & Kater 2002). A microvasculopathy 
formerly attributed to deposition of immune complexes is now suspected to arise from activation of 
complement and appears to be the most common microscopic brain finding in SLE. Single photon 
emission computed tomography (SPECT) and magnetic resonance spectroscopy (MRS) studies 
suggest that both cerebral atrophy and cognitive dysfunction in SLE patients may be related to 
chronic diffuse cerebral ischemia. However, these are nonspecific findings, as patients without 
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overt NPSLE manifestations also show these changes and the brain can be histologically normal in 
a patient with NP manifestation (Brey 2007).  
 
Numerous epidemiologic studies have showed evidence of accelerated and premature 
atherosclerosis in patients with SLE. Inflammation plays an important role in the pathogenesis of 
both SLE and atherosclerotic disease.  Traditional Framingham risk factors do not fully account for 
the elevated and premature risk seen in SLE patients and other factors i.e.  inflammatory mediators 
may also be important in the development of these complications. Premature atherosclerosis is 
induced in SLE patients by chronic inflammatory processes, dyslipoproteinemia, renal disease and 
treatment with corticosteroids. However, steroid treatment could actually prevent atherosclerosis as 
well, because it suppresses inflammation, which is implicated in atherosclerosis. The results of 
studies about the effect of steroid treatment are conflicting (Esdaile et al 2001; Jennekens & Kater 
2002; Rhew et al 2006; de Leeuw et al 2009).  .  
 
Endothelial injury is the initial step in atherogenesis. It can occur from a variety of causes e.g. shear 
stress, viruses, toxins, immune complexes, oxidative stress and complement activation. Injury 
results in endothelial dysfunction and an inflammatory response which plays a role in all stages of 
atherogenesis and in the progression of atherosclerosis. This inflammatory response includes the 
expression of adhesion molecules on the endothelium, secretion of cytokines to recruit further 
inflammatory cells and induce proliferation of macrophages and smooth muscle cells, 
differentiation of macrophages and uptake of oxidized LDL by macropahges to become foam cells, 
with formation of fatty streak and subsequent atheromatous plaque. The final step is release of 
matrix metalloproteinases (MMPs) and tissue factor by macrophages resulting in plaque rupture and 
thrombus formation (Rhew et al 2006).   
 
The study of endothelial injury is difficult due to inaccessibility of the endothelium in humans. 
Endothelial cell activation has been demonstrated in SLE by the presence of increased levels of 
VCAM-1, thrombomodulin (TM) and von Willebrand factor (vWf), and by increased expression of 
adhesion molecules in skin biopsy specimens of SLE patients (de Leeuw et al 2009). Circulating 
endothelial cells (CECs) have recently shown to serve as a new marker for micro-vascular injury. 
CECs are thought to be mature cells that have detached from the intimal monolayer in response to 
endothelial injury. An increased number of CECs has been observed in patients with SLE and an 
association to the disease activity has also been found (Elshal et al 2009). 
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In addition to being directly responsible for clinical NP syndromes, alternatively vasculopathy may 
enhance blood-brain barrier permeability, thus facilitating the access of pathogenic antibodies from 
the circulation into the CNS (Hanly 1998).  
 
 
7.2.2. Coagulopathies, cardiac emboli and hematologic changes  
 
The relation between APL and CNS involvement in SLE was first reported in 1984 and has later 
been confirmed; an association of APL with arterial and venous thrombosis in patients with SLE 
has been shown reliably (Toubi et al 1995). APS is defined by arterial and/or venous thrombosis 
and recurrent fetal loss in the presence of APLs (Cuadrado et al 2000; Dignat-George et al 2004). 
The diagnosis of APS is based on clinical and laboratory criteria, defined by strict guidelines. The 
original clinical and laboratory criteria for the identification of APS patients were published in 
1999, in the so-called Sapporo criteria. In 2006 these criteria were revised (Devreese et al 2010). 
 
APLs potentially contribute to stroke by two pathways, interaction with the blood vessel wall and 
with the coagulation cascade (Moore & Lisak 1995). Several studies have shown that the binding of 
aPL to endothelial cells induces endothelial activation and/or injury, transforming their 
antithrombotic surface into a prothrombotic one that could contribute to the acquired 
hypercoagulable state associated with APS. Activated endothelial cells induce the release of these 
endothelial-cell derived microparticles. They are pro-coagulant vesicles formed by the endothelial 
cell membrane after injury or activation. It has been proposed that the generation of microparticles 
in APS and SLE patients results from an autoimmune process involving APL (Dignat-George et al 
2004; Elshal et al 2009).  
 
The European Working Party on SLE followed up a cohort of 1000 patients for a 10-year period 
and found that thromboses were the most common cause of death and were always associated with 
APLs (Cervera et al 2003). Other abnormalities leading to a hypercoaguable state in SLE include 
decreased fibrinolysis, decreased plasminogen activation, and impaired formation of prostacyclin 
(Moore & Lisak 1995). Cerebral emboli derived from valvular or endocardial vegetations or from 
carotid plaques may also be the cause of cerebral ischaemia (Jennekens & Kater 2002). 
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7.3. Non-immune mediated effects 
 
Neurologic complications of SLE may also result from abnormalities not directly related to the 
primary disease. The major aetiologies in this group are infections, toxins, and metabolic 
derangements. Infection remains still a leading cause of morbidity and mortality in SLE. The 
frequency of infections results from the patients` immunosuppression both by medication and by 
the underlying disease. Corticosteroids and anti-hypertensive medications can produce neurologic 
and psychiatric symptoms. Metabolic abnormalities affecting the nervous system include uremia 
and disorders of electrolyte levels (Moore & Lisak 1995). 
 
8. Radiological findings of NPSLE 
 
MRI is more sensitive than computer tomography (CT) for brain lesions associated with NPSLE 
and, in contemporary practice, is the preferred anatomic imaging modality. MRI relies on two 
properties of the water molecule that occur after exposure to a depolarizing radio frequency pulse 
whilst in a constant magnetic field. These properties are T1 relaxation and T2 depolarization. 
Typically on a T1 weighted image of the brain, the grey matter appears grey, the white matter is 
white and CSF is dark. T2 weighted imaging is almost the reverse with fluid being bright, such as 
CSF and inflammatory oedema. There is reversal of the grey and white matter signal intensities, 
with white matter being darker than grey matter. To enhance the conspicuity of pathological lesions, 
on T2-weighted images the CSF signal can be dampened to highlight areas of intra and extracellular 
oedema. This fluid-attenuating inversion recovery sequence (FLAIR) can be used when imaging the 
brain. Intravenous contrast media MRI, typically gadolinium, can also be used. Using T2-weighted 
imaging and FLAIR sequence allows visualization of high signal lesions most clearly (Graham et al 
2003). 
 
Imaging studies are important in the management of SLE patients with NP involvement for 
detecting not only changes caused by SLE but also evidence of alternative diagnoses (Sibbitt et al 
1989; Huizinga et al 2001; Peterson et al 2005; Castellino et al 2008). Abnormalities on MRI 
scanning have been found in 19-70% of SLE patients (Hanly et al 2005). No specific MRI 
abnormalities have been associated with CNS involvement in SLE. Cortical stroke, global atrophy, 
nonspecific foci of increased signal in both grey and white matter on T2-weighted images, cerebral 
venous thrombosis, venous infarction, and rarely, intracranial calcifications have been reported on 
MRI scans of NPSLE patients (Kozora et al 1998; Sibbitt et al 1999; Govoni et al 2004). 
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Small punctate lesions in white matter are most common MRI findings, they have been reported 
both in SLE patients with or without NP involvement (Jacobs et al 1988; Mc Cune & Golbus 1988; 
Sibbitt et al 1989; Cauli et al 1994; Gonzales-Crespo et al 1995; Chinn et al 1997; Hanly 1998, 
Kozora et al 1998). These lesions are concentrated in subcortical white matter, especially in the 
frontoparietal regions, but may be seen elsewhere. Periventricular lesions have been particularly 
associated with APS and can be impossible to differentiate on MRI from multiple sclerosis. White 
matter hyperintensities increase with age in the general population and are also associated with 
hypertension. The meaning of these lesions in NPSLE is still doubtful, they have been considered as 
microinfarcts, demyelination plaques or gliotic lesions. Histopathologic analysis suggests that these 
lesions are a vascular phenomenon representing small infarcts with loss of nerve fibres and local 
gliosis (Sibbitt et al 1999; Jennekens & Kater 2002; Peterson et al 2005; Govoni et al 2004; 
Castellino 2008). The presence of them has been found to associate with duration and severity of 
the disease, past history of CNS involvement and APL. However, the relevance of these lesions to a 
specific NPSLE episode is disputable (Jarek et al 1994; Gonzales-Crespo et al 1995; Kozora et al 
1998; Sibbitt et al 1999; Peterson et al 2005). They have been suggested to underlie cognitive 
disorder of SLE patients without any other NP manifestations but contradictory arguments have 
also been presented (Hanly & Liang 1997; Kozora et al 1998).  
 
Focal neurological symptoms of NPSLE have been found to correlate with structural abnormalities, 
but MRI is usually normal in NPSLE patients with diffuse symptoms. In one study, only 19% of 
patients with diffuse presentations had an abnormal MRI scan (Peterson et al 2005). However, when 
diffuse manifestations are also accompanied by generalized seizures, MRI shows multiple small, 
high-intensity lesions that often resolve with treatment (West et al 1995; Kozora et al 1998; 
Hermosillo-Romo & Brey2002; Govoni et al 2004).  The differentiation of acute active disease 
from old chronic lesions is also difficult. The use of gadolinium has been shown to be helpful in 
delineating active inflammatory lesions (Peterson et al 2005). 
 
A significant degree of brain atrophy has been recognized in patients with SLE, even with SLE 
patients without NP involvement in comparing with healthy controls. Atrophic changes have been 
found to be more marked in patients with a history of previous overt NPSLE. The aetiology of 
cerebral atrophy in SLE patients is unknown. The role of steroid use, disease activity and disease 
duration in cerebral atrophy is unclear (Chinn et al 1997, Hanly 1998, Kozora et al 1998). 
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The finding of a normal MRI scan is common in NPSLE and this has prompted the research of 
other MR-based techniques as well as radionuclide brain scanning to increase sensitivity in the 
assessment of NPSLE. The applification of several technologies to MR scanning has provided 
additional opportunities to assess brain metabolism and function. In recent years major advances in 
neuroimaging techniques has allowed a great improvement in the understanding of SLE 
pathogenesis (Hanly 2005; Peterson 2005; Castellino 2007).  
 
Magnetic resonance angiography (MRA) permits visualization of cerebral blood flow, although it 
is probably not optimal for visualization of flow in small calibre vessels that are the ones primarily 
involved is NPSLE (Castellino et al 2005; Hanly et al 2005). 
 
Magnetic resonance spectroscopy (MRS) is a non-invasive MRI technique that allows the 
biochemical metabolities in brain tissue to be quantified, thereby providing indirect evidence of 
cellular changes. The amount of N-acetyl (NA) compounds, which reflect the quantity and integrity 
of neuronal cells, has been found to be reduced in SLE patients with cognitive dysfunction. An 
association with elevated IgG APL and cerebral atrophy has also been found. MRS has revealed 
neurometabolic abnormalities even in white and gray matter that appears normal on conventional 
MRI. Such abnormalities are believed to reflect neuronal injury or loss and demyelination and have 
been found during active and quiescent The changes observed are not specific to NPSLE. At this 
time, MRS is a tool for research purposes only (Peterson et al 2005; Hanly et al 2005, Muscal & 
Brey 2006). 
 
Diffusion-weighted imaging (DWI) is a MRI application which measures the diffusion of water in 
the brain. It is highly effective in the detection of hyperacute brain injury, in particular acute 
ischemia following stroke. So far, few small studies have evaluated DWI in NPSLE. Two of them 
showed an overall increase in diffusion in NPSLE compared with healthy controls, suggesting 
inflammation with loss of white-matter integrity (Peterson et al 2005; Castellino et al 2008). 
 
Magnetization transfer imaging (MTI) is a quantitative MRI technique that is sensitive to 
macroscopic and microscopic brain tissue changes. It measures the magnetization transfer ratio 
which can be displayed as histograms. MTI is particularly suited to the detection and quantification 
of diffuse brain damage. Decreased MTR has been correlated with global neurological, psychiatric 
and cognitive functioning in NPSLE and also with anticardiolipin antibodies (Bosma et al 2002; 
Hanly et al 2005; Castellino et al 2008). 
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Positron emission tomography (PET) is a nuclear medicine technique which explores both brain 
glucose metabolism and cerebral blood flow. Even though PET has high sensitivity, it is abnormal 
in 100% patients with active NPSLE, due to low specificity, limited availability, excessive cost and 
elevated dose radiations it is rarely applied in daily clinical practise. Single photon emission 
computed tomography (SPECT) is more easily available nuclear medicine technique which 
provides semi quantitative analysis of regional cerebral blood flow and metabolism. It is exquisitely 
sensitive and in studies of SLE patients has identified both diffuse and focal deficits which may be 
fixed or reversible (Hanly et al 2005; Castellino et al 2008). 
 
 
 
9. Diagnosis and follow up of NPSLE 
 
There is no single diagnostic test that is sensitive and specific for SLE-related neuropsychiatric 
manifestations. The assessment of individual patients is based on clinical neurologic and 
rheumatologic evaluation, immunoserologic testing, brain imaging, and psychiatric and 
neuropsychological assessment. The spectrum of diagnostic tests available is listed in table 6. An 
important consideration in the diagnostic approach to a patient with possible NP manifestation is 
whether the syndrome is convincingly attributed to SLE, a complication of the disease or its 
therapy, or whether it reflects a coincidental disease. Infection is a major cause of central nervous 
system syndromes in hospitalized SLE patients so it always has to be suspected. Examination of 
CSF should be considered primarily to exclude infection. Measurement of CSF autoantibodies, 
cytokines and biomarkers of neurologic damage is still a subject of research. APL are the 
circulating antibodies most likely to provide the greatest diagnostic yield. Neuroimaging should 
include a modality to assess brain structure and another to assess brain function. Currently the most 
accessible and available techniques are MRI and SPECT (Hanly et al 2005; Brey 2007; Castellino 
et al 2007).  
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Table 6. Investigations in the assessment of SLE patients for NP disease (Hanly & Harrison 
2005). 
 
Type of investigation 
 
CSF   Exclude infection 
   Autoantibodies  
   Cytokines  
   Biomarkers  
 
Autoantibodies  Antiphospholipid 
   Antiribosomal  
   Antineuronal  
 
Neuroimaging  Brain structure (CT, MRI) 
   Brain function (PET, SPECT, MRI, MRA, MRS, MTI,  
   DWI, FMRI) 
 
Neuropsychological assessment 
CSF, cerebrospinal fluid; CT, computerized tomography; DWI, diffusion weighted imaging; fMRI, 
functional MRI; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; MRS, 
magnetic resonance spectroscopy; MTI, magnetization transverse imaging; PET, positron emission 
tomography; SPECT, single photon emission computed tomography 
   
  
10. Treatment of NPSLE 
 
 
The management of patients with SLE includes symptomatic, immunosuppressive and 
anticoagulant therapies, but evidence for the efficacy of the treatment modalities commonly used is 
largely limited to uncontrolled trials and anecdotal experience. The key to treatment is to first 
establish the correct diagnosis by carefully considering all possible aetiologies, both SLE-related 
and those which are not. The choice depends on the most probable underlying pathogenic 
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mechanism and the severity of the presenting NP syndrome. Potential aggravating factors such as 
hypertension, infection, toxic effects of therapy and metabolic abnormalities have to be identified 
and treated. Immunosuppressive therapy may be associated with several opportunistic infections of 
the brain and differentiation between primary CNS involvement and CNS infection may be 
extremely difficult. Patients with mild manifestations may need symptomatic treatment only, for 
example, anticonvulsants, antidepressants, anxiolytics and antipsychotic medications, whereas more 
severe acute nonthrombotic CNS manifestations may require intravenous pulse cyclophospamide 
therapy. Immunosuppressive therapy with hydroxychloroquine, corticosteroids, azathioprine, 
methotrexate and cyklophosphamide are used to varying degrees (Table 7.). Plasmapheresis may 
also be added in patients with more severe illness refractory to conventional treatment (Navarrette 
& Brey 2000; Hermosillo-Romo & Brey 2002; Sanna et al 2003; Hanly et al 2005).   
 
Hydroxychloroquine (HCQ) is commonly used to treat mild disease. Recently it has been postulated 
that HCQ should be given to most patients with SLE during the whole course of the disease because 
high levels of evidence were found that antimalarials prevent lupus flares and increase long-term 
survival of patients with SLE. The precise mechanism of action is not well understood, but it is 
suspected that antimalarials may function as immunomodulators in systemic inflammatory disorders 
(Navarrete & Brey 2000). They might operate by inhibiting the activation of intracellular TLRs. It 
has been suggested that they can slightly increase the pH within endosome in antigen-presenting 
cells or B cells interfering with autoantigen presentation. The pH elevation reduces the affinity 
binding between immune complex containing nucleic acids and intracellular TLRs, decreasing the 
expression of type I interferon genes which represent an early stage in the pathogenesis of SLE 
(Doria et al 2008). HCQ has relatively minor side effects and it also reduces the incidence of 
thrombotic events and lessens the hyperlipidemic effects of prednisone. It can be used during 
pregnancy. Hydroxychloroquine is also a potential additional treatment for APS (Navarrete & Brey 
2000; Ruiz-Irastorza et al 2010). 
 
Although the approach to corticosteroid therapy remains largely empirical, corticosteroids continue 
to represent the first line of treatments for SLE with suspected diffuse CNS involvement. Tablets of 
prednisone are given orally and the dose is individualized. High-dose glucocorticoids are indicated 
for acute severe CNS manifestations. 1 g of intravenous methylprednisolone is given daily or every 
other day for a total of three to six doses. A randomized controlled clinical trial comparing long-
term use of cyclophosphamide and methylprednisolone reported a better overall therapeutic control 
of SLE-related neurologic manifestations with monthly intravenous cyclophosphamide. The use of 
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intravenous cyclophospamide is the recommended current practise in cases of acute severe CNS 
disease, in those refractory to corticosteroids or when a steroid-sparing effect is desired. It is 
administered in a dose of 750 to 3000 mg/m2; no more than 1000 mg is given as a single dose 
(Navarrette & Brey 2000; Hermosillo-Romo & Brey 2002; Sanna et al 2003; Hanly et al 2005; Brey 
2007; Muscal & Brey 2010). 
 
Plasmapheresis is useful to remove free antibodies, complement components and circulating 
immune complexes. The efficacy of plasmapheresis is anecdotal and it seems that patients who 
respond to this treatment are those with more severe illness, refractory to corticosteroids and 
cyclophosphamide therapy, and with the highest levels of circulating immune complexes; generally 
it is considered for the treatment of NPSLE only when all other possibilities have been tried and 
have been found to be ineffective (Navarrette & Brey 2000; Sanna et al 2003). 
 
Intravenous immunoglobulin (IVIg) has proved to be useful in the treatment of autoimmune and 
inflammatory neurological diseases, but there are only few reports of the use of IVIg in NPSLE. 
However, beneficial effects of high-dose IVIg have been shown in a patient with SLE and acute 
severe CNS disease, including psychosis (Sanna et al 2003). The mechanism of action of IVIg is 
unclear, but possibilities include an anti-idiotypic antibody effect, Fc receptor blockade, suppressor 
cell enhancement, and inhibition of lymphocyte proliferation (Navarrette & Brey 2000). 
 
In general, the current treatment for SLE, not only neuropsychiatric one, is nonspecific and is 
associated with serious adverse effects by causing generalized immunosuppression. In addition, a 
significant number of lupus patients show only partial or no response to the current therapies. 
Therefore, more specific treatments for SLE are sought. Especially in interest are therapies that 
target B-cells, including B-cell depletion using monoclonal antibodies that bind B-cell surface 
antigens. Rituximab and epratuzumap have shown good therapeutic results (Tieng et al 2008). In 
ten patients with refractory NPSLE, despite intensive treatment, treatment with rituximab resulted 
in rapid improvement of CNS-related manifestations, particularly acute confusional state. It also 
improved cognitive dysfunction, psychosis and seizures (Tokunaga et al 2007). Other B-cell 
targeted therapies are focused on specific B-cell functions involving inactivation of autoreactive B-
cells via tolerance induction, blockade of costimulatory signals, or blockade of cytokines that 
stimulate B-cells. Many different biological agents have been used in recent and ongoing studies, 
but up to now breakthroughs emerging from randomized Phase III trials have been rare (Tieng et al 
2008; Haubiz 2010). 
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Anticoagulation is strongly indicated for focal disease when APLs are implicated and such therapy 
will usually be lifelong. The use of antiplatelet or anticoagulant therapy in SLE patients with APLs 
for the treatment of cognitive dysfunction without evidence of thromboembolic phenomena has 
never been studied and remains controversial. In APS, possible future therapies are statins, 
rituximab, and new anticoagulant drugs (Ruiz-Irastorza et al 2010). So far there is no data to 
support or refute the use of pharmacologic agents developed for the treatment of cognitive 
dysfunction associated with Alzheimer´s disease and attention deficit disorder, in the treatment of 
SLE-associated cognitive dysfunction (Hanly et al 2005).  
 
Nonpharmacologic approaches are also important in SLE patients with psychiatric disorders and 
cognitive dysfunction. In a study, SLE patients receiving psychological group intervention have 
showed a significant and sustained improvement in several symptoms, such as depression, anxiety, 
and overall mental burden. Lupus patients with verified cognitive dysfunction can be referred for 
cognitive rehabilitation to a neuropsychologist (Hanly et al 2005; Muscal & Brey 2010). 
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Table 7. Immune-modulating therapy for neuropsychiatric systemic lupus erythematosus 
(Navarrette & Brey 2000) 
 
Therapeutic agent  Indications 
 
 
High-dose glucocorticoids  Seizures in the presence of active SLE 
   Cerebral vasculopathy* 
   Any CNS manifestation in the presence of active SLE 
 
Intravenous pulsed   Cerebral vasculopathy* 
cyclophosphamide  Nonthrombotic focal neurologic deficits in SLE* 
   Transverse myelitis* 
 
Hydroxychloroquine  Long-term control of active SLE 
   Antiplatelet effect 
   Cholesterol-lowering effect 
 
Intravenous immunoglobulin Any CNS manifestation unresponsive to glucocorticoid  
   therapy, cytotoxic therapy, or the combination 
 
Plasmapheresis Any CNS manifestation unresponsive to glucocorticoid 
therapy, cytotoxic therapy, the combination, or intravenous 
immunoglobulin 
 
 
*May require the combination of both high-dose glucocorticoid and intravenous 
cyclophosphamide 
CNS, central nervous system; SLE, systemic lupus erythematosus 
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AIMS OF THE STUDY 
 
The purpose of this cross-sectional, population-based study was to 
 
1. describe the prevalence of NP syndromes in a Finnish population of  SLE patients and 
classify the syndromes according to the ACR nomenclature and case definitions.  
2. assess the validity of the ACR nomenclature and case definitions for NPSLE 
3. investigate whether there is any association between the volumes of MRI lesions and NP 
manifestations in SLE 
4. evaluate and test the hypothesis whether serum MMP-9 levels are associated with NP 
manifestations or cerebral MRI abnormalities in SLE patients 
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PATIENTS AND METHODS 
 
 
1. Patients and study design 
 
The study base was Pirkanmaa Health Care District located in Southern Finland with a population 
of 440 000.  The majority of the new SLE patients in the area are seen at Tampere University 
Hospital. Patients with SLE were identified by using the computerized data-base of Tampere 
University Hospital, the three District Hospitals and the local outpatient clinic. Medical records of 
both in- and out patients coded for the diagnosis of SLE between January 1980 and December 1997 
were examined to select patients who fulfilled four or more of the 1982 revised ACR criteria for the 
disease, were aged 16-65 years and of native Finnish origin, and resident in the study area. Patients 
with another connective tissue disease were excluded.  
 
A total of 110 SLE patients were identified. Of these, 15 patients had died and 37 did not meet the 
inclusion criteria. The remaining 58 patients were contacted by mail and 46 of them (79%) agreed 
to participate in the study. The control group consisted of 46 individuals randomly identified from 
the Finnish Population Register, with matching on age, sex, level of education and municipality of 
residence. Similar eligibility criteria were applied as for the cases.   
 
All participants gave their written informed consent. The study protocol was approved by the local 
Ethics Committee.  
 
 
 
2. Methods 
 
2.1. Clinical examination  
 
A complete medical history was obtained from all patients and a clinical neurological examination 
was performed by the same neurologist (H.A.) between November 1998 and May 1999.  
Furthermore, patient files were thoroughly perused in order to find evidence of past neurological 
disorders. The diagnosis of various NP syndromes was based upon the clinical impression 
following history, clinical neurologic examination and review of the medical records and 
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performance in neuropsychological testing. All past and present NP syndromes were listed and 
classified according to the standardized ACR nomenclature and case definitions (ACR 1999) (I and 
II) or according to the modified ACR nomenclature and case definitions (II) (III and IV) (Tables 3 
and 12). If one of the NP syndromes was identified, a patient was considered to have NPSLE. 
Individual disease activity was quantified by using the ECLAM (Vitali et al 1992). Accumulated 
NP abnormality was assessed by using the SLICC/ACR damage index (Gladman & Urowitz 1999). 
The NP manifestations of the damage index scored were cognitive impairment, major psychosis, 
seizures requiring therapy for 6 months, cerebral vascular accident, cranial or peripheral neuropathy 
(excluding optic) and transverse myelitis. Current and previous use of steroid and other 
immunosuppressive medication was recorded. A cumulative lifetime dose of glucocorticoids  
(expressed as grams of prednisolone) was determined from the patients’ records. 
 
 
2.2. Serological and immunological methods 
 
Blood samples for laboratory studies were obtained from all patients and controls at the time of the 
study. Laboratory tests included a complete blood count, erythrocyte sedimentation rate (ESR), 
serum complement components (C3, C4 and CH50), anti-dsDNA, ANA and APL. APL were tested 
measuring IgG type anticardiolipin antibodies (ACL) by ELISA (commercial kit). Results were 
expressed in GPL units. ACL were reported as either medium positive (15-80 GPL) or high positive 
(>80 GPL). In cases where ACL were positive, also 2-glycoprotein antibodies (2GPAbG) were 
measured by ELISA and reported as negative (<20 SGU) or positive (>20 SGU). In SLE patients, 
serum creatinine and urinalysis were also measured to determine the disease activity index. 
 
Quantitation of immunoreactive matrix metalloproteinase-9 (MMP-9) was carried out by enzyme-
linked immunosorbent assay (ELISA) (Diabor Ltd, Finland). This method is described in study III. 
The monoclonal antibody GE-213 recognizes both pro and activated forms of human MMP-9 and 
the complex of MMP-9 with its inhibitor TIMP-1 (Soini et al 1994, Nikkari et al 1996). In two 
patients and three controls, determination of MMP-9 level was not successful. 
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2.3. Neurophysiological methods 
 
Neurophysiological tests included electroneuromyography (ENMG), which was performed only on 
12 patients with clinical signs or symptoms suggesting polyneuropathy. 
 
 
2.4. Neuropsychological methods 
 
All patients and controls were submitted to a battery of standardized neuropsychological tests in 
order to detect possible impairment in one or more of the subsequent cognitive domains: simple 
attention, complex attention, memory, visuo-spatial processing, language, reasoning/problem 
solving, psychomotor speed, and executive functions. The test battery included is described in study 
I. It took an average of 3-4 hours to complete the assessment.  
 
The individual test results were converted into standard scores, which were compared with the 
available normative data (Delis 1987; Wechsler 1992; Lezak 1995; Heaton et al 1993). Regarding 
any of the eight cognitive domains, subjects with a total score of two or more standard deviations 
(SD) below the normative value were considered to be impaired. Premorbid level of functioning 
was estimated by using the two best scores from WAIS-R, excluding Digit Symbol Substitution 
Test and Digit Span. Education and occupation of the subject were taken into consideration in 
assessment of individual test performance. The same method was used to determine the highest 
level of functioning in controls. Cognitive dysfunction was classified as mild if there were deficits 
in less than three dimensions, as moderate if there were deficits in three or four dimensions, and as 
severe if there were deficits in at least five dimensions.  
 
Assessment of depression was based on clinical interview and the Beck Depression Inventory (BDI) 
(Beck et al 1974). On BDI, scores from 10 to 17 were considered to be mild, scores from 18 to 24 to 
be moderate and scores over 24 to indicate severe depression. However, the final grading of 
depression was based on a clinical interview by the psychologist. Anxiety was evaluated by the 
psychologist on clinical interview. 
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2.5. Neuroradiological methods 
 
Cerebral MRI was performed on 43 SLE patients and 43 healthy controls. The Signa Easy Vision 
1.5T MRI imaging system (General Electric Medical Systems, Milwaukee, WS, USA) was used for 
all examinations. All MRI scans were read in a blinded manner by an experienced neuroradiologist 
(PD) who did not have access to any demographic or clinical data. The MRI study was carried out 
within six months of the clinical evaluation (the mean time was 11.1+11.6 weeks for the SLE 
patients and 17.1+7.6 weeks for the controls). The MRI protocol included sagittal T1-weighted, 
axial T1-weighted, axial T2-weighted and coronal fluid-attenuated inversion recovery (FLAIR) 
sequences. The imaging protocol also included axial 3-dimensional (3-D) T2 fast spin-echo and 
gadolinium diethylenetriamine pentaacetic acid-enhanced 3-D T1 spoiled gradient images for 
segmentation and volumetric analysis. Segmentation and volumetric analysis were performed using 
the segmentation software called Anatomatic, operating in PC/Windows95
™
 environment 
(Heinonen et al 1998; Heinonen et al 1998; Dastidar et al 1999).  Segmentation and volumetric 
measurements of hypointense lesions in T1-weighted images and hyperintense lesions on T2-
weighted images were performed separately.  
 
The criteria for SLE-related imaging abnormalities were as follows: gliotic infarcts and gliotic 
plaques seen as hypointense lesions on T1-weighted images and microinfarcts, ischemic lesions, 
demyelinating plaques as well as small punctate white matter lesions localized to the periventricular 
and subcortical areas on T2-weighted images. Small age-related lesions were excluded from 
analysis. The criteria for age-related changes were as follows: small periventricular T2-weighted 
high signal intensity changes in the area of frontal and occipital horns; few scattered well-defined 
small-size (<3mm) T2-weighted high signal intensity changes in the area of centrum semiovale not 
visible on T1-weighted images, and widened Virchow-Robin spaces seen as low signal intensity 
areas on FLAIR images. Measurements were expressed as volume/cm
3
. 
 
The marker for cerebral atrophy was relative intracranial cerebrospinal fluid (CSF) space volume. 
Volumetric measurement of total CSF spaces was done by assessing the total volume of the 
ventricular and peripheral CSF spaces, expressed as volume/cm
3
. Total intracranial volume was 
measured by calculating together the volume of all the segmented grey and white matter and 
intracranial CSF spaces. Relative intracranial CSF space volume was determined by dividing the 
total intracranial CSF space volume by the total brain volume.  
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Inter- and intra-observer variability was studied to evaluate the accuracy of the volumetric 
measurement of the lesions; the methods and results are described in study IV. 
 
2.6. Statistical analysis 
 
The prevalence of each condition included in the ACR criteria was calculated for SLE cases and 
controls. The odds ratio (OR) was calculated as the ratio of discordant pairs with a positive case to 
pairs with a positive control.  The data were analyzed with conditional logistic regression methods, 
using presence or absence of SLE as the outcome measure and various diagnostic criteria as 
explanatory variables.  
 
Pearson Exact Chi-Square test for cross-tabulated data, two-sample Student´s T-test and Mann-
Whitney U-test were used to evaluate the association between the occurrence of any NP 
manifestation and current or prior steroid use. The limit for significance was set equal to 0.05.  
 
Differences in MRI parametres between the study groups were determined using the Mann-Whitney 
U Test. The correlations between MRI parametres and laboratory values and cumulative dose of 
glucocorticoids were analyzed using Spearman’s rank order correlation. The criterion for statistical 
significance was p-value less than 0.05. 
 
Differences in levels of serum MMP-9 between study groups were tested by using the Mann-
Whitney U Test or nonparametric ANOVA. The correlation between MRI parametres and serum 
MMP-9 levels was analyzed using Spearman’s rank order correlation. Differences in levels of 
serum MMP-9 between ECLAM and SLICC/ACR groups were tested by using analysis of variance 
(ANOVA). The criterion for statistical significance was p-value less than 0.05. 
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RESULTS 
 
 
 
1. Basic characteristics of SLE patients and controls 
 
 
The study group consisted of 39 female and 7 male SLE patients, with a mean age of 45+13 years 
(range 20-64), and a similar number of matched controls (Table 8). The mean disease duration since 
diagnosis of SLE was 14+8 years (range 2-37) and the mean number of ACR SLE criteria fulfilled 
was 5.5+1.2 (range 4-9) (Table 9). The mean ECLAM score was 1.7 (range 0-4) indicating a very 
mild disease activity. Patients had completed 13+2.7 (range 8-18) and controls 13+ 3.4 (range 7-20) 
years of education. At the time of the study, 25 patients (54%) were using glucocorticoids, seven 
(15%) were on antimalarials, five (11%) on azathioprine, two (4%) on methotrexate and one (2%) 
on cyclosporin. Nineteen patients (41%) were without specific medication. For those who had taken 
glucocorticoids, the median cumulative lifetime dose of prednisolone was 26 grams (range 1-89). A 
total of four patients (9%) had never used glucocorticoids. 
 
 
Table 8. Baseline characteristics of 46 SLE patients and 46 controls. 
________________________________________________________________________________ 
  SLE patients  Controls   
  Mean (SD)  Mean (SD) 
   
Age, years    45 (12.6)  45 (12.7)   
Sex (M/F)  7/39  7/39 
Disease duration,yrs 14.2 (8.0)  - 
Education years, mean 13 (2.7)  13 (3.4)   
______________________________________________________________________________ 
 
*Statistics:Mann-Whitney U Test 
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Table 9. The diagnostic ACR criteria in 46 SLE patients. 
 
____________________________________________________ 
 Criterion                                                   n (%) 
____________________________________________________ 
 
Malar rash   26 (57) 
Discoid rash    4 (9) 
Photosensitivity  28 (61) 
Oral ulcers    8 (17) 
Arthritis   31 (67) 
Serositis   12 (26) 
Renal disorder  18 (39) 
Neurologic disorder   4 (9) 
Hematologic disorder  33 (72) 
Immunologic disorder  43 (93) 
Antinuclear antibody  46 (100) 
_____________________________________________________ 
 
 
 
 
2. NP syndromes 
 
According to the ACR nomenclature and case definitions, at least one NP syndrome was identified 
in 42 of 46 patients (91%). Five patients (11%) had one, 12 patients (26%) had two, 15 patients 
(33%) had three, four patients (9%) had four, four patients had five (9%) and two patients (4%) had 
six NP syndromes, whereas only in four patients was no evidence of  NP syndromes detected. Np 
syndromes detected in patients and controls are shown in Table 10. 
 
The most frequent single manifestation was cognitive dysfunction, detected in 37 patients (80%). 
Memory dysfunction was the most affected domain registered in 20 patients (43%), followed by 
deficits in simple attention, visuospatial processing and psychomotor speed, each in 12 patients 
(26%). Only 14 out of 37 patients (38%) with cognitive dysfunction by testing complained of 
cognitive problems, mostly defined as impairment of memory, concentration and word finding. 
Similar complaints were also done by two patients showing no cognitive deficits by testing. 
 
Headache was diagnosed in 25 patients (54%). This syndrome consisted of migraine without aura in 
six (24 %), migraine with aura in 12 (48%) and tension headache in seven patients (28%). Cluster 
headache and pseudotumor cerebri were not detected.  
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Depression was detected in 15 patients by BDI and in five additional patients by psychological 
interview, totalling mood disorder in 20 patients (43%). It consisted of a major depressive-like 
episode in 18 and a mood disorder with mixed features in two patients. The severity was mild in 16 
and moderate/severe in four cases. 
 
Clinical findings possibly related to polyneuropathy were detected in 13 patients (sensory defects in 
four and sensorimotor in nine patients). However, only four patients had subjective symptoms (gait 
disorder, numbness). An ENMG was performed for 12 patients (one patient died before the 
examination) and the electrophysiological findings were consistent with polyneuropathy in only 
three of them. 
 
Seven patients (15%) had a history of cerebrovascular disease. Five patients had had a stroke 
syndrome, one of them twice. TIA was occurred in two patients, and in one patient, a chronic 
multifocal disease was diagnosed. No intracerebral hemorrhages were recorded. Mean time since 
the diagnosis of SLE to the occurrence of the first stroke or TIA was 10.7 years (range 1-18). In 
four patients cerebrovascular disease was concomitant with systemic disease activity. APL were 
moderately positive in four patients with cerebrovascular disease. 
 
Epileptic seizures were reported in four patients (9%). In three of them, the diagnosis of epilepsy 
had been made and they were all on anticonvulsants. The first seizure occurred in all of them after 
the diagnosis of SLE. One patient had experienced only one tonic clonic seizure, which had 
occurred during a disease flare. All three patients with epilepsy had a moderately positive level of  
APL. 
 
An acute confusional state had occurred in three patients (7%).  In two of them, symptoms had 
manifested simultaneously with a lupus flare. In one patient, mild disturbance of consciousness had 
lasted for a week, in the other, moderate symptoms had abated within a month. The third patient had 
experienced two severe episodes of confusional state within a year. At the first time, her symptoms 
improved a little within two weeks, leaving, however, a significant memory deficit as a residual 
symptom. After the second episode, further cognitive decline was noticed.   
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Three patients (7%) had a history of cranial neuropathy, which was in all cases an optic neuritis. In 
one patient, an optic neuritis had occurred 16 years before and in another 29 years before the 
diagnosis of SLE.  In the third patient, optic neuritis manifested 5 years after SLE diagnosis.  
 
One patient (2%) was diagnosed to suffer from myasthenia gravis. The duration of the disease was 
26 years and its severity according to Osserman classification was IIA (mild generalized 
myasthenia with no crises and good response to drugs). The presenting symptoms of myasthenia 
gravis included diplopia, bilateral ptosis, and physical activity related weakness of lower extremities 
and they appeared about ten years after the diagnosis of SLE 
 
One patient (2%) had a demyelinating syndrome. The neurological symptoms appeared with 
subacute onset 18 years after the diagnosis of SLE. In cerebrospinal fluid examination, IgG index 
was elevated and eight oligoclonal bands were present indicating intrathecal synthesis.  Increased 
signal in periventricular white matter and at the level of corona radiata on T2-weighted MRI scans 
was observed. Both aCL (151 GPL) and 2GPAbG (333 SGU) were in high positive range. 
 
One patient (2%) had had aseptic meningitis three years prior to the diagnosis of SLE. 
 
One patient (2%) had an episode of involuntary, choreoathetotic movements occurring in all limbs.  
The severity of the symptom was moderate.  This episode occurred nine years after the diagnosis of 
SLE and abated within a year without recurrence. It was associated with a disease flare.   
 
In addition, the following neurological symptoms, not included in the ACR nomenclature, were 
identified in SLE patients. Nine patients (20%) suffered from fatigue, three (7%) had essential 
tremor, and two had had bacterial meningitis. Writer’s cramp, myopathy, sleep apnea and carpal 
tunnel syndrome occurred each in one patient. Urinary problems occurred in five patients (11%). 
Four of them had slight/moderate urge incontinency and one patient slight difficulty in initiation. 
The diagnosis of fatigue and urinary problems was based entirely on subjective complaints of the 
patients.  
 
A total of six NP syndromes defined by ACR were not identified in this population. These include 
inflammatory demyelinating polyradiculoneuropathy, autonomic disorder, mononeuropathy, 
myelopathy, plexopathy and psychosis. 
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There was a statistically significant association between a history of headache and current steroid 
use (2= 4.114, p=0.043). Compared with other SLE patients, those with a history of epileptic 
seizures (65.0gm versus 23.0gm; t= 3.319, p= 0.002) or cerebrovascular disease (45.4gm versus 
22.7gm; t= 2.288, p= 0.028) had a higher cumulative lifetime dose of steroids. No other statistically 
significant associations between the occurrence of NP manifestation and steroid use were noticed. 
 
 
 
Table 10.  Neuropsychiatric syndromes in SLE-patients and controls   n  (%). 
 
Neuropsychiatric syndrome  Patient Control OR(95%CI) 
    n   (%) n   (%)  
  
 
Cognitive dysfunction   37  (80) 13  (28) 9.0  (2.7-29.7) 
  Mild    26 11 
  Moderate      7  2 
  Severe      4  0 
Headache    25  (54) 11  (24) 3.0  (1.3-7.1) 
  Migraine without aura      6   4 
  Migraine with aura   12  5 
  Tension headache    7  2 
Mood disorders   20  (44)  4   (9) 9.0(2.1-38.8) 
  Major depressive like episode  18  4 
  Mood disorder with mixed features    2  0 
Polyneuropathy   13  (28)  5  (11) 3.7  (1.0-13.1) 
  ENMG confirmation     3  0 
Cerebrovascular disease 
*
     7  (15)  0   
  Stroke syndrome     5 
  Transient ischemic attack     2 
  Chronic multifocal disease    1 
Anxiety disorder     6  (13) 3   (7) 2.0  (0.5-8.0) 
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Table 10.   continues 
___________________________________________________________________________ 
Neuropsychiatric syndrome  Patient Control OR  (95 %CI) 
    n  (%)  n  (%)                                    
 
Seizures     4   (9) 1   (2) 4.0  (0.5-35.8) 
Acute confusional state    3   (7)  0  
Neuropathy, cranial

    3   (7)  0   
Aseptic meningitis    1   (2) 0  
Demyelinating syndrome    1 0   
Movement disorder    1 0   
Myasthenia gravis    1 0   
___________________________________________________________________________ 
 
*
one patient had both a stroke and a TIA 

optic neuritis in all cases 
 
 
 
3. Validity of the ACR criteria for NP syndromes 
 
 
All syndromes included in the proposed ACR criteria for NPSLE were more frequent among SLE 
patients than controls (Table 10). However, most syndromes were also found among controls, 
which resulted in low specificity. At least one NP syndrome was identified in 42 SLE patients 
(91%) and 25 controls (54%). This corresponds to an odds ratio (OR) of 9.5, 95% CI 2.21-40.8, and 
yields a specificity of 0.46 (21/46) and a detection rate of 91% (42/46) among SLE patients (Table 
11). 
 
To improve the criteria, revised criteria based on objective findings only were constructed (Table 
12). Anxiety and headache were entirely excluded, as well as mild depression, mild cognitive 
dysfunction (with deficits in less than three dimensions) and polyneuropathy unconfirmed by 
ENMG. With these modifications, the proportion of controls fulfilling at least one of the criteria 
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was substantially lower (7% versus 54%). Also the proportion of SLE patients with at least one 
objective criterion was half of that for the proposed ACR criteria (46% versus 91%). With a cut-
point of one, the OR for the revised criteria was 7.00 (95% CI 2.09-23.47), with a specificity of 0.93 
(43/46) and detection rate among SLE cases 46% (21/46).  
 
No major differences in the validity of the revised criteria were observed, when compared by age, 
sex or disease duration. The revised criteria showed a slightly higher correlation with 
neuropsychiatric SLICC damage index than the proposed ACR criteria (r=0.79 versus 0.58, 
respectively). Neither ACR nor the revised criteria were correlated with current disease activity, as 
measured with ECLAM (r=0.08 for both). 
 
 
Table 11.  Number of the ACR criteria and the revised criteria for neuropsychiatric SLE 
among patient and control groups.  
___________________________________________________________________________ 
ACR criteria  Patients Controls OR (95%CI)  Specificity 
___________________________________________________________________________ 
>0  42 25 9.5 (2.2-40.8) 0.46 
>1  37 10 7.8 (2.7-22.0) 0.78 
>2  25 2 24.0 (3.3-177.4) 0.96 
>3  10  -    1.00 
Revised criteria 
>0  21 3 7.0 (2.1-23.5) 0.93 
>1  9  0   1.00 
>2   6  0    1.00 
>3   2  0   1.00 
___________________________________________________________________________ 
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Table 12.The modified criteria for neuropsychiatric SLE. 
_________________________________________________________________________________ 
 
 
Central nervous system   Peripheral nervous system 
______________________________________________________________________________
    
  Aseptic meningitis     Acute inflammatory demyelinating polyradiculo- 
  Cerebrovascular disease     neuropathy 
  Demyelinating syndrome    Autonomic disorder 
  Movement disorder (chorea)    Mononeuropathy, single/multiplex 
  Myelopathy      Myasthenia gravis 
  Seizure disorders     Neuropathy, cranial 
  Acute confusional state     Plexopathy 
  Cognitive dysfunction (moderate or severe)   Polyneuropathy (with ENMG confirmation) 
  Severe depression 
  Psychosis 
_________________________________________________________________________________ 
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4. Neuroradiological findings 
 
 
4.1. The values of MRI parametres 
 
The analysis based on Anatomatic
 
segmentation software showed that both the mean volume of T1-
weighted lesions (representing primarily gliotic infarcts) and the mean volume of T2-weighted 
lesions was higher in SLE patients than in controls (p=0.019 and p<0.0001, respectively). In the 
assessment of brain atrophy it was found that the mean relative intracranial CSF space volume was 
significantly higher in SLE patients compared with healthy controls (p<0.001). The values of MRI 
parametres in SLE patients and controls are described in study IV, Table 2. 
 
 
4.2. Association of MRI findings with NP manifestations 
 
The cerebral MRI parametres were determined separately in 19 patients with NPSLE and 24 
patients without (non-NPSLE). All the measured parametres were statistically significantly higher 
in patients with NPSLE than in patients with non-NPSLE (Table 2. in study IV).  
 
The relationship between MRI parametres and all but two NP manifestations was investigated in 
SLE patients (myasthenia gravis and polyneuropathy were excluded) (Table 13). SLE patients with 
cognitive impairment had more significant cerebral atrophy (p=0.008) and significantly larger 
volumes of T2-weighted lesions (p<0.001) and a trend for larger volumes of T1-weighted lesions 
(p=0.077) than patients who were tested as cognitively normal. The SLE patients with a history of 
cerebrovascular disease had increased volumes of T1-weighted lesions (p=0.004) and T2-weighted 
lesions (p<0.001), but also brain atrophy (p=0.001). SLE patients with epileptic seizures had more 
significant cerebral atrophy than patients without (p<0.001) and also T1-weighted lesions 
(p=0.049). Of the other neuropsychiatric manifestations only a single patient with a movement 
disorder had a statistically significantly higher volume of T1-weighted lesions than the patients 
without (p=0.047).  
 
Neuropsychiatric damage index SLICC correlated significantly with all the measured MRI 
parametres in SLE patients (Table 14). 
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Table 13. MRI volumes in the classified neuropsychiatric manifestations in 43 SLE patients. 
 
 
Neuropsychiatric 
manifestation  Relative intracranial CSF           
   volume 
  n mean p-level
*
   
      
    
Cognitive dysfunction 
 Yes 10 0.25 0.008   
No 33 0.17   
Cerebrovascular disease 
 Yes  6 0.28 0.001   
 No 37 1.18   
Seizure disorders    
 Yes 4 0.33 <0.001  
 No 39 0.18   
Severe depression  
 Yes 4 0.23 0.86   
 No 39 0.19 
Neuropathy, cranial 
 Yes 3 0.21 0.40 
 No 40 0.19   
Acute confusional state 
 Yes 2 0.26 0.20  
 No 41 0.19     
Movement disorder 
 Yes 1 0.32 0.14   
 No 42 0.19  
Aseptic meningitis 
 Yes 1 0.28 0.28   
 No 42 0.19   
Demyelinating syndrome 
 Yes 1 0.15 0.70  
 No 42 0.19    
 
 
Abbreviations: MRI, magnetic resonance imaging; SLE, systemic lupus erythematosus; CSF, 
cerebrospinal fluid. 
*Statistical significance was based on Mann-Whitney U-test 
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Table 13. continues 
 
 
T1-weighted lesions   T2-weighted 
   lesions         
Neuropsychiatric 
 manifestation n mean p-level
*
 mean p-level 
       
    
Cognitive dysfunction 
 Yes 10 0.98 0.077 2.01 <0.001 
 No 33 0.32  1.08    
Cerebrovascular disease 
 Yes  6 1.97 0.004 2.29 <0.001   
 No 37 0.23  1.13    
Seizure disorders    
 Yes 4 2.19 0.049 1.95 0.167  
 No 39 0.30  1.23   
Severe depression  
 Yes 4 0.14 0.762 1.59 0.319   
 No 39 0.50  1.27  
Neuropathy, cranial 
 Yes 3 0.19 0.911 1.51 0.451  
 No 40 0.49  1.28    
Acute confusional state 
Yes                  2 3.76 0.434 2.09 0.124  
No                 41 0.31  1.26    
Movement disorder 
 Yes 1 7.51 0.047 2.46 0.186 
 No 42 0.30  1.27  
Aseptic meningitis 
 Yes 1 0.00 0.698 2.12 0.233 
 No 42 0.48  1.28    
Demyelinating syndrome 
 Yes 1 0.36 0.465 1.67 0.791  
 No 42 0.47  1.29 
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4.3. Association of MRI findings with other clinical features 
 
 
Correlations between the MRI parametres and clinical features of patients (Table 14) and controls 
were measured. A significant correlation was detected between the duration of SLE and cerebral 
atrophy (r=0.39, p=0.010), but not between the disease duration and the volumes of T1-weighted or 
T2-weighted lesions. The volumes of T2-weighted lesions correlated positively with age both in the 
SLE patient (r=0.33, p=0.03) and in the control groups (r=0.42, p=0.005). A significant correlation 
between age and cerebral atrophy was also observed in the controls (r=0.53, p=0.020) but not in 
SLE patients. No significant correlation between MRI parametres and the activity index ECLAM 
was found. Similarly, no association was detected between MRI parametres and the use of 
medication, but a clear positive correlation between the cumulative dose of glucocorticoid and 
parameter of cerebral atrophy was found (p=0.023). 
 
In SLE patients, no association was detected between the MRI parametres and laboratory findings. 
Instead, in the control group, a positive significant correlation was found between the volumes of 
T2-weighted lesions and all the measured complement levels (r=0.31, p=0.04 for complement C3; 
r=0.49, p=0.001 for complement C4; r=0.36, p=0.02 for CH50) and between cerebral atrophy and 
complement C4 (r=0.44, p=0.003). 
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Table 14. Correlations of MRI volumes with various clinical features in 43 SLE patients. 
 
 
MRI parameter Age Duration Cumulative ECLAM NP-SLICC  
   of SLE dose of  score score 
    steroid  
Relative intracranial 0.22 0.39* 0.38* 0.040 0.69** 
CSF space volume  
T1-weighted volume 0.17 0.11 0.40* -0.23 0.52** 
T2-weighted volume 0.031* 0.19 0.22 -0.024 0.69** 
 
Abbreviations: MRI, magnetic resonance imaging; SLE, systemic lupus erythematosus; ECLAM , 
European Consensus Lupus Activity Measurement; NP-SLICC, Neuropsychiatric Systemic Lupus 
International Collaborating Clinics 
Statistical values were determined by Spearman’s rank order correlation test: * p<0.05, ** p<0.01 
 
 
 
5. Serological and immunological findings 
 
The mean level of MMP-9 in SLE patients was 56.7+39.4 g/l (mean+SD) and in controls 
58.8+23.9 g/l. The difference did not reach statistical significance (p=0.13). Other laboratory 
values in patients and controls are presented in Table 15. 
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Table 15.  Laboratory parametres of SLE patients and controls. 
 
________________________________________________________________________________ 
  SLE patients  Controls  p* 
  Mean (SD)  Mean (SD) 
    
Serum MMP-9 (g/L) 56.7 (39.4)  58.8 (23.8)  0.13 
B-Leucocytes (10
9
L
-1
) 5.7 (2.7)  6.0 (1.5)  0.20 
B-Haemoglobin (g/l) 131.0 (14.0)  134.2 (11.2)  0.28 
B-Thrombocytes (10
9
L
-1
) 253.4 (135.3) 250.0 (51.9)  0.38 
Serum C3 (g/L) 0.90 (0.31)  1.04 (0.20)  0.008 
Serum C4 (g/L) 0.14 (0.09)  0.22 (0.06)  <0.001 
Serum CH50 (unit/mL) 53.5 (24.3)  70.3 (17.4)  <0.001 
ESR (mm/h)  23.2 (16.3)  9.0 (6.3)  <0.001 
Anti-dsDNA(U/L) 159.4 (238.0) 40.2 (1.8)  <0.001 
ANA  1258.3 (1042.4) 90.4 (49.5)  <0.001 
ACL  12.9 (24.5)  2.3 (8.42)  <0.001 
______________________________________________________________________________ 
 
Abbreviations: MMP-9, matrix metalloproteinase-9; C3, C4 and CH50, complement levels; ESR, 
erythrocyte sedimentation rate; anti-dsDNA, anti-double stranded DNA antibodies; ANA, 
antinuclear antibodies; aCL, IgG type anticardiolipin antibodies. *Statistics:Mann-Whitney U Test 
 
 
5.1 Correlation of MMP-9 with serological indicators of disease activity  
 
Correlations between serological indicators of disease activity and MMP-9 levels in SLE patients 
and controls were measured (Table 3. in study III). A highly significant positive correlation was 
observed between serum MMP-9 levels and leucocytes both in patients and in controls (p <0.0001 
for both) and a significant negative correlation between serum MMP-9 levels and levels of anti-
dsDNA and ANA in SLE patients. No significant correlation of serum MMP-9 with aCL was 
detected.  
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A highly significant negative correlation was observed between serum ANA and a leucosytes 
(p=0.001) and a significant correlation between serum dsDNA and leucosytes (p=0.034). 
 
 
5.2. Association of serum MMP-9 levels with NP manifestations  
The relationship between concentrations of serum MMP-9 and NP manifestations in 44 patients 
with SLE was investigated (Table 16). The mean serum MMP-9 level in NPSLE patients (n=20) 
was 73.2 +46.1 g/l. and 42.8 + 26.8 g/l in non-NPSLE patients (n=24); the difference between 
mean values was statistically significant (p=0.009) (Figure 1. in study III). When evaluating serum 
MMP-9 concentrations in respect to different NP manifestations, the levels were significantly 
higher in patients diagnosed to be cognitively impaired (80.8+45.8 g/l) than in those with normal 
cognitive function (48.6+34.2 g/l; p=0.027). In other NP syndromes, no statistically significant 
higher or lower concentrations of MMP-9 were identified (Table 4. in study III). In SLE patients 
with polyneuropathy, mean serum MMP-9 levels were twice as high as in patients without 
polyneuropathy (106.2 g/l versus 53.0 g/l), but probably due to the small number of patients, the 
result did not reach statistical significance (p=0.087). This was also note in a single SLE patient 
with a demyelinating syndrome who had almost a threefold serum concentration of MMP-9 
compared with patients without this demyelinating syndrome (137.8 g/l versus 54.8 g/l, 
p=0.136).  
 
  
 
5.3. Association of serum MMP-9 levels with lupus disease activity and neuropsychiatric 
damage index   
 
Regression analysis to examine associations between levels of serum MMP-9 and SLE disease 
activity and NP damage indexes was performed. The mean ECLAM score was 1.6 (range 0 to 5) 
indicating a very low disease activity. There was no significant relationship between individual 
MMP-9 levels and ECLAM scores in ANOVA. The mean NP-SLICC damage value was also low, 
0.57+1.00. Unlike in ECLAM index, high serum MMP-9 levels tended to correlate with high NP-
SLICC damage indeces, reaching a statistical significance in ANOVA (p=0.048). 
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5.4. Association of serum levels of MMP-9 with treatment status  
 
The relationship between serum MMP-9 activity and treatment modalities in patients with SLE was 
investigated. No significant differences in serum levels of MMP-9 were found between the patients 
receiving either glucocorticoids or other immunomodulatory treatment and those who were not on 
any immunosuppressive treatment. Likewise, no significant correlation was observed between a 
cumulative lifetime dose of glucocorticoids and serum MMP-9 levels. 
 
 
5.5. Correlation of serum MMP-9 levels with MRI parameters   
 
In SLE patients, a positive significant correlation was observed both between the levels of serum 
MMP-9 and T1-lesions (r=0.33, p=0.031) and between the levels of serum MMP-9 and T2-lesions 
(r=0.37, p=0.015).  No association was detected between the levels of serum MMP-9 and relative 
intracranial CSF space volume (Table 16.). In healthy controls, no correlations between levels of 
serum MMP-9 and MRI parametres were found. 
 
 
 
 
Table 16. Correlation of matrix metalloproteinase-9 values with quantitative magnetic 
resonance imaging (MRI) volumes in patients with SLE. 
 
 
MRI- parameter     R p * 
 
T1-weighted volume, (cm
3
)    0.33 0.031 
T2-weighted volume, (cm
3
)   0.371 0.015 
Relative intracranial CSF space volume   0.092 0.564 
 
Abbreviations: CSF, cerebrospinal fluid.  
*Statistics: Spearman’s rank order correlation test. 
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DISCUSSION 
 
 
1. NP manifestations in patients with SLE 
 
All neuropsychiatric manifestations 
 
In this population-based study of 46 SLE patients, 91% were identified to have at least one NP 
syndrome. In previous studies, the prevalence of NPSLE has been significantly lower with 
psychiatric disorders and epileptic seizures being the most frequent NP manifestations (Estes & 
Christian 1971; Feinglas et al 1976; Gibson & Myers 1976; Grigor et al 1987; Sibley et al 1992).
 
The impact of those early works resulted in the selection of psychosis and epileptic seizures to 
represent neurological involvement as a part of the original diagnostic criteria for SLE. 
 
The main reason for the exceptionally high prevalence of NP involvement in this study may be that 
the ACR nomenclature and case definitions used as the basis of the classification of NP syndromes, 
includes a wide array of different neurological and psychiatric features. In most former studies the 
diagnosis of NPSLE was entirely based on major neurologic and psychiatric involvement, including 
cerebrovascular event, neuropathy, movement disorder, transverse myelitis, epileptic seizures, 
meningitis, organic brain syndrome and psychosis. In addition to these clinical syndromes, patients 
with SLE present with a number of minor neurologic and psychiatric problems. Although being 
now included in the ACR nomenclature, there is no unanimous agreement among investigators 
whether all these minor complications should be counted as manifestations of NPSLE or not. 
 
This study was the first one to utilize the ACR nomenclature, but later some studies based on it 
have been published. In their longitudinal study, Brey et al evaluated 128 unselected patients with 
SLE. The subjects had a mean age and a mean educational level similar to ours, but mean disease 
duration was lower. Investigators discovered one or more NPSLE syndromes in 80% of the patients. 
The ACR standardized neuropsychological testing was performed in a subset of 67 patients. As in 
our study, the three most common neuropsychiatric symptoms in this cohort were cognitive 
dysfunction (79%), headache (57%), and psychiatric disorders (Brey et al 2002). In a study by 
Afeltra et al, NPSLE was found in 72% of 61 SLE patients; the most common NP manifestation 
was again cognitive dysfunction in half of the patients, followed by mood disorders (27%), 
cerebrovascular disease (24%) and headache (21%). When patients with mild deficits were not 
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considered, the prevalence of cognitive dysfunction was decreased to 21%.  Prevalence of NPSLE 
was significantly higher in patients with APS (Afeltra et al 2003). In a retrospective review of 323 
consecutive patients with SLE, 185 (57%) had NP manifestations according to the ACR 
nomenclature (Sanna et al 2003). In a study by Hanly et al, the prevalence of NP disease in an 
unselected cohort of 111 SLE patients was 37% (Hanly et al 2004). In both of these latter studies, 
headache was the most frequent NP manifestation.  In summary, the minor NP manifestations are 
predominant NP features in newer studies based on the ACR nomenclature. 
 
Another important difference between this study and the former works is the patient selection. No 
other population-based study on the prevalence of NPSLE has been published so far. In the previous 
studies patients have been gathered from academic referral centers, which is likely to be biased in 
terms of disease severity in comparison with the general population. Furthermore, with the advent 
of more sensitive diagnostic tests and accompanying greater awareness of SLE, much milder forms 
of the disease are now being recognized than were a few decades ago. Especially the availability of 
standardized neuropsychological assessment technique has highlighted the awareness of cognitive 
deficits (Sibley et al 1992; Hanly et al 1997).  Unexpectedly, the total amount of NP manifestations 
in our work was higher than in older ones, but this fact can mainly be explicated by the use of ACR 
nomenclature as the basis of classification. The greater amount of minor NP manifestations, 
especially cognitive dysfunction must be associated with more sensitive diagnostic testing. 
 
  
Cognitive impairment 
 
Cognitive impairment was the most frequent finding occurring in 37 (80%) patients. Previously 
reported prevalence rates have been lower, ranging between 21-66% (Carbotte et al 1986; Hay et al 
1992; Hanly et al 1992; Ginsburg et al 1992; Hanly et al 1994; Hanly et al 1997). This may be 
partly explained by the higher mean age and longer disease duration of our patients than in the 
previous studies. Furthermore, the battery of neuropsychological tests carried out by us was 
extensive, requiring up to 3 hours to complete, compared to for example 1,5 h in some studies 
(Hanly et al 1992)  The most plausible explanation, however, pertains to the criteria of cognitive 
impairment. According to the ACR nomenclature, individual patients were defined as cognitively 
impaired if they demonstrated impairment in one or more of eight areas of cognitive ability. In 70% 
of our patients with cognitive impairment, the dysfunction was classified as mild, implying that the 
impairment was established in only one or two cognitive domains. Eleven patients had three or 
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more impaired areas, fulfilling the criteria for cognitive impairment used by Hanly et al. Based on 
this definition, only 24% of our study population would have been classified as having a cognitive 
impairment. This figure is in accordance with prevalence rates of 21% in a study of 70 unselected 
SLE patients and 26% in a study of 73 patients (Hanly et al 1992; Hay et al 1992). 
 
In the newer studies based on the ACR nomenclature system, the prevalence of cognitive 
impairment has varied between 3% and 79%. Brey et al found that cognitive dysfunction, detected 
by a battery of neuropsychological tests done in half of the patients, was the most frequent single 
NPSLE manifestation, with an overall prevalence of 79% but severe impairment was seen only in 
6% of the patients (Brey et al 2002). According to the Italian study including 61 SLE patients who 
all received neuropsychological testing, the prevalence of cognitive impairment was 52% (Afeltra et 
al 2003). In a Canadian study only three of 111 patients with SLE were found to have cognitive 
deficits. Neuropsychological testing, however was done only if indicated following clinical 
assessment (in six patients) (Hanly et al 2004). The lack of routinely used neuropsychological 
testing is supposed to lead to underestimate the actual prevalence rate of cognitive impairment and 
simultaneously the overall frequency of NP disease. This statement is supported by the finding that 
only 38% of our patients with cognitive dysfunction in neuropsychological tests complained of 
cognitive problems. 
 
Headache 
 
In this study population, 25 patients (54%) had suffered from headache, with a life-time prevalence 
of migraine and tension headache being 39% and 15%, respectively. In former studies, the 
prevalence of migraine in SLE has varied from 34% to 40% (Omdal et al 1988; Vazques-Cruz et al 
1990; Markus & Hopkinson 1992), but two studies found no difference in the occurrence of 
headache between SLE patients and matched controls (Sfikakis et al 1998; Ferdandez-Nebro et al 
1999). In a study by Brey, the prevalence rate of 57% was near ours (Brey et al 2002). There is 
controversy concerning headache as a NP manifestation. Episodes of migraine attacks have been 
reported to parallel the systemic disease activity in some patients (Brandt & Lessel 1978; Abel et al 
1980; Appenzeller & Costallat 2004), but they have also been associated with psychological distress 
and social problems (Sfikakis et al 1998; Waterloo et al 2000) 
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Psychiatric manifestations 
 
There is a wide variation in the reported prevalence of psychiatric manifestations. The majority of 
recent reports on NPSLE have focused on the occurrence of milder psychiatric features such as 
depression and anxiety, whereas, in contrast to older studies, low prevalence of psychosis has been 
noticed (Sibley et al 1992; Hay et al 1992). These results corroborate this finding: 80% of patients 
with mood disorder had mild depression requiring no medication, while nobody had experienced 
any episode of psychosis. In a study by Brey, the presence of psychiatric manifestations was 
common (74%), although past or current psychosis was rare (Brey et al 2002). So far, no consensus 
exists whether the minor psychiatric manifestations represent primary NPSLE.  
 
Cerebrovascular disease 
 
Cerebrovascular disease was diagnosed in seven (15%) of SLE patients. In other studies based on 
the ACR nomenclature, the frequency of cerebrovascular disease has varied from 2% to 18%, these 
rates are in accordance with older studies (Estes & Christian 1971; Feinglas et al 1976, Gibson & 
Myers 1976; Grigor et al 1987; Sibley et al 1992; Brey et al 2002; Sanna et al 2003; Hanly et al 
2004). Patients with SLE who have had a stroke or TIA are at high risk, up to 57%, for recurrent 
cerebral ischemia (Futrell et al 1992). Two of seven patients with cerebrovascular disease had a 
recurrence of stroke or TIA and one had a chronic multifocal disease. Previously it has been 
reported that the major period of risk for the first stroke is during the first five years of SLE (Futrell 
& Millikan 1989) but in our patients with cerebrovascular disease, range of time between the 
diagnosis of SLE and the first cerebrovascular attack was 1-18 years with the mean of 10.7 years. A 
significantly higher cumulative lifetime dose of steroids in SLE patients with a history of 
cerebrovascular disease obviously reflects the serious character of this subgroup.   
 
Neuropathy 
 
A mild, symmetrical distal sensory or sensorimotor neuropathy is the most common form of 
peripheral neuropathies in SLE. A 28% frequency of polyneuropathy in the present study is 
certainly overestimated, and greatly influenced by the fact that the ACR nomenclature system does 
not demand an ENMG confirmation of polyneuropathy. The corresponding prevalence of ENMG 
confirmed polyneuropathy in this series was 7%, being in accordance with the previous studies and 
near the prevalence rates in newer studies by Sanna and Costallat (2-3%) (Estes & Christian 1971; 
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Feinglass et al 1976; Gibson & Myers 1976; Grigor et al 1978; Omdal et al 1988; Hietaharju et al 
1993; Sanna et al 2002; Costallat et al 2001). In a study by Brey, the prevalence rate without 
ENMG confirmation was higher, 22% (Brey et al 2002). Becauce no quantitative sensory testing 
was performed in our study, there exists a possibility of small fiber polyneuropathy in patients with 
normal ENMG findings. If taken into consideration that only one of these patients had symptoms 
correlating with polyneuropathy, it can be assumed, that at least the majority of them had no 
neuropathy at all. 
 
Demyelinating syndrome 
 
One of the patients fulfilled the ACR nomenclature criteria for a demyelinating syndrome. A 
diagnosis of MS had been established, but it is assumed that the true cause for her neurological 
symptoms was APS. APS is defined by the persistent presence of APA in patients with recurrent 
venous or arterial thromboembolism or pregnancy morbidity. It can occasionally mimic MS (Scott 
et al 1994; Cuadrado et al 2000). This patient had neurological and MRI findings similar to MS, but 
a high positive titer of aCL together with the history of thrombocytopenia and deep venous 
thrombosis strongly favors the diagnosis of APS. Oligoclonal banding has been described to occur 
in patients with secondary APS due to SLE (Cuadrado et al 1994). It is to be recommended that 
future revisions of the ACR nomenclature system specifically exclude APS in the diagnosis of a 
demyelinating syndrome. 
 
2. Validity of the ACR nomenclature and case definitions 
 
In this population-based material, the ACR criteria and case definitions for NPSLE had a low 
specificity, i.e. they were not able to differentiate SLE patients from controls. Ideally, case 
definitions should be based on SLE activity in the nervous system manifested as neurologic 
dysfunction (Moore & Lisak 1995). No underlying neurologic dysfunction, however, has been 
demonstrated for several syndromes listed under case definitions in the current ACR nomenclature 
for NPSLE. A more stringent set of criteria based solely on manifestations of neurologic injury is 
proposed. 
 
Signs of minor CNS dysfunction were frequent among both SLE patients and controls, which led to 
poor specificity and lack of distinction between the two groups.  For example, it is very difficult to 
justify the inclusion of headaches: although they were more common among cases than controls 
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(54% vs. 24%), the high prevalence among controls did not allow distinction between NPSLE and 
other conditions manifesting as headache. It has been reported that up to 40% of individuals 
experience severe disabling headache at least one per year (Jennekens & Kater 2002). In a 
Norwegian study, headaches were not associated with SLE disease activity (Waterloo et al 2000). 
Tension-type headache in SLE patients was associated with psychological distress and depressive 
mood, while migraine was associated only with a tendency to social isolation and anxiety. Thus, 
although headache might be a component of active SLE in individual patients, it is more likely that 
the majority of headaches in SLE patients are due to non-SLE causes. Furthermore, ACR case 
definitions do not include EMG for diagnosing polyneuropathy. The results of this study, with more 
than 10% of controls presenting with sensory or motor symptoms, indicate that subjective 
symptoms are too vague and unspecific and EMG confirmation is required to demonstrate 
neurologic injury.  
 
Despite its frequency, mild cognitive dysfunction was not specific for NPSLE as it was also 
detected in a quarter of controls.  According to ACR case definitions, documented impairment in 
one of the cognitive domains is sufficient for the diagnosis of cognitive dysfunction.  Previously, it 
has been proposed that the minimum of three impaired domains are required (Hanly et al 1992). 
Results of this study indicate that this is required for detecting clinically relevant 
neuropsychological defect. 
 
Mild depression and anxiety are common in otherwise healthy subjects and even more so among 
patients with chronic diseases (Patton et al 1999, Soderlin et al 2000). They can be regarded as 
psychological responses to illness and therefore are not specific for NPSLE (Rogers et al 1996). 
Functional brain imaging techniques have demonstrated that major depression is associated with 
both reversible and irreversible neurophysiological abnormalities in some structures (Drevets 1998). 
An association to APL and anti-ribosomal-P-antibodies has also been found (Arnett et al 1996). 
Major depression can be considered analogous to psychosis in psychiatric morbidity, and its 
inclusion in the diagnostic criteria for NPSLE is justified. 
 
The results of this study demonstrate inadequate performance of the proposed ACR criteria. It 
appears that there are no pathognomic manifestations, but NPSLE has shared features with other 
CNS conditions. Therefore, revised criteria are needed to distinct NPSLE from other conditions. 
Discriminating accurately between NP manifestations truly attributable to SLE is of highest 
importance to achieve homogenous patient subsets, a prerequisite for studies focused on 
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pathogenesis. We derived criteria based on neurologic injury or dysfunction and excluded 
conditions that may not indicate a neurologic dysfunction. Higher correlation of SLICC with the 
revised criteria than ACR criteria lends further credence to our approach.  To support the basis of 
classification, further research on organic nervous system damage with pathogenetic mechanisms 
specific to SLE is warranted. 
 
Our revised criteria for NPSLE have already been used in an international inception cohort study, in 
which 572 patients with SLE were enrolled within 15 months after having fulfilled the ACR SLE 
classification criteria. All NP events were identified using the ACR case definitions. Decision rules 
were derived to determine the proportion of NP disease attributable to SLE, and onset of an NP 
event prior to the enrollment window, the identification of at least one non-SLE factor or  the 
occurrence of minor NP events defined by our study classified the NP event as not attributable to 
SLE. The results indicate that 158 patients (28%) had at least one NP event around the time of 
diagnosis of SLE, of which only a minority (19%-38%) were attributed to SLE. However, formal 
neuropsychological assessments were not performed routinely on all patients and the 5.4% 
prevalence of cognitive dysfunction suggests an underestimation of clinically important cognitive 
disorders. An interesting finding in this study was that regardless of attribution, the occurrence of 
NP events in these newly diagnosed patients was associated with reduced quality of life and 
increased organ damage   (Hanly et al 2007). 
 
Jennekens and Kater have systematically searched the literature from 1980 to 2002 for CNS 
manifestations in SLE. The syndromes found were evaluated with the authors´ inclusion criteria for 
SLE attribution. They ended up with 16 syndromes and compared their findings with the ACR case 
definitions. They consider as a disadvantage of the ACR system the concealment of differences in 
health risks by pooling the items. Furthermore, the items of the system do not all belong to the same 
dimension; one is pathological and the others are clinical. The authors have proposed a modification 
of the ACR nomenclature system. Migraine is left out since the investigators cannot find any 
support for SLE induction. Anxiety and mood disorder have been included to the modified system 
but they should be handled separately, since they are likely to be predominantly psychoreactive in 
many patients though, in some cases, there may be a role for biological factors. Acute confusional 
state is replaced by delirium, as this term is used by DSM-IV. Demyelination syndrome is replaced 
by “myelopathy and optic neuropathy (Devic`s syndrome)” which refers to clinical syndromes in 
contrast to demyelination syndrome, which has no clear clinical annotation. (Jennekens & Kater 
2002). 
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Despite of its deficiency, the ACR nomeclature is a step into the right direction in evaluating SLE 
patients with NP disorders. These criteria will certainly increase the consistency in the classification 
of patients and standardize clinical descriptions in clinical research. The identification and 
categorization of the major neurological and psychiatric syndromes in SLE seems to be adequate. It 
is hoped that in future the understanding of mechanisms of the minor NP manifestations will be 
improved, leading to more precise formulation of the classification criteria of NPSLE. 
 
 
 
3. Neuroradiological findings in patients with NPSLE 
 
Brain atrophy 
 
SLE patients had more evidence of cerebral atrophy in MRI scans than the controls, this result 
supports previous findings (McCune & Golbus 1988; Chinn et al 1997; Kozora et al 1998). The 
aetiology of cerebral atrophy in SLE patients is unknown. It has been suggested to reflect an 
ongoing CNS involvement, to result from a long-standing glucocorticoid use, or to be a 
combination of both of these processes (Kovacs et al 1993). In our SLE patients, a clear correlation 
was detected between cerebral atrophy and the cumulative dose of glucocorticoids but the current 
use of glucocorticoids or any other medication was unrelated with atrophic changes. Chinn et al 
(Chinn et al 1997) found no association between either the current or past use of steroids or the total 
amount of steroid used and the presence of atrophy in 47 SLE patients, but in another study, a trend 
for significant relationship between cerebral atrophy and prednisone dose was observed (Kozora et 
al 1998).  In recent studies, Appenzeller and colleagues detected no association between the total 
corticosteroid use and cerebral and corpus callosum volumes in adult SLE patients but an 
association with hippocampal atrophy was found (Appenzeller et al 2005, Appenzeller et al 2006). 
Brain MRI abnormalities were recently reported in a consecutive cohort of 97 SLE patients enrolled 
within 9 months of diagnosis. Brain atrophy was seen in 18% of patients, which suggests that the 
brain may be affected early in the course of SLE. Although perhaps worsened by high cumulative 
corticosteroid use, the development of brain atrophy may not be dependent of it (Muscal & Brey 
2010). 
 
It has been speculated whether cerebral atrophy is responsible for some of the NP manifestations 
related to SLE (Kovacs et al 1993). In this study, the patients with NPSLE had higher volumes 
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indicating cerebral atrophy than the patients without NPSLE. Furthermore, cerebral atrophy was 
increased in SLE patients with cognitive dysfunction, cerebrovascular disease and seizure disorder 
compared with SLE patients without these NP manifestations. Previously, no correlation has been 
demonstrated between quantitative measures of non-specific abnormalities in cerebral MRI and 
measures of brain function. Kozora et al found no association between cerebral lesions measured by 
quantified MRI analyses and functional abnormalities determined by comprehensive 
neuropsychological testing in 20 SLE patients without overt central nervous system disease (Kozora 
et al 1998). After our work, in one study a reduction in cerebral and corpus callosum volumes was 
demonstrated to associate with cognitive impairment and other CNS manifestations (Appenzeller et 
al 2005). Our results are also in accordance with a study by Bosma et al, in which the presence of 
cognitive dysfunction and psychiatric abnormalities in a sample of 24 patients with NPSLE 
correlated with cerebral atrophy. This study utilized a new sensitive MRI technique, volumetric 
magnetic transfer imaging (MTI). Contrary to the findings of this study, the results did not indicate 
a relationship between duration of SLE and cerebral atrophy (Bosma et al 2002) 
   
T1- and T2-weighted lesions 
 
In our study, the volumes of both T1- and T2-weighted lesions were significantly higher in SLE 
patients than in controls. Similarly, NPSLE patients had increased volumes of both lesion types in 
comparison with non-NPSLE patients. T1-weighted lesions included only gliotic infarcts and gliotic 
demyelinating lesions, T2-weighted ones also microinfarcts, ischemic lesions and non-gliotic 
demyelinating lesions. It is generally known, that T2-weighted images of the brain reveal in many 
SLE patients small punctate lesions localized mainly in the periventricular and subcortical white 
matter. These lesions may represent small-vessel vasculopathy, which has been suggested to be a 
pathogenetic mechanism in those SLE patients who have cognitive disorder as a sole 
neuropsychiatric manifestation (Jennekens & Kater 2002). Our results support this hypothesis since 
volumes of T2-weighted lesions were statistically significantly higher in SLE patients with 
cognitive dysfunction than those without. On the other hand, the volumes of T1-weighted lesions 
representing gross infarcts did not have an association with cognitive impairment.  
 
Correlations to ECLAM and SLICC 
 
SLE activity index ECLAM score did not correlate with any of the MRI parameters. In two 
previous studies, such correlation has been noticed (Cauli et al 1994; Taccari et al 1994). The 
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opposite findings may be due to considerably low ECLAM scores in SLE patients of this study, 
since most of them were in good health at the time of the assessment. Instead, neuropsychiatric 
SLICC damage index score correlated positively with all the measured MRI parameters. This is in 
accordance with the results of Sanna et al, demonstrating the presence of significantly higher values 
of SLICC score in patients with abnormal brain MRI (Sanna et al 2000). Of other clinical features, 
person’s age correlated positively with the volumes of T2-weighted lesions both in patients and in 
controls.  
 
The present study confirms in a population-based sample that both brain atrophy and occurrence of 
gliotic infarcts, microinfarcts, other ischemic lesions and demyelinating lesions were significantly 
more common in patients with SLE than in general population. Second, previous studies have not 
been able to show any relationship between cerebral MRI abnormalities and specific 
neuropsychiatric dysfunctions. In this study, cerebral atrophy correlated with cognitive dysfunction, 
cerebrovascular disease and seizure disorder. Contrary to other findings, a clear correlation was also 
detected between cerebral atrophy and the cumulative use of corticosteroids.  
 
 
 
4. Serum levels of MMP-9 in patients with NPSLE 
 
MMPs are a family of zinc-containing endo-proteinases produced by a variety of inflammatory 
cells. All of the cell types that exist in the CNS are potential sources of MMPs. (Lijnen 2001; 
Trysberg & Tarkowski 2002). The growing list of MMPs is currently grouped into collagenases, 
gelatinases, stromelysins and membrane-type MMPs (Cuzner & Opdenakker 1999). So far, a total 
of 22 human MMPs have been identified (Kalela 2002). 
 
MMPs can degrade a variety of extracellular matrix components (Lijnen 2001). They have a 
multitude of regulatory functions, including control of influx of inflammatory mononuclear cells 
into the CNS, participation in myelin destruction and disruption of the integrity of the blood-brain 
barrier (Trysberg & Tarkowski 2004). The extracellular matrix alterations mediated by MMPs are 
critical for normal development and tissue homeostasis but they are also central to a range of 
pathological processes (Sobel 2001). Increased activity of MMPs has been implicated in numerous 
disease processes including malignancies, cardiovascular diseases and autoimmune diseases such as 
multiple sclerosis, Guillain-Barré syndrome, and rheumatoid arthritis (Gijbles et al 1992; Ahrens et 
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al 1996; Zucker et al. 1999; Lee et al 1999; Cuzner & Opdenakker 1999; Creange et al 1999; Kalela 
et al 2002).  
 
Serum levels of MMP-9 
 
In the present study, the serum levels of MMP-9 were analyzed. No significant difference in the 
consentration of serum MMP-9 was found in SLE patients and controls. This finding is not in 
accordance with a previous study, which showed a significant increase of MMP-9 activity in the 
sera of 40 SLE patients compared with 25 healthy controls (Faber-Elmann et al 2002). However, 
our patients with NPSLE had significantly higher levels of serum MMP-9 than the patients without. 
In addition, a positive correlation of serum MMP-9 levels with NP-SLICC index was detected. 
These two observations corroborate the primary hypothesis according to which MMP-9 levels may 
reflect CNS injury in SLE patients.  
 
Our results are supported by a recent study by Trysberg et al, in which intrathecal MMP-9 levels 
were determined in 123 patients with SLE. Intrathecal MMP-9 levels were significantly increased in 
patients with NPSLE compared with SLE patients without CNS involvement. In this study, 
significant correlations between MMP-9 and intrathecal levels of neuronal and glial degradation 
products were also noted, indicating ongoing intrathecal degeneration in the brains of SLE patients 
expressing MMP-9 (Trysberg et al 2004). 
 
MMP-9 and ECLAM 
 
It has been speculated upon whether MMPs are related to disease activity in SLE or not. In a 
previous study, a positive correlation between MMP-9 concentration and disease activity scores was 
observed but only in men (Faber-Elman et al 2002). In this study, no association between MMP-9 
levels and ECLAM scores was found in either sex. This may be partly explained by that at the time 
of the assessment, the majority of our patients were in good health and, as a consequence, the 
ECLAM scores in general were not high. In fact, if the levels of MMP-9 truly parallel the disease 
activity, they would be expected to be low in our patients. 
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MMP-9 and vasculopathy 
 
Cerebral small-vessel vasculopathy has been suggested to underlie the cognitive disorder in SLE 
(Jennekens & Kater 2002); present findings support the hypothesis since volumes of T2-weighted 
lesions were statistically significantly higher in SLE patients with cognitive dysfunction than in 
those without. Moreover, the patients with cognitive deficits had higher serum concentrations of 
MMP-9 than patients who had normal cognitive functions. In addition, in SLE patients, serum 
MMP-9 levels associated with T1- and T2-hyperintensities in MRI scans. These findings tempt us 
to speculate that MMP-9 concentration relates to the underlying pathological process, small-vessel 
vasculopathy. The pathogenesis of vasculopathy in the brain is not clear (Jennekens & Kater 2002). 
The finding of the association between leucocyte count and serum MMP-9 concentration in both 
SLE patients and in healthy controls confirms previous reports by Kalela et al. and supports the 
concept of MMP-9 being a useful marker of inflammation (Kalela et al 2000). Furthermore, these 
findings may indicate that there is an inflammatory process behind small angiopathic changes in the 
brain of SLE patients. The elevated MMP-9 levels in SLE patients with cognitive dysfunction may 
reflect an ongoing active process, since elevated plasma MMP-9 concentrations after acute coronary 
syndromes and successful reperfusion of acute myocardial infarction are reversible and gradually 
decrease to the level of normal control subjects (Kalela et al 2002; Hirohata et al 1997; Kai et al 
1998).  
 
MMP-9 in neurological diseases 
 
This study was the first to investigate the correlation of serum MMP-9 concentration with MRI 
abnormalities in SLE, but the results are in agreement with former studies of MMP-9 levels, which 
have shown increase of MMP activity in patients with stroke and vascular dementia i.e., clinical 
states associated with vasculopathy (Hughes et al 1998; Rosenberg et al 2001). In line with present 
findings in SLE patients, a significant positive correlation between high serum levels of MMP-9 
and the number of T1-weighted gadolinium-enhancing MRI lesions in MS patients has been 
reported (Lee et al 1999). Increased CSF and serum levels of MMP-9 in patients with MS and 
expression of MMP-9 in demyelinating lesions have suggested that MMPs may have importance in 
the pathogenesis of this disease (Gijbles et al 1992; Lee et al 1999; Cuzner et al 1999). MMP-9 has 
also been related to other autoimmune disorders such as Guillain-Barré syndrome and experimental 
autoimmune neuritis (Hughes et al 1998; Creange et al 1999). In relation to these diseases, it has 
been assumed that MMP-9 participates in degradation of myelin basic protein, a major component 
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of both CNS and peripheral nervous system myelin (Creange et al 1999). Interestingly, 
demyelinating syndrome, which may clinically resemble MS, is listed as one of the manifestations 
of NPSLE.  In this study, one of the patients was diagnosed to have a demyelinating syndrome and 
she had a high consentration of MMP-9. 
 
This study is the first one to evaluate MMP-9 concentration in NPSLE. It suggests that elevated 
levels of serum MMP-9 in patients with SLE may indicate NP involvement. Thus, a determination 
of serum MMP-9 level may be a useful tool in follow-up of these patients and give support to the 
clinical suspicion of NPSLE. High serum levels of MMP-9 in a SLE patient should keep the 
clinicians on the alert for small-vessel cerebral vasculopathy and prompt them to evaluate the 
presence of additional stroke risk factors and need for possible therapeutic measures. A tendency to 
cognitive dysfunction in SLE patients with high MMP-9 concentration should also be taken into 
consideration.  
 
 
 
Study limitations 
 
This case series consisted of a population-based prevalence sample of SLE patients; a need for this 
kind of study design has widely been recognized. The participation rate of 78% in this study is very 
good. Prevalence sampling has a disadvantage of selecting less severe cases with favorable 
prognosis (Rothman & Greenland 1998). In present study, however, both deceased subjects and 
non-participants had a lower mean ACR score than participants, indicating lack of selection by 
severity. The differences between evaluated patients and eligible patients who could not be enrolled 
were small and are not likely to substantially effect the results. 
 
The lifetime incidence of the various syndromes may be skewed by the intensive search for 
cognitive syndromes contrasted with the less intensive search for subtle cerebral infarcts. In our 
study, however, we tried to follow the ACR case definitions as accurately as possible and, as stated 
by ACR on cerebrovascular disease, “the finding of unidentified bright objects on MRI without 
clinical manifestation is not classified at the present time”. On the other hand, ACR definitions 
imply that all eight cognitive domains should be included in neuropsychological tests. 
 
90 
 
The main weakness of the study is a small sample size and therefore the results need to be 
interpreted with caution. As a cross-sectional study, the validity of disease history depends on the 
documentation of past disease episodes. It is assumed, that this is unlikely to have a substantial 
effect on the prevalence rates of the NP syndromes, but reliable discrimination between primary 
NPSLE (i.e. caused by immune-mediated direct or indirect effects), secondary NPSLE and 
concurrent disease process becomes problematic. It has been estimated that two thirds of NP 
manifestations in SLE are not directly related to primary NPSLE, but to secondary causes such as 
drugs, infections and  metabolic complications of the disease (secondary NPSLE) (Kovacs et al 
1993; Moore & Lisak 1995).  Prospective analyses would help in discriminating between primary 
and secondary NPSLE. 
 
A study base was defined and all prevalent cases of SLE and population-based controls in it were 
identified. Matching for age, sex and education was used to maximize comparability between cases 
and controls, as well as to minimize loss of information. Ideally, the performance of a diagnostic 
test is assessed against a golden standard revealing the true disease status. However, as no golden 
standard is available for determining the presence of NPSLE, SLE was used as a surrogate measure 
of NPSLE. This is justified by the fact that in a case-control study, specificity in case ascertainment 
is more important than sensitivity, as it results in loss of statistical power, but does not bias the 
results (Drevets et al 1998). Lack of golden standard is likely to underestimate the sensitivity as the 
reference is SLE patients, all of whom do not have NPSLE. Small sample size limited the statistical 
power of the analyses, therefore rare syndromes as manifestations of NPSLE could not be assessed 
in this material. Further studies with larger patient populations are likely to reveal more subtle 
differences between SLE patients and controls. 
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SUMMARY AND CONCLUSIONS 
 
1. At least one NP syndrome was identified in 91% of SLE patients in this population-based study. 
The most frequent single manifestation was cognitive dysfunction followed by headache and mood 
disorder. When mild NP syndromes (mild cognitive deficit, headache, mild depression, anxiety and 
polyneuropathy with normal ENMG findings) were excluded, the prevalence of NPSLE dropped to 
46%. 
 
2. The proposed 19 ACR criteria for NPSLE are neither able to differentiate SLE patients from 
controls nor NPSLE patients from non-NPLSE patients. New revised criteria based on neurologic 
injury and dysfunction were derived and they performed well in this study population.  
 
3. Brain atrophy, cerebrovascular and demyelinating lesions are significantly more common in 
patients with SLE than in general population. Cerebral atrophy in SLE patients is associated with 
cognitive dysfunction, cerebrovascular disease and seizure disorder. There is a connection between 
cerebral atrophy and the cumulative dose of glucocorticoids in patients with SLE.  
 
4. Elevated levels of serum MMP-9 in patients with SLE may indicate NP involvement, especially 
cognitive dysfunction. A determination of serum MMP-9 level can be a useful tool in follow-up of 
SLE patients and give support to the clinical suspicion of NPSLE. High serum levels of MMP-9 in 
SLE patients may reflect small-vessel cerebral vasculopathy and should prompt the clinicians to 
evaluate the presence of additional stroke risk factors and need for possible therapeutic measures. 
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The prevalence of neuropsychiatric
syndromes in systemic lupus
erythematosus
H. Ainiala, MD; J. Loukkola, MA; J. Peltola, MD; M. Korpela, MD, PhD; and A. Hietaharju, MD, PhD
Article abstract—Objective: To describe the prevalence of neuropsychiatric (NP) syndromes in a Finnish population of
patients with systemic lupus erythematosus (SLE) and to classify them according to the recently developed American
College of Rheumatology (ACR) nomenclature and case definitions for NPSLE. Methods: Cross-sectional, population-based
study covering an area with 440,000 people. A total of 58 patients with a definite diagnosis of SLE and aged 16 to 65 years
were found in the computerized database of the area hospitals. Of these, 46 (79%) agreed to participate. The diagnosis of
various NP syndromes was based on clinical impression (H.A.) following history, examination, review of medical records,
and neuropsychologic testing. Results: At least one NP syndrome was identified in 42 patients (91%). The most frequent
manifestation was cognitive dysfunction (n 5 37; 81%), followed by headache (n 5 25; 54%) and mood disorder (n 5 20;
43%). When mild NP syndromes (mild cognitive deficit, headache, mild depression, anxiety, electroneuromyography-
negative polyneuropathy) were excluded, the prevalence of NPSLE dropped to 46%. Conclusions: According to the ACR
nomenclature, there is a high prevalence of NP manifestations in a population-based sample of patients with SLE. Most
NP syndromes were classified as minor; if they were excluded, the 46% prevalence of NPSLE would be slightly less than
estimated in previous studies.
NEUROLOGY 2001;57:496–500
A challenging problem in systemic lupus erythema-
tosus (SLE) is the diagnosis and management of neu-
ropsychiatric (NP) involvement. NPSLE may present
with serious manifestations (e.g., acute confusional
state, seizure disorder, and stroke), but more subtle
deficits such as mild cognitive dysfunction have also
been recognized.1,2 The prevalence of NPSLE ranges
widely between 14 and 75%, reflecting variable diag-
nostic criteria and differences in selection of patients
for study.3,4 A former definition for NPSLE in the
1982 revised American College of Rheumatology
(ACR) criteria for SLE is inadequate because only
two elements, psychosis and seizures, were includ-
ed.5 The ACR has recently developed a standardized
nomenclature system which provides case definitions
for 19 NP syndromes seen in SLE, including report-
ing standards and recommendations for laboratory
and imaging tests.6
We studied the prevalence of NP syndromes in a
Finnish population-based cohort of patients with
SLE and classified the syndromes according to the
ACR nomenclature and case definitions.
Patients and methods. Patient selection. The study
base was Pirkanmaa Health Care District located in south-
ern Finland with a population of 440,000. The majority of
new patients with SLE in the area are seen at Tampere
University Hospital. We identified patients with SLE us-
ing the computerized databases of Tampere University
Hospital, the three District Hospitals, and the local outpa-
tient clinic. Medical records of both in- and outpatients
coded for the diagnosis of SLE between January 1980 and
December 1997 were examined to select patients who ful-
filled four or more of the 1982 revised ACR criteria for the
disease,5 were aged 16 to 65 years and of native Finnish
origin, and resided in the study area. We excluded patients
with another connective tissue disease.
We identified 110 patients with SLE. Of these,15 pa-
tients had died and 37 did not meet the inclusion criteria.
The remaining 58 patients were contacted by mail, and 46
of them (79%) agreed to participate in the study. All partic-
ipants gave written informed consent. The study protocol
was approved by the local Ethics Committee.
Clinical and laboratory evaluation. The diagnosis of
various NP syndromes was based on clinical impression
(H.A.) following history, examination, review of medical
records, and neuropsychologic testing. All past and current
NP syndromes were listed and classified according to the
standardized ACR nomenclature and case definitions6 (ta-
ble1). Individual disease activity was quantified by using
Additional material related to this article can be found on the Neurology
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tents for the August 14 issue to find the title link for this article.
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the European Consensus Lupus Activity Measurement
(ECLAM) scale.7 Current and previous use of steroid
and other immunosuppressive medication was recorded.
Cumulative lifetime dose of steroids (expressed as grams of
prednisolone) was determined from the patients’ records.
Electroneuromyography (ENMG) was performed on patients
with clinical signs/symptoms suggesting polyneuropathy.
Besides routine serological tests, IgG-type anticardiolipin an-
tibodies (aCL) and B2-glycoprotein antibodies (B2GPAbG)
were measured by ELISA (commercial kit).
Neuropsychologic measures. All patients were submit-
ted to a battery of standardized neuropsychologic tests to
detect possible impairment in one or more of the subse-
quent cognitive domains: simple attention, complex atten-
tion, memory, visuo-spatial processing, language,
reasoning/problem solving, psychomotor speed, and execu-
tive functions. The tests were administered by a trained
psychologist. It took an average of 3 to 4 hours to complete
the assessment. The individual test results were converted
into standard scores, which were compared with the avail-
able normative data.8-12 Regarding any of the eight cogni-
tive domains, subjects with a total score of two or more
standard deviations (SD) below the normative value were
considered to be impaired. Cognitive dysfunction was clas-
sified as mild if there were deficits in less than three
dimensions, as moderate if there were deficits in three or
four dimensions, and as severe if there were deficits in at
least five dimensions.
Assessment of depression was based on clinical inter-
view and the Beck Depression Inventory (BDI).13,14 On
BDI, scores from 10 to 17 were considered to indicate mild
depression, from 18 to 24 moderate depression, and
greater than 24 severe depression. However, the final
grading of depression was based on a clinical interview by
the psychologist. Anxiety was evaluated by the psycholo-
gist on clinical interview.
Statistical analysis. Pearson exact x2 test for cross-
tabulated data, two-sample Student’s t-test, and Mann–
Whitney U test were used to evaluate the association
between occurrence of any NP manifestation and current
or prior steroid use. The limit for significance was set
equal to 0.05.
Results. We studied 39 women and seven men, with a
mean age of 45 6 13 years (range 20 to 64). The mean
disease duration since diagnosis of SLE was 14 6 8 years
(range 2 to 37). The mean number of ACR SLE criteria
fulfilled was 5.5 6 1.2 (range 4 to 9). The mean level of
education was 13 6 3 years (range 8 to 18). The mean
ECLAM score was 1.6 (range 0 to 5), indicating a very mild
disease activity. At the time of the study, 25 patients (54%)
were using glucocorticoids, seven (15%) were on antima-
larials, five (11%) on azathioprine, two (4%) on methotrex-
ate, and one (2%) on cyclosporin. Nineteen patients (41%)
were without specific medication. For those who had taken
steroids, the mean cumulative lifetime dose of pred-
nisolone was 26 g (range 1 to 89). A total of four patients
(9%) had never used corticosteroids.
At least one NP syndrome was identified in 42 patients
(91%). Five patients (11%) had one, 12 patients (26%) had
two, 15 patients (33%) had three, four patients (9%) had
four, four patients (9%) had five, and two patients (4%)
had six NP syndromes, whereas only in four patients was
no evidence of NP syndromes detected (table 2).
The most frequent single manifestation was cognitive
dysfunction, detected in 37 patients (81%). Memory dys-
function was the most affected domain registered in 20
patients (43%), followed by deficits in simple attention,
visuospatial processing, and psychomotor speed, each in 12
patients (26%). Only 14 of 37 patients (38%) with cognitive
dysfunction by testing had cognitive problems. Headache
was diagnosed in 25 patients (54%). Depression, consisting
of a major depressive-like episode of mostly mild severity
in 18 and a mood disorder with mixed features in two
patients, was detected in 43% of patients. Clinical findings
possibly related to polyneuropathy were detected in 13
patients, but only four patients had subjective symptoms.
ENMG findings consistent with polyneuropathy were
present in only three of them. Seven patients (15%) had a
history of cerebrovascular disease. No intracerebral hem-
orrhages were recorded. Mean time since the diagnosis of
SLE to the occurrence of the first stroke or transient ische-
mic attack was 11 years (range 1 to 18). In four patients
cerebrovascular disease was concomitant with systemic
disease activity.
One patient (2%) had a demyelinating syndrome. The
neurologic symptoms appeared with subacute onset 18
years after the diagnosis of SLE. In CSF examination, IgG
index was elevated and eight oligoclonal bands were
present, indicating intrathecal synthesis. Increased signal
in periventricular white matter and at the level of corona
radiata on T2-weighted MRI scans was observed. Both
aCL (151 IgG phospholipid unit) and B2GPAbG (333 stan-
dard IgG anti-beta 2 GPI unit) levels were in the high
positive range.
There was an association between history of headache
and current steroid use (x2 5 4.114; p 5 0.043). Compared
with other patients with SLE, those with a history of epi-
leptic seizures (mean 65.0g vs 23.0g; t 5 3.319, p 5 0.002)
or cerebrovascular disease (mean 45.4g vs 22.7g; t 5 2.288,
p 5 0.028) had a higher cumulative lifetime dose of ste-
roids. No other associations between occurrence of NP
manifestation and steroid use were noticed.
Table 1 The neuropsychiatric syndromes in patients with
systemic lupus erythematosus according to the American College
of Rheumatology nomenclature and case definitions3
Central nervous system Peripheral nervous system
Aseptic meningitis Acute inflammatory
demyelinating
polyradiculoneuropathy
Cerebrovascular disease Autonomic disorder
Demyelinating syndrome Mononeuropathy,
single/multiplex
Headache Myasthenia gravis
Movement disorder (chorea) Neuropathy, cranial
Myelopathy Plexopathy
Seizure disorders Polyneuropathy
Acute confusional state
Anxiety disorder
Cognitive dysfunction
Mood disorder
Psychosis
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Discussion. In our study of 46 patients with SLE,
91% were identified to have at least one NP syn-
drome, whereas in previous studies, the prevalence
of NPSLE was significantly lower, ranging from 14
to 75%.15-20
The main explanation for the exceptionally high
prevalence of NP involvement in our study is most
likely that the ACR nomenclature system includes a
wide array of different neurologic and psychiatric
features as diagnostic elements. In most former
studies the diagnosis of NPSLE was entirely based
on major neurologic and psychiatric involvement,
such as cerebrovascular event, neuropathy, move-
ment disorder, transverse myelitis, seizure, meningi-
tis, organic brain syndrome, and psychosis.15-16
Patients with SLE also present with a number of
minor neurologic and psychiatric problems such as
headache, mild depression, anxiety, and cognitive
complaints that have now been included in the new
nomenclature system. If these minor manifestations
and also ENMG-negative polyneuropathy were ex-
cluded, the prevalence of NPSLE in our series would
be 46% instead of 91%.
Another important difference compared with
former studies is in patient selection. To our knowl-
edge, no population-based study on the prevalence of
NPSLE has been published so far. In the previous
studies patients have been gathered from academic
referral centers likely to be biased in terms of dis-
ease severity in comparison with the general popula-
tion. Furthermore, much milder forms of the disease
are now being recognized than a few decades ago.20
Cognitive impairment was the most frequent find-
ing, occurring in 37 patients (80%). Previously re-
ported prevalence rates have been lower, ranging
from 21 to 66%.2,21-26 According to the ACR nomencla-
ture, individual patients were defined as cognitively
impaired if they demonstrated an impairment in one
or more of eight areas of cognitive ability. In 70% of
our patients with cognitive impairment, the dysfunc-
tion was classified as mild, implying that the impair-
ment was established in only one or two cognitive
domains. Eleven patients had three or more im-
paired areas, fulfilling the criteria for cognitive im-
pairment used in other studies.21 Based on this
definition, only 24% of our study population would
have been classified as having a cognitive impair-
ment. This figure is in accordance with prevalence
rates of 21% in a study of 70 unselected patients
with SLE21 and 26% in a study of 73 patients.22
In our study population, 25 patients (54%) had
had headache, with lifetime prevalence of migraine
and tension headache being 39 and 15%. The preva-
lence of tension headache in our study was actually
slightly lower than in the healthy population.27-29
The reported prevalence rates of psychiatric man-
ifestations in SLE have varied from 20 to 70%.22,30
Recent reports have focused on the occurrence of
milder psychiatric features such as depression and
anxiety, whereas, in contrast to older studies, low
prevalence of psychosis has been observed.20,22 Our
results corroborate this finding: 80% of patients with
mood disorder had mild depression requiring no
medication, whereas none had experienced any epi-
sode of psychosis.
Cerebrovascular disease was diagnosed in seven
(15%) of our patients with SLE. In earlier studies,
the frequency of stroke varied from 3 to 19%.15-19,31
Patients with SLE who have had a stroke or tran-
sient ischemic attack are at high risk for recurrent
cerebral ischemia.32 Two of our seven patients with
cerebrovascular disease had a recurrence of stroke or
transient ischemic attack, and one had a chronic
multifocal disease. A significantly higher cumulative
lifetime dose of steroids in patients with SLE with a
history of cerebrovascular disease obviously reflects
the severity of this subgroup.
A mild, symmetric distal sensory or sensorimotor
neuropathy is the most common form of peripheral
neuropathies in SLE.16 A 28% frequency of polyneu-
ropathy in the current study is certainly overesti-
mated, because the ACR nomenclature system does
Table 2 Neuropsychiatric syndromes in 46 patients with systemic
lupus erythematosus
Neuropsychiatric syndrome n (%)
Cognitive dysfunction 37 (80)
Mild 26
Moderate 7
Severe 4
Headache 25 (54)
Migraine without aura 6
Migraine with aura 12
Tension headache 7
Mood disorders 20 (44)
Major depressive-like episode 18
Mood disorder with mixed features 2
Polyneuropathy* 13 (28)
Cerebrovascular disease† 7 (15)
Stroke syndrome 5
Transient ischemic attack 2
Chronic multifocal disease 1
Anxiety disorder 6 (13)
Seizures 4 (9)
Acute confusional state 3 (7)
Neuropathy, cranial‡ 3 (7)
Aseptic meningitis 1 (2)
Demyelinating syndrome 1
Movement disorder (chorea) 1
Myasthenia gravis 1
* ENMG findings consistent with polyneuropathy in three pa-
tients only.
† One patient had had both a stroke syndrome and a transient
ischemic attack.
‡ Optic neuropathy in all cases.
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not demand an ENMG confirmation of polyneurop-
athy. The corresponding prevalence of ENMG-
confirmed polyneuropathy in our series was 7%, in
accordance with the previous studies.15-18,33-34
One of the patients fulfilled the ACR nomencla-
ture criteria for a demyelinating syndrome which
may be reminiscent of MS.35-36 Our patient had neu-
rologic and MRI findings similar to MS, but a high
positive titer of aCL together with the history of
thrombocytopenia and deep venous thrombosis
strongly favors the diagnosis of antiphospholipid
syndrome. Oligoclonal banding has been described to
occur in patients with secondary antiphospholipid
syndrome caused by SLE.36 We suggest that future
revisions of the ACR nomenclature system specifi-
cally exclude antiphospholipid syndrome in the diag-
nosis of a demyelinating syndrome.
The main weakness of the study is the small sam-
ple size, and therefore the results should to be inter-
preted with caution. As a cross-sectional study, the
validity of disease history depends on the docu-
mentation of past disease episodes. We think that
this is unlikely to have a substantial effect on the
prevalence rates of the NP syndromes, but reliable
discrimination between primary NPSLE, second-
ary NPSLE, and concurrent disease process be-
comes problematic. It has been estimated that two-
thirds of NP manifestations in SLE are not
directly related to NPSLE but are due to secondary
causes such as drugs, infections, and metabolic
complications of the disease.37,38 Prospective analy-
ses would help in discriminating between primary
and secondary NPSLE.
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Current management of ALS
Comparison of the ALS CARE Database and the AAN
Practice Parameter
W.G. Bradley, DM, FRCP; F. Anderson, PhD; M. Bromberg, MD; L. Gutmann, MD; Y. Harati, MD;
M. Ross, MD; R.G. Miller, MD; and the ALS CARE Study Group*
Article abstract—Background: The American Academy of Neurology (AAN) ALS Practice Parameter was published in
April 1999. The ALS CARE Database has been collecting data on the management of patients with ALS in North America
since 1996. Objective: To compare the management of patients with ALS in North America as recorded in the ALS CARE
Database with the recommendations of the AAN ALS Practice Parameter. Methods: Data were analyzed from 2018
patients at enrollment and from 373 of these patients who died between enrollment and May 1999. Results: Eighty-two
percent of the enrolled patients reported that they had been given enough information about ALS. Only 54% of patients
with drooling were receiving medication for this problem. Only 41% of those who reported being depressed most of the
time were receiving antidepressant medications. Only 28% of those with dyspnea and only 9.2% of those with a forced vital
capacity ,40% predicted were receiving noninvasive positive pressure ventilator support. Only 30% of those with moder-
ate to severe dysphagia had a gastrostomy tube. Half of the patients who died did so at home, but only 47% of them
received residential hospice services. Although 89% of patients who died were recorded as having done so peacefully, 17%
were reported to have had breathing difficulties (i.e., respiratory distress), 8% anxiety, 3.3% pain, and 2.5% choking.
Advance directives were in place for 90% of the patients who died, and in 97% of cases these directives were followed.
Conclusions: These findings indicate that in the 3-year period prior to the publication of the AAN Practice Parameter,
many but not all patients received the care that is recommended in that parameter; there were deficiencies, particularly in
the key areas of gastrostomy and noninvasive positive pressure ventilation.
NEUROLOGY 2001;57:500–504
The ALS CARE Database has been collecting infor-
mation on patients with ALS, their caregivers, and
their management since July 1996.1-4 Currently
there are 91 clinical sites that have enrolled more
than 2500 patients. The American Academy of Neu-
rology (AAN) ALS Practice Parameter was published
in the April 1999 issue of Neurology.5 One of the
goals of this practice parameter is to influence the
clinical management of patients with ALS. To ob-
serve whether this goal has been achieved, it will be
necessary to monitor the management of patients
with ALS over time after the publication of the prac-
tice parameter. We report here a comparison of the
recommendations of the AAN ALS Practice Parame-
ter with the baseline features of the management of
patients with ALS extracted from the ALS CARE
Database for patients enrolled in the 3-year period
before the publication of the practice parameter. Our
long-term goal is to repeat this study after an inter-
val of a few years to examine the effect of the publi-
cation and dissemination of the AAN ALS Practice
Parameter.
We also intend to determine whether the current
ALS CARE Database questionnaire provides suffi-
Additional material related to this article can be found on the Neurology
Web site. Go to www.neurology.org and scroll down the Table of Con-
tents for the August 14 issue to find the title link for this article.
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Validity of the New American College of
Rheumatology Criteria for Neuropsychiatric Lupus
Syndromes: A Population-Based Evaluation
HANNA AINIALA,1 AKI HIETAHARJU,1 JUKKA LOUKKOLA,1 JUKKA PELTOLA,1 MARKKU KORPELA,2
RIINA METSA¨NOJA,3 AND ANSSI AUVINEN3
Objective. To assess the validity of the recently developed American College of Rheumatology (ACR) nomenclature for
neuropsychiatric systemic lupus erythematosus (NPSLE).
Methods. We conducted a cross-sectional, population-based study covering an area with 440,000 people. A total of 46
patients aged 16 to 65 years fulfilled the criteria for a definite diagnosis of SLE. One control for each patient matched by
age, sex, education, and place of residence was randomly identified from the population register. All patients and controls
underwent a clinical neurologic examination and neuropsychological testing. The data were analyzed using conditional
logistic regression methods.
Results. Forty-two patients (91%) and 25 controls (56%) fulfilled at least one of the ACR NPSLE criteria, which gave an
odds ratio (OR) of 9.5 (95% confidence interval [CI] 2.2–40.8) but low specificity (0.46). Cognitive dysfunction was the
most common syndrome detected in 37 patients (80%). A revised set of 16 criteria excluding the syndromes without
evidence for neuronal damage resulted in improved specificity (OR 7.0, 95% CI 2.1–23.5, specificity 0.93).
Conclusion. The proposed 19 ACR criteria did not differentiate SLE patients from controls, nor NPSLE patients from
other SLE patients. The revised NPSLE criteria proposed by us performed well in our population but should be evaluated
in a larger patient population.
KEY WORDS. Systemic lupus erythematosus; Neuropsychiatric; Diagnosis; Classification; Criteria.
INTRODUCTION
Systemic lupus erythematosus (SLE) has frequent and po-
tentially serious neuropsychiatric (NP) manifestations that
are of importance in the management of the disease. Lack
of a diagnostic gold standard and ambiguous terminology
have hampered epidemiologic research in neuropsychiat-
ric systemic lupus erythematosus (NPSLE). The reported
prevalence of NPSLE varies widely, from 14% to 75%,
because of inconsistent classifications and selected patient
populations in tertiary referral centers (1,2). A nomencla-
ture system recently developed by the American College of
Rheumatology (ACR; formerly the American Rheumatism
Association) is the first step toward standardized and in-
ternationally accepted classification of NPSLE (3). This
nomenclature comprises case definitions including diag-
nostic criteria, exclusions, and methods of ascertainment
for a total of 19 syndromes (3) (Table 1). The purpose of
this cross-sectional, population-based study is to assess
the validity of the ACR nomenclature and case definitions
for NPSLE.
PATIENTS AND METHODS
Patients. The study base was Pirkanmaa Health Care
District, located in southern Finland, with a population of
440,000 in 1998. The majority of new SLE patients in the
area are referred to Tampere University Hospital for diag-
nostic evaluation and therapeutic planning. In some cases,
diagnosis and followup are done in a local rheumatologic
outpatient clinic or in any of the 3 district hospitals. All
SLE patients were identified from computerized discharge
1Hanna Ainiala, MD, Aki Hietaharju, MD, PhD, Jukka
Loukkola, MA, Jukka Peltola, MD, Department of Neurology
and Rehabilitation, Tampere University Hospital, Tampere,
Finland; 2Markku Korpela, MD, PhD, Department of Inter-
nal Medicine, Division of Rheumatology, Tampere Univer-
sity Hospital, Tampere, Finland; 3Riina Metsa¨noja, BSc,
Anssi Auvinen, MD, PhD, School of Public Health, Univer-
sity of Tampere, Tampere, Finland.
Address correspondence to Hanna Ainiala, MD, Depart-
ment of Neurology and Rehabilitation, Tampere University
Hospital, PO Box 2000, FIN-33521 Tampere, Finland. E-
mail: jukkaps@koti.soon.fi.
Submitted for publication March 23, 2001; accepted June
4, 2001.
ARTHRITIS CARE & RESEARCH 45:419–423, 2001
ORIGINAL ARTICLE
© 2001, American College of Rheumatology
Published by Wiley-Liss, Inc. 419
registers of Tampere University Hospital, the 3 district
hospitals, and the local outpatient clinic. Medical records
of all patients with the diagnosis of SLE between January
1980 and December 1997 were examined to select patients
who 1) fulfilled 4 or more of the ACR revised criteria for
the disease (4), 2) were alive in 1998, 3) were 16 to 65 years
of age in 1998, 4) were of native Finnish origin, and 5)
were resident in the study area. Exclusion criteria were
other coexistent connective tissue diseases, such as rheu-
matoid arthritis, mixed connective tissue disease, Sjo¨gren’s
syndrome, or progressive systemic sclerosis.
A total of 58 eligible patients were identified. They were
contacted by mail, and 46 of them (79%) gave consent for
participation. The control group consisted of 46 individu-
als randomly identified from the Finnish Population Reg-
ister, with matching by age, sex, level of education, and
municipality of residence. Similar eligibility criteria were
applied as for the patients. All participants gave a written
informed consent, and the study protocol was approved by
the local Ethics Committee.
The study group consisted of 39 female and 7 male SLE
patients, with a mean age of 45  13 years (range 20–64),
and a similar number of matched controls. The mean dis-
ease duration since diagnosis of SLE was 14  8 years
(range 2–37), and the mean number of ACR SLE criteria
fulfilled was 5.5  1.2 (median 5, range 4–9). The mean
European Consensus Lupus Activity Measurement
(ECLAM) score was 1.7 (range 0–4), indicating very mild
disease activity. Patients and controls had completed 13 
2.7 (range 8–18) and 13  3.4 (range 7–20) years of edu-
cation, respectively.
Methods. All patients and controls gave a complete
medical history and underwent a clinical neurologic ex-
amination, performed by the same neurologist (HA) be-
tween November 1998 and May 1999. Disease activity was
quantified using the ECLAM (5). Accumulated NP abnor-
mality was assessed by using the Systemic Lupus Interna-
tional Collaborating Clinics/American College of Rheuma-
tology (SLICC/ACR) damage index (6).
The diagnoses of neuropsychiatric syndromes were
based on both past medical history and current findings in
clinical examination. All syndromes detected in these pa-
tients were classified according to the standardized ACR
nomenclature and case definition system for NPSLE (3). In
both SLE patients and controls with clinical signs or symp-
toms suggesting polyneuropathy, electroneuromyography
(ENMG) was performed.
Neuropsychological measures. In accordance with the
ACR case definitions, all patients and controls completed
a battery of neuropsychological tests in order to detect
possible impairment in one or more of the cognitive do-
mains, including simple attention, complex attention,
memory, visual-spatial processing, language, reasoning/
problem-solving, psychomotor speed, and executive func-
tions. The test battery included Wechsler Adult Intelli-
gence Scale-Revised (WAIS-R; Information, Vocabulary,
Digit Span, Comprehension, Picture Completion, Block
Design, and Digit Symbol Substitution subtests); Wechsler
Memory Scale-Revised (Logical Memory and Drawings 1
hour delayed); California Verbal Learning Test; Continu-
ous Performance Test; Simple Reaction Time (right and
left hand); Wisconsin Card Sorting Test (computerized
version, WCST-CV2); Boston Naming Test; Verbal Flu-
ency; Category Fluency; Trail Making A; Trail Making B;
and Stroop. Tests were administered by a trained clinical
psychologist (JL). An average of 3 to 4 hours was required
to complete the tests.
The individual test results were converted into standard
scores, which were compared with the available normative
data (7–11). Subjects with a total score that was 2 or more
standard deviations (SD) below the normative value in any
of the 8 cognitive domains were considered impaired.
Premorbid level of functioning was estimated by using the
2 best scores from WAIS-R, excluding the Digit Symbol
Substitution and Digit Span subtests. Education and occu-
pation of the subject were taken into consideration in
assessment of individual test performance. The same
method was used to determine the highest level of func-
tioning in controls. Cognitive dysfunction was classified as
mild if there were deficits in fewer than 3 dimensions,
moderate if there were deficits in 3 or 4 dimensions, and
severe if there were deficits in at least 5 dimensions.
Assessment of depression was based on clinical inter-
view and the Beck Depression Inventory (BDI) (12,13). On
the BDI, scores between 10 and 17 were considered as
mild, scores between 18 and 24 as moderate, and scores
Table 1. The neuropsychiatric syndromes in systemis lupus erythematosus according to
the American College of Rheumatology nomenclature and case definitions (3)
Central nervous system Peripheral nervous system
Aseptic meningitis Acute inflammatory demyelinating
polyradiculo-neuropathyCerebrovascular disease
Demyelinating syndrome Autonomic disorder
Headache Mononeuropathy, single/multiplex
Movement disorder (chorea) Myasthenia gravis
Myelopathy Neuropathy, cranial
Seizure disorders Plexopathy
Acute confusional state Polyneuropathy
Anxiety disorder
Cognitive dysfunction
Mood disorder
Psychosis
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over 24 as severe depression. However, the final grading of
depression was based on clinical interview by the psychol-
ogist. Anxiety was evaluated by the psychologist on clin-
ical interview.
Statistical methods. The prevalence of each condition
included in the ACR criteria was calculated for SLE cases
and controls. The odds ratio (OR) was calculated as the
ratio of discordant pairs with a positive patient to pairs
with a positive control. The data were analyzed with con-
ditional logistic regression methods, using presence or
absence of SLE as the outcome measure and various diag-
nostic criteria as explanatory variables.
RESULTS
All syndromes included in the proposed ACR criteria for
NPSLE were more frequent among SLE patients than con-
trols (Table 2). However, most syndromes were also found
among controls, which resulted in low specificity. At least
one NP syndrome was identified in 42 SLE patients (91%)
and 25 controls (54%). This corresponds to an OR of 9.5
(95% confidence interval [CI] 2.21–40.8) and yields a
specificity of 0.46 (21/46) and a detection rate of 91%
(42/46) among SLE patients (Table 3).
To improve the criteria we constructed revised criteria
based on objective findings only (Table 4). We excluded
entirely anxiety and headache, as well as mild depression,
mild cognitive dysfunction (with deficits in fewer than 3
dimensions) and polyneuropathy unconfirmed by ENMG.
With these modifications, the proportion of controls ful-
filling at least 1 of the criteria was substantially lower (7%
versus 54%). Also, the proportion of SLE patients with at
least 1 objective criterion was half of that for the proposed
ACR criteria (46% versus 91%). With a cut-point of 1 the
OR for the revised criteria was 7.0 (95% CI 2.09–23.47),
with a specificity of 0.93 (43/46) and detection rate among
SLE cases of 46% (21/46).
No major differences in the validity of the revised crite-
ria were observed when compared by age, sex, or disease
duration. The revised criteria showed a slightly higher
correlation with the neuropsychiatric SLICC damage index
than the proposed ACR criteria (r  0.79 and r  0.58,
respectively). Neither ACR nor our revised criteria were
correlated with current disease activity, as measured with
ECLAM (r  0.08 for both).
DISCUSSION
In this population-based sample, the ACR criteria and case
definitions for NPSLE had a low specificity (i.e., could not
differentiate SLE patients from controls). Ideally, case def-
initions should be based on SLE activity in the nervous
system manifested as neurologic dysfunction (14). In most
previous studies the diagnosis of NPSLE was based en-
tirely on the presence of major neurologic and psychiatric
impairment, including cerebrovascular event, neuropathy,
movement disorder, transverse myelitis, seizure, meningi-
Table 2. Neuropsychiatric syndromes in SLE patients and controls
Neuropsychiatric syndrome
Patient
n (%)
Control
n (%) OR (95% CI)
Cognitive dysfunction 37 (80) 13 (28) 9.0 (2.7–29.7)
Mild 26 11
Moderate 7 2
Severe 4 0
Headache 25 (54) 11 (24) 3.0 (1.3–7.1)
Migraine without aura 6 4
Migraine with aura 12 5
Tension headache 7 2
Mood disorders 20 (44) 4 (9) 9.0 (2.1–38.8)
Major depressive-like episode 18 4
Mood disorder with mixed features 2 0
Polyneuropathy 13 (28) 5 (11) 3.7 (1.0–13.1)
ENMG confirmation 3 0
Cerebrovascular disease* 7 (15) 0 
Stroke syndrome 5
Transient ischemic attack 2
Chronic multifocal disease 1
Anxiety disorder 6 (13) 3 (7) 2.0 (0.5–8.0)
Seizures 4 (9) 1 (2) 4.0 (0.5–35.8)
Acute confusional state 3 (7) 0 
Neuropathy, cranial† 3 (7) 0 
Aseptic meningitis 1 (2) 0 
Demyelinating syndrome 1 0 
Movement disorder 1 0 
Myasthenia gravis 1 0 
* One patient had both a stroke and a transient ischemic attack.
† Optic neuritis in all cases.
SLE  systemic lupus erythematosus; ENMG  electroneuromyography.
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tis, organic brain syndrome, and psychosis. No underlying
neurologic injury, however, has been demonstrated for
several syndromes listed under case definitions in the
current ACR nomenclature for NPSLE. We propose a more
stringent set of criteria based solely on manifestations of
neurologic injury.
Signs of minor CNS dysfunction were frequent among
both SLE patients and controls, which led to poor speci-
ficity and lack of distinction between the 2 groups. For
example, it is very difficult to justify the inclusion of
headaches: Although they were more common among pa-
tients than controls (54% versus 24%), the high preva-
lence among controls did not allow distinction between
NPSLE and other conditions manifesting as headache. In a
recent report, headaches were not associated with disease
activity (15). Tension-type headache in SLE patients was
associated with psychological distress and depressive
mood, while migraine was associated only with a ten-
dency to social isolation and anxiety. These findings indi-
cate that headaches are not a NP manifestation in SLE.
Furthermore, ACR case definitions do not include ENMG
for diagnosing polyneuropathy. Our results, with more
than 10% of controls presenting with sensory or motor
symptoms, indicate that subjective symptoms are too
vague and unspecific, and ENMG confirmation is required
to demonstrate neurologic injury.
Despite its frequency among SLE cases, mild cognitive
dysfunction was not specific for NPSLE, because it was
also detected among one fourth of controls. According to
ACR case definitions, documented impairment in one of
the cognitive domains is sufficient for the diagnosis of
cognitive dysfunction. Previously, it has been proposed
that a minimum of 3 impaired domains is required (16).
Our results indicate that this is required for detecting
clinically relevant neuropsychological defect.
Mild depression and anxiety are common in otherwise
healthy subjects and even more so among patients with
chronic diseases (17,18). They can be regarded as psycho-
logical responses to illness and therefore not specific for
NPSLE (19). Functional brain imaging techniques have
demonstrated that major depression is associated with
both reversible and irreversible neurophysiological abnor-
malities in some structures (20). Major depression can be
considered analogous to psychosis in psychiatric morbid-
ity, and its inclusion in the diagnostic criteria for NPSLE is
probably justified.
Our results demonstrate inadequate performance of the
proposed ACR criteria. It appears that NPSLE has no pa-
thognomonic manifestations but does share features with
other CNS conditions. Therefore, revised criteria are
needed to distinguish NPSLE from other conditions. We
derived criteria based on neurologic injury and excluded
conditions that do not indicate a neurologic dysfunction.
A higher correlation with SLICC for our revised criteria
Table 3. Number of American College of Rheumatology (ACR) criteria and revised
criteria for neuropsychiatric SLE among patient and control groups
Patients Controls OR (95% CI) Specificity
ACR criteria
 0 42 25 9.5 (2.2–40.8) 0.46
 1 37 10 7.8 (2.7–22.0) 0.78
 2 25 2 24.0 (3.3–177.4) 0.96
 3 10 —  1.00
Revised criteria
 0 21 3 7.0 (2.1–23.5) 0.93
 1 9 0  1.00
 2 6 0  1.00
 3 2 0  1.00
SLE  systemic lupus erythematosus.
Table 4. The modified criteria for neuropsychiatric systemic lupus erythematosus
Central nervous system Peripheral nervous system
Aseptic meningitis Acute inflammatory demyelinating
polyradiculo-neuropathyCerebrovascular disease
Demyelinating syndrome Autonomic disorder
Movement disorder (chorea) Mononeuropathy, single/multiplex
Myelopathy Myasthenia gravis
Seizure disorders Neuropathy, cranial
Acute confusional state Plexopathy
Cognitive dysfunction (moderate or
severe)
Polyneuropathy (with ENMG* confirmation)
Severe depression
Psychosis
* ENMG  electroneuromyography.
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than for ACR criteria lends further credence to our ap-
proach. To support our basis of classification, further re-
search on organic nervous system damage with pathoge-
netic mechanisms specific to SLE is warranted.
We were able to define a study base and identify all
prevalent cases of SLE and population-based controls in it.
Matching for age, sex, and education was used to maxi-
mize comparability between patients and controls, as well
as to minimize loss of information. In principle, there are
2 possible designs for evaluating diagnostic criteria. First,
a direct approach would encompass assessment of patients
suspected of having the target condition (i.e., representing
a true clinical context and comparing the test being eval-
uated with a gold standard). Yet this is not feasible for
NPSLE because of the lack of accessible defining criteria
for NPSLE (i.e., a gold standard). Therefore, the only way
to evaluate the criteria is by comparing patients with the
disease and a sample of subjects without it. Because no
definite method for identifying patients with NPSLE is
available, we compared the prevalence of symptoms pro-
posed as criteria and case definitions for NPSLE between
SLE patients (instead of NPSLE patients) and controls. In
other words, we used SLE as a proxy for NPSLE. This is
logical because, by definition, NPSLE can occur only
among patients with SLE. However, SLE is a necessary but
not sufficient condition for NPSLE; that is, it is a sensitive
but not specific definition. It has been shown that this
leads to some loss of statistical power but does not bias the
results (21). Even though the proposed ACR criteria are
designed for use among SLE patients, evaluation of their
sensitivity and specificity is not possible without a control
group free of SLE.
Small sample size limited the statistical power of the
analyses; therefore, rare syndromes as manifestations of
NPSLE could not be assessed in our material. Further
studies with larger patient populations are likely to reveal
more subtle differences between SLE patients and con-
trols.
The diagnostic criteria for NPSLE proposed by ACR
appear to have specificity that is too low and a detection
rate that is unrealistically high to be clinically useful.
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Increased Serum Matrix Metalloproteinase 9 Levels in
Systemic Lupus Erythematosus Patients With
Neuropsychiatric Manifestations and
Brain Magnetic Resonance Imaging Abnormalities
Hanna Ainiala,1 Aki Hietaharju,1 Prasun Dastidar,1 Jukka Loukkola,1 Terho Lehtima¨ki,2
Jukka Peltola,1 Markku Korpela,1 Tomi Heinonen,3 and Seppo T. Nikkari4
Objective. To evaluate whether serum matrix met-
alloproteinase 9 (MMP-9) levels are associated with
neuropsychiatric manifestations, particularly cognitive
dysfunction, as evaluated by neuropsychological testing
and brain magnetic resonance imaging (MRI) abnor-
malities in patients with systemic lupus erythematosus
(SLE).
Methods. MMP-9 determinations were made in
44 patients with SLE and 43 healthy controls who
underwent a clinical neurologic and neuropsychological
investigation in order to identify neuropsychiatric man-
ifestations. Cerebral MRI scans with volumetric estima-
tion of intracranial cerebrospinal fluid spaces, T1-
weighted lesions, and T2-weighted lesions were
performed for all subjects. SLE activity was assessed by
the European Consensus Lupus Activity Measure
(ECLAM) index, and accumulated neuropsychiatric ab-
normality was assessed by the Systemic Lupus Interna-
tional Collaborating Clinics (SLICC)/American College
of Rheumatology damage index.
Results. No significant difference was found in
serum MMP-9 levels between the overall group of SLE
patients and controls. However, SLE patients who had
at least 1 neuropsychiatric manifestation (NPSLE pa-
tients) had significantly higher serum MMP-9 concen-
trations than did SLE patients without neuropsychiatric
syndromes (P  0.009). Among patients with NPSLE,
those with cognitive deficits had significantly higher
concentrations of serum MMP-9 than did those with
normal cognitive function (P  0.027). Furthermore,
serum MMP-9 levels had a significant positive correla-
tion with the volumes of T1-weighted and T2-weighted
lesions in the brain MRI (P  0.031 and P  0.015,
respectively). The concentration of serum MMP-9 cor-
related significantly with the SLICC index but not with
the ECLAM index.
Conclusion. Elevated levels of serum MMP-9 in
patients with SLE may reflect neuropsychiatric involve-
ment, particularly cognitive dysfunction. The serum
MMP-9 concentration may be associated with small-
vessel cerebral vasculopathy and increased risk of cere-
bral ischemic events in patients with SLE.
Neuropsychiatric manifestations of systemic lu-
pus erythematosus (SLE) are common and may affect
up to two-thirds of patients with this disease. According
to the definition of neuropsychiatric SLE (NPSLE), this
condition includes neurologic syndromes of the central,
peripheral, and autonomic nervous system and the psy-
chiatric syndromes observed in patients with SLE for
which other causes have been excluded (1). The patho-
genesis of NPSLE is still unclear, but recent studies on
neuroimaging have greatly advanced the understanding
of this disease, which appears to be caused by both acute
and chronic brain injury induced by the complex patho-
logic processes of SLE (2). An important cause of the
central nervous system (CNS) syndromes in SLE is
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ischemia due to narrowing or occlusion of small vessels
(3). The most commonly observed cerebral magnetic
resonance imaging (MRI) abnormalities include cortical
stroke, global atrophy, and nonspecific foci of increased
signal in both gray and white matter, even though no
consistent pattern of abnormality is characteristic of
NPSLE (4). In general, the diagnosis of NPSLE is
difficult, because no single laboratory marker or imaging
modality serves as a gold standard, and the diagnosis is
primarily clinical (5).
Matrix metalloproteinases (MMPs) are a family
of zinc-containing endoproteinases that can degrade a
variety of extracellular matrix components (6). MMP-9
is a gelatinase that is secreted by several cell types of the
vessel wall, including macrophages, T lymphocytes, en-
dothelial cells, and smooth muscle cells (7).
Macrophage-produced MMP-9 has been shown to play a
role in the pathogenesis of atherosclerosis by weakening
the arterial wall; this process can result in plaque rupture
and thereby in thrombus formation and occlusion of the
artery (8). The principal function of MMP-9 produced
by T cells is to enhance T cell migration through
connective tissue (9). Increased activity of MMPs has
been implicated in numerous disease processes, includ-
ing malignancies, cardiovascular diseases, and auto-
immune diseases such as multiple sclerosis, Guillain-
Barre´ syndrome, and rheumatoid arthritis (10–16). To
date, serum MMP-9 levels in SLE have been investi-
gated in only one study, the results of which showed that
MMP-9 activity is significantly elevated in patients com-
pared with controls (17).
The aim of this study was to evaluate and test the
hypothesis that serum MMP-9 levels are associated with
neuropsychiatric manifestations or cerebral MRI abnor-
malities in patients with SLE.
PATIENTS AND METHODS
Patient selection. The study group comprised 39
women and 7 men with SLE (mean  SD age 45  13 years
[range 20–64 years]) and a similar number of matched con-
trols. The total patient sample was the same as that described
in our previous report (18). The study base was Pirkanmaa
Health Care District, located in southern Finland, with a
population of 440,000. We identified patients with SLE by
using the computerized databases of Tampere University
Hospital, the 3 district hospitals, and a local outpatient clinic.
Medical records of both inpatients and outpatients coded for
the diagnosis of SLE between January 1980 and December
1997 were examined to select patients who fulfilled 4 of the
1982 revised American College of Rheumatology (ACR) cri-
teria for the disease (19), were ages 16–65 years and of native
Finnish origin, and resided in the study area. Patients with
other connective tissue diseases were excluded.
We identified 110 patients with SLE. Of these, 15
patients had died, and 37 did not meet the inclusion criteria.
The remaining 58 patients were contacted by mail, and 46 of
them (79%) agreed to participate in the study. The mean SD
time since diagnosis of SLE was 14  8 years (range 2–37
years), and the median number of ACR SLE criteria fulfilled
was 5 (range 4–9). The control group consisted of 46 individ-
uals randomly identified from the Finnish Population Register,
who were matched with patients for age, sex, level of educa-
tion, and municipality of residence. Eligibility criteria similar
to those for the patients were applied. All participants gave
written informed consent, and the study protocol was approved
by the local ethics committee.
Clinical evaluation. The diagnosis of various neuropsy-
chiatric syndromes was based on the clinical impression of one
evaluator (HA) following review of the medical history, clinical
examination, review of medical records, and neuropsycholog-
ical testing. All past and present neuropsychiatric syndromes
were listed and classified according to the modified ACR
nomenclature and case definitions (20) (Table 1). If one of the
neuropsychiatric syndromes was identified in a patient, he or
she was considered to have NPSLE. NPSLE was identified in
21 (46%) of the 46 patients.
All patients and controls completed a 3-hour battery of
neuropsychological tests administered by the same psycholo-
gist; details regarding the procedure and analysis of neuropsy-
chological measures have been described elsewhere (18). The
number of the ACR revised diagnostic criteria for SLE, and
current and previous use of steroids and other immunosup-
pressive medication were recorded. A cumulative lifetime dose
of steroids (expressed as grams of prednisolone) was deter-
mined from the patient records. Individual disease activity was
quantified using the European Consensus Lupus Activity
Measurement (ECLAM) scale (21). Accumulated neuropsy-
chiatric abnormality was assessed using the Systemic Lupus
International Collaborating Clinics (SLICC)/ACR damage in-
dex (22). Neuropsychiatric manifestations of the damage index
that were scored included cognitive impairment, major psycho-
sis, seizures requiring therapy for 6 months, cerebral vascular
accident, cranial or peripheral neuropathy (excluding optic),
and transverse myelitis.
Table 1. Neuropsychiatric syndromes in 46 patients with SLE*
Neuropsychiatric syndrome No. (%)
Cognitive dysfunction 11 (24)
Cerebrovascular disease 7 (15)
Seizure disorder 4 (9)
Acute confusional state 3 (7)
Neuropathy, cranial 3 (7)
Polyneuropathy 3 (7)
Aseptic meningitis 1 (2)
Demyelinating syndrome 1 (2)
Movement disorder (chorea) 1 (2)
Myasthenia gravis 1 (2)
* Nine patients had 1 neuropsychiatric manifestation. SLE  sys-
temic lupus erythematosus.
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Laboratory evaluation. Quantitation of immunoreac-
tive MMP-9 was carried out by enzyme-linked immunosorbent
assay (ELISA; Diabor, Oulu, Finland). ELISAs were per-
formed on 96-well microtiter plates using standard protocols.
Recombinant MMP-9 was used as a standard. The microtiter
plate was coated with the monoclonal antibody (code GE-213),
and samples and standards were added. The bound proteins
were detected with a secondary polyclonal antibody produced
in chicken against MMP-9. Peroxidase-labeled anti-chicken
IgG (Chemicon, Temecula, CA) was used for detection of the
bound secondary antibody, and o-phenylenediamine tablets
(KemEnTec, Copenhagen, Denmark) were used to visualize
the peroxidase label. The color formation was measured at 450
nm on an Anthos 2000 microplate reader (Anthos Labtec
Instruments, Frederick, MD), and calculations were done
using a Multicalc program (Wallac, Turku, Finland). The
monoclonal antibody recognizes both free MMP-9 and that
bound to its inhibitor, tissue inhibitor of metalloproteinases 1
(23). Determination of the MMP-9 level was carried out
concurrently with the clinical and neuropsychological evalua-
tion. In 2 patients and 3 controls, determination of the MMP-9
level was not successful.
Other serologic tests included a complete blood cell
count, erythrocyte sedimentation rate, serum creatinine con-
centration, and serum complement levels (CH50 and compo-
nents C3 and C4). Antinuclear antibodies (ANAs), anti–
double-stranded DNA (anti-dsDNA) antibodies, IgG type
anticardiolipin antibodies (aCL), and 2-glycoprotein I
(2GPI) antibodies were measured by ELISA.
Neuroradiologic examinations. Cerebral MRI was per-
formed on 43 SLE patients and 44 healthy controls. The Signa
Easy Vision 1.5T MRI imaging system (General Electric
Medical Systems, Milwaukee, WI) was used for all examina-
tions. All MRI scans were read in a blinded manner by an
experienced neuroradiologist (PD) who did not have access to
any demographic or clinical data. MRI scans in patients and
controls were performed a mean  SD of 11.1  11.6 weeks
and 17.1  7.6 weeks, respectively, after the clinical evaluation
was performed and blood was drawn. The MRI protocol
included sagittal T1-weighted, axial T1-weighted, axial T2-
weighted, and coronal fluid-attenuated inversion recovery
(FLAIR) sequences. The imaging protocol also included axial
3-dimensional (3-D) T2 fast spin-echo and gadolinium-
diethylenetriaminepentaacetic acid–enhanced 3-D T1 spoiled
gradient-echo images for segmentation and volumetric analy-
sis. Segmentation and volumetric analysis were performed
using the segmentation software Anatomatic, operating in
PC/Windows 95 environment (24–26). Segmentation and volu-
metric measurements of hypointense lesions on T1-weighted
images and hyperintense lesions on T2-weighted images were
performed separately.
T1-weighted images showed only gliotic infarcts, and
T2-weighted images showed also microinfarcts, ischemic le-
sions, and demyelinating lesions. Any small T2-weighted hy-
perintense lesions that looked like age-related changes were
excluded. The criteria for age-related changes were as follows:
small periventricular T2 high-signal-intensity changes in the
area of frontal and occipital horns, few scattered well-defined
small-size (3 mm) T2 high-signal-intensity changes in the
area of centrum semiovale that are not visible on T1-weighted
images, and widened Virchow-Robin spaces that are seen as
low-signal-intensity areas on FLAIR images. Measurements
were expressed as volume/cm3.
The markers for cerebral atrophy were intracranial
cerebrospinal fluid (CSF) space volume and relative intracra-
nial CSF space volume. Volumetric measurement of total
intracranial CSF spaces was done by assessing the total volume
of the ventricular and peripheral CSF spaces, expressed as
volume/cm3. Total intracranial volume was measured by cal-
culating together the volume of all the segmented gray and
white matter and intracranial CSF spaces. Relative intracranial
CSF space volume was defined as volumetric measurement of
relative intracranial CSF space, and was determined by divid-
ing the total intracranial CSF space volume by the total brain
volume.
Statistical analysis. All statistical analyses were per-
formed on a microcomputer using SPSS software (version 11.0,
2002; SPSS, Chicago, IL). The significance of differences in the
levels of serum MMP-9 between study groups was determined
using the Mann-Whitney U test or nonparametric analysis of
Table 2. Baseline characteristics and laboratory values in 46 SLE patients and 46 controls*
Characteristic SLE patients Controls P
Age, years 45  12.6 45  12.7 –
No. men/no. women 7/39 7/39 –
Disease duration, years 14.2  8.0 – –
Education completed, years 13 2.7 13  3.4 –
Serum MMP-9, g/liter† 56.7  39.4 58.8  23.8 0.13
B leukocytes, 109/liter 5.7  2.7 6.0  1.5 0.20
B hemoglobin, gm/liter 131.0 14.0 134.2 11.2 0.28
B thrombocytes, 109/liter 253.4  135.3 250.0 51.9 0.38
Serum C3, gm/liter 0.90  0.31 1.04  0.20 0.008
Serum C4, gm/liter 0.14  0.09 0.22  0.06 0.001
Serum CH50, units/ml 53.5  24.3 70.3  17.4 0.001
ESR, mm/hour 23.2  16.3 9.0  6.3 0.001
Anti-dsDNA antibodies, units/liter 159.4 238.0 40.2  1.8 0.001
Antinuclear antibodies, titer 1,258.3 1042.4 90.4 49.5 0.001
Anticardiolipin antibodies, GPL units 12.9 24.5 2.3  8.42 0.001
* Except where indicated otherwise, values are the mean  SD. SLE  systemic lupus erythematosus;
MMP-9  matrix metalloproteinase 9; ESR  erythrocyte sedimentation rate; anti-dsDNA  anti–
double-stranded DNA; GPL  IgG phospholipid. P values were determined by Mann-Whitney U test.
† Determined in 44 patients and 43 controls.
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variance (ANOVA). The correlation between MRI parameters
and serum MMP-9 levels was analyzed using Spearman’s rank
correlation. Differences in the levels of serum MMP-9 between
the ECLAM and SLICC/ACR groups were tested by ANOVA.
P values less than 0.05 were considered significant.
RESULTS
Serum levels of MMP-9 and serologic indicators
of disease activity in SLE patients and controls. The
mean  SD level of MMP-9 was 56.7  39.4 g/liter in
SLE patients and 58.8  23.8 g/liter in controls (P 
0.13). A comparison of all laboratory parameters be-
tween SLE patients and controls is presented in Table 2.
Correlations between serologic indicators of disease
activity and MMP-9 levels in SLE patients and controls
are shown in Table 3. A highly significant positive
correlation was observed between serum MMP-9 levels
and leukocytes in both patients and controls (P 0.0001
for both), and a significant negative correlation was
observed between serum MMP-9 levels and levels of
anti-dsDNA and ANA in SLE patients. No significant
correlation of serum MMP-9 with aCL or 2GPI anti-
bodies was detected.
Neuropsychiatric manifestations and serum lev-
els of MMP-9. The relationship between concentrations
of serum MMP-9 and neuropsychiatric manifestations in
44 patients with SLE was investigated (Table 4). NPSLE
was diagnosed in 20 patients (45%), and the mean SD
serum MMP-9 level in this group was 73.2  46.1
g/liter. In the remaining 24 patients without NPSLE,
the mean  SD MMP-9 level was 42.8  26.8 g/liter;
the difference between mean values was statistically
significant (P  0.009) (Figure 1). When serum MMP-9
concentrations were evaluated with respect to different
neuropsychiatric manifestations, the levels were signifi-
cantly higher in patients in whom cognitive impairment
was diagnosed (80.8  45.8 g/liter) than in those with
normal cognitive function (48.6  34.2 g/liter; P 
0.027). In other neuropsychiatric syndromes, no statisti-
cally significantly higher or lower concentrations of
MMP-9 were identified (Table 4). In SLE patients with
polyneuropathy, the mean SD serum levels of MMP-9
were twice as high as those in patients without polyneu-
ropathy (106.2  56.3 g/liter versus 53.0  36.3 g/
liter), but, probably because of the small number of
patients, the difference did not reach statistical signifi-
Table 3. Correlations between serum MMP-9 levels and laboratory
test results in 44 patients with SLE and 43 controls*
Laboratory parameter
Patients Controls
r P r P
B leukocytes 0.68 0.001 0.55 0.0001
Serum C4 0.42 0.005 0.28 0.07
B thrombocytes 0.40 0.007 0.10 0.54
B hemoglobin 0.33 0.03 0.34 0.02
Serum C3 0.30 0.05 0.09 0.57
Serum CH50 0.28 0.07 0.22 0.16
Anticardiolipin
antibodies
0.04 0.79 0.13 0.41
2-glycoprotein I
antibodies
0.22 0.32 – –
Anti-dsDNA 0.34 0.02 0.19 0.23
ESR 0.04 0.81 0.002 0.10
Antinuclear antibodies 0.43 0.003 0.23 0.14
* P values were determined by Spearman’s rank order correlation test.
See Table 2 for definitions.
Table 4. Comparison of serum MMP-9 levels (g/liter) in 44 SLE patients, by presence or absence of
specific neuropsychiatric manifestations*
Manifestation
Neuropsychiatric
manifestations
No neuropsychiatric
manifestations
P
No. of
patients
MMP-9
level
No. of
patients
MMP-9
level
Cognitive dysfunction 11 80.8 45.8 33 48.6 34.2 0.027
Cerebrovascular disease 7 76.3 43.9 37 53.0 38.1 0.092
Seizure disorder 4 82.9 50.1 40 54.0 38.0 0.111
Severe depression 4 27.9 12.2 40 59.5 40.1 0.072
Polyneuropathy 3 106.2 56.3 41 53.0 36.3 0.081
Acute confusional state 3 62.4 26.0 41 56.2  40.4 0.442
Neuropathy, cranial 2 43.9 45.6 42 57.3  39.6 0.652
Aseptic meningitis 1 11.6 43 57.7 39.3 0.106
Demyelinating syndrome 1 137.8 43 54.8 37.8 0.125
Movement disorder 1 79.2 43 56.1  39.7 0.288
Myasthenia gravis 1 64.1 43 56.5  39.9 0.503
* Values are the mean  SD. P values were determined by nonparametric analysis of variance. See Table
2 for definitions.
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cance (P  0.081). Similarly, in the 1 SLE patient with a
demyelinating syndrome, the serum concentration of
MMP-9 was almost 3-fold higher than the mean  SD
concentration in the 43 patients without a demyelinating
syndrome (137.8 g/liter versus 54.8 37.8 g/liter; P
0.125). There was no statistically significant difference in
the cumulative lifetime dose of glucocorticoids between
SLE patients with and those without cognitive dysfunc-
tion.
Lupus disease activity/neuropsychiatric damage
index and serum levels of MMP-9. Regression analysis
to examine associations between levels of serum MMP-9
and SLE disease activity and neuropsychiatric damage
indexes was performed. The mean ECLAM score was
1.6 (range 0–5), indicating very low disease activity.
ANOVA revealed no significant relationship between
individual MMP-9 levels and ECLAM scores. The mean
(SD) neuropsychiatric SLICC damage index score was
also low (0.57  1.00 [range 0–4]), with 32 patients
having a score of 0, 6 patients having a score of 1, 5
patients having a score of 2, 2 patients having a score of
3, and 1 patient having a score of 4. Serum MMP-9
concentrations tended to be higher in patients with
higher neuropsychiatric SLICC damage index scores,
except in the 1 patient who had a score of 4. The result
across these neuropsychiatric SLICC damage index
score groups was statistically significant by ANOVA
(P  0.048). Serum MMP-9 levels did not correlate with
disease duration (r  0.18, P  0.25). The mean level of
serum MMP-9 was 65.7 g/liter in patients with a history
of nephritis and 50.4 g/liter in patients without such a
history; this difference did not reach statistical signifi-
cance (P  0.21). Similarly, no significant correlation
between serum MMP-9 and creatinine levels was ob-
served in SLE patients (r  0.27, P  0.075).
Treatment status and serum levels of MMP-9.
The relationship between serum MMP-9 activity and
treatment modalities in patients with SLE was investi-
gated. At the time of the study, 25 patients were
receiving glucocorticoids, 7 were being treated with
antimalarial agents, 5 were receiving azathioprine, 2
were receiving methotrexate, and 1 patient was receiving
cyclosporine. Eleven patients were receiving both glu-
cocorticoids and cytotoxic drugs. A total of 19 patients
(41%) were not receiving specific medication. No signif-
icant differences in serum levels of MMP-9 were found
between the patients receiving either glucocorticoids or
other immunomodulatory treatment and those who
were not receiving any immunosuppressive treatment.
Similarly, no significant correlation was observed be-
tween cumulative lifetime dose of glucocorticoids and
serum MMP-9 levels (r  0.25, P  0.12).
MRI parameters and levels of serum MMP-9.
Using Anatomatic segmentation software, it was esti-
Figure 1. Serum matrix metalloproteinase 9 concentrations in patients with neuropsychiatric
systemic lupus erythematosus (NPSLE) and in patients without NPSLE (nNPSLE). Statistical
significance between the groups was determined by Mann-Whitney U test.
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mated that the mean  SD volume of T1 lesions was
0.47  1.42 volume/cm3 in SLE patients versus 0.08 
0.30 volume/cm3 in controls (P  0.0085), and the
mean  SD volume of T2 lesions was 1.30  0.68
volume/cm3 versus 0.30  0.11 volume/cm3, respectively
(P  0.001). In the assessment of brain atrophy it was
found that the mean intracranial CSF space volume in
patients was 129.1  39.9 volume/cm3, compared with
83.6  18.3 volume/cm3 in controls (P  0.001). The
mean  SD relative intracranial CSF space volume was
0.19  0.07 in patients versus 0.11  0.01 in controls
(P  0.001). In SLE patients, a positive significant
correlation was observed both between the levels of
serum MMP-9 and T1 lesions (r  0.33, P  0.031) and
between the levels of serum MMP-9 and T2 lesions (r 
0.37, P  0.015). No association was detected between
the levels of serum MMP-9 and intracranial CSF space
volume or relative intracranial CSF space volume. (Ta-
ble 5). The cumulative lifetime dose of glucocorticoids
showed a positive correlation with intracranial CSF
space volume (r  0.35, P  0.028) and relative intra-
cranial CSF space volume (r  0.36, P  0.023), but not
with T1 and T2 lesions in SLE patients. In healthy
controls, no correlations between the levels of serum
MMP-9 and MRI parameters were observed.
DISCUSSION
We analyzed the concentrations of serum
MMP-9 in 44 patients with SLE and 43 healthy controls
and found no significant differences between the 2
groups. Our findings are not consistent with those from
a previous study, which showed a significant increase of
MMP-9 activity in the sera of 40 SLE patients compared
with 25 healthy controls (17). Among other MMPs that
have been studied, MMP-3 levels have been found to be
elevated in SLE patients, and specifically in those with
lupus nephritis (27,28). An increase in MMP-1 and
MMP-2 activity has not been demonstrated in SLE (27).
In our study, patients with NPSLE had signifi-
cantly higher levels of serum MMP-9 than did SLE
patients without neuropsychiatric disease. In addition, a
positive correlation of serum MMP-9 levels with the
neuropsychiatric SLICC index score was detected. These
2 observations corroborate our primary hypothesis, ac-
cording to which MMP-9 levels may reflect CNS injury
in patients with SLE.
There has been speculation regarding whether or
not metalloproteinases are related to disease activity in
SLE. In a previous study, a positive correlation between
the MMP-9 concentration and disease activity scores
was observed, but only in men (17). In our study, no
association between MMP-9 levels and ECLAM scores
was found in either sex. This may be partly explained by
the fact that at the time of the assessment, the majority
of our patients were in good health (only 1 patient was
hospitalized); as a consequence, the ECLAM scores in
general were not high. In fact, if levels of MMP-9 truly
parallel disease activity, these levels would be expected
to be low in our patients.
Cognitive deficits occur in 21–81% of patients
with SLE, depending on the criteria used and patient
selection (18,29–34). In our study, based on a 3-hour
battery of neuropsychological tests, cognitive deficits
were diagnosed in 24% of the patients with SLE. Cog-
nitive abnormalities in SLE may not be cumulative over
time but may follow an evanescent course due to irre-
versible and, in part, reversible ischemic changes in the
brain (3,35). Cerebral small-vessel vasculopathy (i.e.,
ischemia due to the narrowing or occlusion of small
vessels, arteries, and veins) has been suggested to un-
derlie the cognitive disorder in SLE (3). In our patients,
serum MMP-9 levels were associated with T1 and T2
hyperintensities, which are major MRI indices of cere-
bral infarcts and may be derived from atherosclerosis in
cerebral or carotid vessels (embolic infarcts). Moreover,
our patients with cognitive deficits had higher serum
concentrations of MMP-9 than did the SLE patients with
normal cognitive function. These findings tempt us to
speculate that the MMP-9 concentration relates to the
underlying pathologic process, small-vessel vasculopa-
thy. In our study, the elevated MMP-9 levels in SLE
patients with cognitive dysfunction may reflect an ongo-
ing, active process, because elevated plasma MMP-9
concentrations after acute coronary syndromes and suc-
cessful reperfusion of acute myocardial infarction are
reversible and gradually decrease to the levels observed
in normal control subjects (11,36,37). This may also
Table 5. Correlation of MMP-9 values with quantitative MRI vol-
umes in SLE patients*
MRI parameter r P*
T1-weighted volume, cm3 0.33 0.031
T2-weighted volume, cm3 0.371 0.015
Total intracranial CSF
space volume, cm3
0.004 0.982
Relative intracranial CSF
space volume
0.092 0.564
* MMP-9  matrix metalloproteinase 9; MRI  magnetic resonance
imaging; SLE  systemic lupus erythematosus; CSF  cerebrospinal
fluid. Statistical values were determined by Spearman’s rank correla-
tion test.
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explain why serum MMP-9 levels in SLE patients with a
history of stroke were not high.
In previous studies of primary arteritis, macro-
phages within the inflamed artery wall showed increased
expression of MMP-9, which was reflected also as in-
creased serum levels of the enzyme (38). MMP-9 is a
proteolytic enzyme that can degrade a variety of extra-
cellular matrix components. By cleaving type IV colla-
gen of the basement membrane and other extracellular
matrix proteins, MMP-9 may favor leukocyte migration
into the artery wall (6,9). In addition, MMP-9 expression
is related to blood–brain barrier disruption after cere-
bral ischemia (39).
In MRI, T1-weighted hypointensities include pri-
marily gliotic infarcts, but also (to a lesser extent) gliotic
demyelinating plaques, which were not seen in our study.
T2-weighted images are more sensitive in detecting
microinfarcts and other ischemic lesions in spite of
possible superimposed abnormalities (4). Previous find-
ings have shown that ischemia is the main cause of CNS
manifestations in SLE, and cerebral small-vessel angiop-
athy is the predominant histopathologic abnormality (3).
Typical abnormalities on brain MRI are small punctate
lesions of increased signal intensity, localized mainly in
the periventricular and subcortical white matter, known
also as white matter hyperintensities. The pathogenesis
of these small infarcts in the brain is not clear (3). Our
finding of the association between leukocyte count and
serum MMP-9 concentration in both SLE patients and
healthy controls confirms previous reports by Kalela et
al (40) and supports the concept of MMP-9 being a
useful marker of inflammation. Furthermore, our find-
ings may indicate that there is an inflammatory process
behind these small angiopathic changes in the brains of
patients with SLE.
This study is the first to investigate the correla-
tion between MMP-9 concentrations and MRI abnor-
malities in SLE, but the results are in accordance with
those of earlier studies of MMP-9 levels, which showed
increased MMP activity in patients with stroke and
vascular dementia (i.e., clinical states associated with
vasculopathy) (41,42). Consistent with our findings in
SLE patients, a significant positive correlation between
high serum levels of MMP-9 and the number of T1-
weighted gadolinium-enhancing MRI lesions in patients
with multiple sclerosis has been reported (12). The
findings of increased CSF and serum levels of MMP-9 in
patients with multiple sclerosis and expression of
MMP-9 in demyelinating lesions have suggested that
metalloproteinases may have importance in the patho-
genesis of this disease (12–14). MMP-9 has also been
related to other autoimmune disorders such as Guillain-
Barre´ syndrome and experimental autoimmune neuritis
(15,43). In relation to these diseases, it has been as-
sumed that MMP-9 participates in the degradation of
myelin basic protein, a major component of both CNS
and peripheral nervous system myelin (15). Interest-
ingly, demyelinating syndrome, which may clinically re-
semble multiple sclerosis, is listed as one of the mani-
festations of NPSLE. In our study, 1 patient was
diagnosed as having demyelinating syndrome, and she
had a high level of MMP-9 activity.
This is the first study in which MMP-9 concen-
trations in patients with NPSLE were evaluated. Accord-
ing to the results, elevated levels of serum MMP-9 in
patients with SLE are associated with neuropsychiatric
involvement, and cognitive dysfunction in particular.
The findings further suggest a relationship between
MMP-9 levels and ischemic changes on cerebral MRI,
thus supporting the hypothesis that cerebral small-vessel
vasculopathy may underlie the cognitive decline in SLE.
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Cerebral MRI abnormalities and their association with
neuropsychiatric manifestations in SLE: a population-based study
H Ainiala1, P Dastidar2, J Loukkola1, T Lehtima¨ki3, M Korpela4, J Peltola1, A Hietaharju1
1Departments of Neurology, Neurosurgery, and Rehabilitation, 2Diagnostic Radiology, 3Laboratory of Atherosclerosis Genetics, Tampere
University Hospital and Tampere University, and 4Department of Internal Medicine, Division of Rheumatology, Tampere University
Hospital, Tampere, Finland
Objective: To evaluate the volumetric brain magnetic resonance imaging (MRI) findings in a population-based
sample of systemic lupus erythematosus (SLE) patients and to detect a possible relationship between cerebral
MRI abnormalities and specific neuropsychiatric (NP) manifestations.
Methods: The study population consisted of patients with SLE (n543) in Pirkanmaa Health Care District,
Finland and of a sex- and age-stratified reference group from the general population (n543). In addition
to a clinical neurological investigation, all subjects received a detailed neuropsychological assessment and
an MRI study. Volumetric measures of cerebral atrophy as well as T1- and T2-weighted lesions were obtained.
SLE activity was assessed by the European Consensus Lupus Activity Measure (ECLAM) index, and
accumulated NP abnormalities were measured by the Systemic Lupus International Collaborating
Clinics (SLICC) damage index. A cumulative lifetime dose of glucocorticoids was determined from the patient
records.
Results: Compared with controls, SLE patients had increased volumes of both T1- and T2-weighted lesions
(p50.019 and pv0.0001, respectively) and increased cerebral atrophy (pv0.001). All the measured
MRI parameters were statistically significantly higher in NPSLE than in non-NPSLE patients. In SLE
patients, cerebral atrophy was associated with cognitive dysfunction, epileptic seizures, and cerebrovascular
disease; T1-weighted lesions were associated with epileptic seizures and T2-weighted lesions with cognitive
dysfunction. All MRI parameters correlated significantly with the SLICC index but not with the ECLAM index.
A positive correlation was found between a cumulative dose of glucocorticoids and cerebral atrophy in SLE
patients.
Conclusion: MRI abnormalities, including brain atrophy and T1- and T2-weighted lesions, are significantly more
common in patients with SLE than in the general population and they are related to specific NP manifestations.
Our findings also provide support for the organic aetiology of cognitive dysfunction in SLE.
Neuropsychiatric (NP) manifestations are a major
cause of morbidity and mortality in patients with
systemic lupus erythematosus (SLE); the frequency
ranging from 14% to 91% in different published series
(1–4). The diagnosis of NPSLE is primarily based on
the clinical picture; there is no single laboratory
marker or imaging modality to serve as a golden
standard (5). Despite many different types of brain
magnetic resonance imaging (MRI) changes
described in NPSLE, no consistent pattern of
abnormality has been associated with the condition
(6, 7). MRI abnormalities such as cortical stroke,
global atrophy, non-specific foci of increased signal
in both grey and white matter on T2-weighted
images, cerebral venous thrombosis, or intracranial
calcification are not specific for NPSLE (6).
Furthermore, the frequent appearance of white-
matter hyperintensities in normal subjects has raised
questions regarding the specificity of these findings
(7). The heterogeneous nature of NPSLE might be
one reason for the inconsistent correlation between
clinical symptoms and brain MRI findings. The
study cohorts have also been heterogeneous, with
some of them including patients with active and some
with inactive NPSLE (6).
We have investigated a population-based sample of
43 SLE patients and an equal number of healthy
controls. A clinical neurological examination and a
3-h neuropsychological investigation were under-
taken for all subjects. A total of 19 of the SLE patients
(44%) were diagnosed with NPSLE. Cerebral MRI,
using a computer-assisted quantitative technique, was
Hanna Ainiala, Department of Neurology Neurosurgery and
Rehabilitation, Tampere University Hospital, PO Box 2000,
FIN-33521, Tampere, Finland.
E-mail: jukkaps@koti.soon.fi
Received 3 October 2004
Accepted 11 April 2005
376 Scand J Rheumatol 2005;34:376–382
www.scandjrheumatol.dk
# 2005 Taylor & Francis on license from Scandinavian Rheumatology Research Foundation
DOI: 10.1080/03009740510026643
performed to estimate the volumes of T1- and T2-
weighted lesions and cerebral atrophy.
Our primary goal was to evaluate the brain MRI
findings in a population-based sample of SLE
patients. The secondary goal was to detect a possible
relationship between cerebral MRI abnormalities
and specific NP manifestations of SLE. We also
wanted to determine whether corticosteroid use is
related to brain atrophy.
Methods
Patient selection
The total patient sample was the same as that
described in our previous report (4). The study base
was Pirkanmaa Health Care District, located in
southern Finland, with a population of 440 000. We
identified patients with SLE by using the computer-
ized databases of Tampere University Hospital, the
three District Hospitals, and a local outpatient clinic.
Medical records of both inpatients and outpatients
coded for the diagnosis of SLE between January 1980
and December 1997 were examined to select patients
who fulfilled four or more of the 1982 revised
American College of Rheumatology (ACR) criteria
for the disease (8), were aged between 16 and 65
years, and were of native Finnish origin. Patients
with another concomitant connective tissue disease
were excluded.
We identified 110 patients with SLE. Of these, 15
patients had died and 37 did not meet the inclusion
criteria. The remaining 58 patients were contacted by
mail, and 46 of them (79%) agreed to participate in
the study. The control group consisted of 46
individuals randomly identified from the Finnish
Population Register, who were matched with patients
for age, sex, level of education, and municipality of
residence. Eligibility criteria similar to those for the
patients were applied. Three patients were not able to
complete the MRI investigation due to claustropho-
bia, and they, as well as their matched controls, were
excluded from the study. All participants gave their
written informed consent, and the study protocol was
approved by the local ethics committee. The clinical
data are shown in Table 1.
Clinical evaluation
The diagnosis of various NP syndromes was based on
the clinical evaluation (HA), including review of the
medical history, clinical examination, medical
records, and neuropsychological testing. All past
and present NP syndromes were listed and classified
according to the modified ACR nomenclature and
case definitions (9–10). If at least one of the NP
syndromes was identified in an SLE patient, he or she
was considered to have NPSLE.
All SLE patients and controls completed a 3-h
battery of neuropsychological tests administered by
the same psychologist; details regarding the proce-
dure and analysis of the neuropsychological mea-
sures have been described elsewhere (4). The number
of the ACR revised diagnostic criteria for SLE and
current and previous use of oral glucocorticoids
and other immunosuppressive medications were
recorded. A cumulative lifetime dose of glucocorti-
coids (expressed as grams of prednisolone) was
determined from the patient records. Individual
disease activity was quantified using the European
Consensus Lupus Activity Measurement (ECLAM)
scale (11). Accumulated NP abnormalities were
assessed using the Systemic Lupus International
Collaborating Clinic (SLICC)/ACR damage index
(12). The NP manifestations scored for the damage
index included cognitive impairment, major psycho-
sis, seizures requiring therapy for at least
6 months, cerebral vascular accident, cranial or
peripheral neuropathy (excluding optic), and trans-
verse myelitis.
Neuroradiological examinations
Cerebral MRI was performed on 43 SLE patients
and 43 healthy controls. The Signa Easy Vision 1.5T
Table 1. Baseline characteristics of 43 SLE patients and 43 healthy controls (means¡SD).
SLE patients Controls
Age (years) 44.7¡12.8 44.7¡12.8
Sex, M/F 6/37 6/37
Education (years) 12.7¡2.7 12.5¡3.4
Number of ACR SLE criteria 5.5¡1.2 –
Disease duration (years) 14.5¡8.1 –
Number of NP syndromes 0.84¡1.25 0.07¡0.26
ECLAM score 1.58¡1.24 –
NP-SLICC score 0.56¡1.0 –
Cumulative dose of glucocorticoids (g) 15.9¡24.1 –
SLE, systemic lupus erythematosus; NP syndrome, neuropsychiatric syndrome; ECLAM, European Consensus Lupus Activity Measurement;
NP-SLICC, Neuropsychiatric Systemic Lupus International Collaborating Clinics.
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MRI imaging system (General Electric Medical
Systems, Milwaukee, WS, USA) was used for all
examinations. All MRI scans were read in a blinded
manner by an experienced neuroradiologist (PD)
who did not have access to any demographic or
clinical data. The MRI study was carried out within 6
months of the clinical evaluation (the mean time was
11.1¡11.6 weeks for the SLE patients and 17.1¡7.6
weeks for the controls). The MRI protocol included
sagittal T1-weighted, axial T1-weighted, axial T2-
weighted, and coronal fluid-attenuated inversion
recovery (FLAIR) sequences. The imaging protocol
also included axial three-dimensional (3D) T2
fast spin-echo and gadolinium diethylenetriamine
pentaacetic acid-enhanced 3D T1 spoiled gradient
images for segmentation and volumetric analysis.
Segmentation and volumetric analysis were per-
formed using the segmentation software
Anatomatic, operating in a PC/Windows952 envir-
onment (13–15). Segmentation and volumetric mea-
surements of hypointense lesions in T1-weighted
images and hyperintense lesions in T2-weighted
images were performed separately.
Our criteria for SLE-related imaging abnormalities
were as follows: gliotic infarcts and gliotic
plaques seen as hypointense lesions on T1-weighted
images and microinfarcts, ischaemic lesions, demye-
linating plaques, as well as small punctate white-
matter lesions localized to the periventricular and
subcortical areas on T2-weighted images. Small age-
related lesions were excluded from analysis.
The criteria for age-related changes were as follows:
small periventricular T2-weighted high-intensity sig-
nal changes in the area of the frontal and occipital
horns; few scattered, well-defined, small (v3 mm),
T2-weighted high-intensity signal changes in
the area of the centrum semiovale not visible on T1-
weighted images, and widened Virchow–Robin
spaces seen as low-intensity signal areas on
FLAIR images. Measurements were expressed as
volume/cm3.
The marker for cerebral atrophy was relative
intracranial cerebrospinal fluid (CSF) space volume.
Volumetric measurement of total CSF spaces was
carried out by assessing the total volume of the
ventricular and peripheral CSF spaces, expressed as
volume/cm3. Total intracranial volume was measured
by adding together the volume of all the segmented
grey and white matter and intracranial CSF spaces.
Relative intracranial CSF space volume was deter-
mined by dividing the total intracranial CSF space
volume by the total brain volume.
Inter- and intra-observer variability was studied to
evaluate the accuracy of the volumetric measurement
of the lesions. In the inter-observer study, sets of
MRI images of 10 randomly selected patients were
analysed independently by three experienced obser-
vers and one experienced neuroradiologist (PD). In
the intra-observer study, the same neuroradiologist
segmented the same set of MR images four times at
2-week intervals. The results were 1.0% and 3% for
relative intracranial CSF space volumes, 5.0% and
1.3% for T2-weighted lesions, and 7.5% and 2.5% for
T1-weighted lesions in inter-observer and intra-
observer variability, respectively.
Statistical analysis
Data were analysed using the microcomputer version
of the Statistical Package for Social Sciences version
11.5 (SPSS, Chicago, IL, USA). Differences in MRI
parameters between the study groups were deter-
mined using the Mann–Whitney U-Test. The corre-
lations between MRI parameters and laboratory
values and cumulative dose of glucocorticoids were
analysed using Spearman’s rank order correlation.
The criterion for statistical significance was a p-value
less than 0.05.
Results
The analysis based on Anatomatic segmentation
software showed that both the mean volume of T1-
weighted lesions (representing primarily gliotic
infarcts) and the mean volume of T2-weighted lesions
were higher in SLE patients than in controls
(p50.019 and pv0.0001, respectively). In the assess-
ment of brain atrophy it was found that the
mean relative intracranial CSF space volume was
significantly higher in SLE patients than in healthy
controls (pv0.001). The values of the MRI para-
meters in SLE patients and controls are shown
in Table 2.
Association of MRI findings with NP manifestations
The cerebral MRI parameters were determined
separately in 19 patients with NPSLE and in 24
patients without (nNPSLE). All of the measured
parameters were statistically significantly higher in
NPSLE than in nNPSLE patients (Table 2). The
relationship between MRI parameters and all but
two NP manifestations was investigated in SLE
patients (myasthenia gravis and polyneuropathy were
excluded) (Table 3). SLE patients with cognitive
impairment had more significant cerebral atrophy
(p50.008) and significantly larger volumes of T2-
weighted lesions (pv0.001) and a trend for
larger volumes of T1-weighted lesions (p50.077)
than patients who were tested as cognitively normal.
The SLE patients with a history of cerebrovascular
disease had increased volumes of T1-weighted lesions
(p50.004) and T2-weighted lesions (pv0.001),
but also brain atrophy (p50.001). SLE patients
with epileptic seizures had more significant cerebral
378 H Ainiala et al
www.scandjrheumatol.dk
atrophy than patients without (pv0.001) and more
also T1-weighted lesions (p50.049). Of the other
NP manifestations, only a single patient with a
movement disorder had a statistically significantly
higher volume of T1-weighted lesions than the
patients without (p50.047). The NP damage
Table 2. Cerebral MRI parameters in 43 SLE patients, 43 healthy controls, 19 patients with neuropsychiatric SLE (NPSLE) and 24 patients
without neuropsychiatric SLE (nNPSLE).
MRI parameter volume SLE patients Controls p-value* NPSLE patients nNPSLE patients p-value*
(mean¡SD) n543 n543 n519 n524
Relative intracranial CSF
space volume
0.19¡0.07 0.11¡0.12 v0.001 0.23¡0.79 0.16¡0.04 0.002
T1-weighted volume, cm3 0.47¡1.42 0.09¡0.30 0.019 0.73¡1.76 0.27¡1.01 0.007
T2-weighted volume, cm3 1.30¡0.68 0.29¡0.11 v0.001 1.70¡0.68 0.97¡0.50 0.001
MRI, magnetic resonance imaging; SLE, systemic lupus erythematosus; CSF, cerebrospinal fluid.
*Statistical significance was based on the Mann–Whitney U-test.
Table 3. MRI volumes in the classified neuropsychiatric manifestations in 43 SLE patients.
Neuropsychiatric manifestation n
Relative intracranial CSF volume T1-weighted lesions T2-weighted lesions
Mean p-value* Mean p-value* Mean p-value
Cognitive dysfunction
Yes 10 0.25 0.008 0.98 0.077 2.01 v0.001
No 33 0.17 0.32 1.08
Cerebrovascular disease
Yes 6 0.28 0.001 1.97 0.004 2.29 v0.001
No 37 1.18 0.23 1.13
Seizure disorders
Yes 4 0.33 v0.001 2.19 0.049 1.95 0.167
No 39 0.18 0.30 1.23
Severe depression
Yes 4 0.23 0.86 0.14 0.762 1.59 0.319
No 39 0.19 0.50 1.27
Neuropathy, cranial
Yes 3 0.21 0.40 0.19 0.911 1.51 0.451
No 40 0.19 0.49 1.28
Acute confusional state
Yes 2 0.26 0.20 3.76 0.434 2.09 0.124
No 41 0.19 0.31 1.26
Movement disorder
Yes 1 0.32 0.14 7.51 0.047 2.46 0.186
No 42 0.19 0.30 1.27
Aseptic meningitis
Yes 1 0.28 0.28 0.00 0.698 2.12 0.233
No 42 0.19 0.48 1.28
Demyelinating syndrome
Yes 1 0.15 0.70 0.36 0.465 1.67 0.791
No 42 0.19 0.47 1.29
MRI, magnetic resonance imaging; SLE, systemic lupus erythematosus; CSF, cerebrospinal fluid.
*Statistical significance was based on the Mann–Whitney U-test.
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index SLICC correlated significantly with all the
measured MRI parameters in SLE patients (Table 4).
Association of MRI findings with other clinical features
Correlations between the MRI parameters and
clinical features of patients (Table 4) and controls
were measured. A significant correlation was
detected between the duration of SLE and cerebral
atrophy (r50.39, p50.010), but not between the
disease duration and the volumes of T1- or T2-
weighted lesions. The volumes of T2-weighted lesions
correlated positively with age both in the SLE
patients (r50.33, p50.03) and in the controls
(r50.42, p50.005). A significant correlation between
age and cerebral atrophy was also observed in the
controls (r50.53, p50.020) but not in the SLE
patients. No significant correlation between MRI
parameters and the activity index ECLAM was
found. Similarly, no association was detected
between MRI parameters and the use of medication,
but a clear positive correlation between the cumula-
tive dose of glucocorticoid and parameters of
cerebral atrophy was found (p50.023). In SLE
patients, no association was detected between the
MRI parameters and laboratory findings. Instead, in
the control group, a positive significant correlation
was found between the volumes of T2-weighted
lesions and all the measured complement levels
(r50.31, p50.04 for C3; r50.49, p50.001 for C4;
r50.36, p50.02 for CH50) and between cerebral
atrophy and C4 (r50.44, p50.003).
Discussion
This study examined the results of volumetric MRI
of the brain in 43 patients with SLE and in the same
number of matched controls. Nineteen SLE patients
(44%) had had NPSLE, but only one of them had
an acute NP manifestation at the time of the
examination.
SLE patients had more evidence of cerebral
atrophy in MRI scans than the controls. Increased
incidence of cerebral atrophy has previously been
reported in SLE patients with and without a history
of NP manifestations (7, 16–17). According to a
volumetric analysis by Chinn et al (16), the mean
parameter indicating atrophy was statistically sig-
nificantly higher in SLE patients than in controls.
The aetiology of cerebral atrophy remains unknown.
It might reflect ongoing CNS involvement, resulting
from long-standing glucocorticoid use, or be a com-
bination of both of these processes (5). In our SLE
patients, a clear correlation was detected between
cerebral atrophy and the cumulative dose of gluco-
corticoids, but the current use of glucocorticoids or
any other medication was unrelated to atrophic
changes. Chinn et al (16) found no association
between either the current or past use of steroids or
the total amount of steroid used and the presence of
atrophy in 47 SLE patients, but in another study, a
trend for a significant relationship between cerebral
atrophy and prednisone dose was observed (7).
It has been suggested that cerebral atrophy might
be responsible for some of the NP manifestations
related to SLE (5). We recognized that the patients
with NPSLE had higher volumes, indicating cerebral
atrophy, than the patients without NPSLE.
Furthermore, cerebral atrophy was increased in
SLE patients with cognitive dysfunction, cerebrovas-
cular disease, and seizure disorder compared with
SLE patients without these NP manifestations.
Previously, no correlation has been demonstrated
between quantitative measures of non-specific
abnormalities in cerebral MRI and measures of brain
function. Kozora et al (7) found no association
between cerebral lesions measured by quantified
MRI analyses and functional abnormalities deter-
mined by comprehensive neuropsychological
testing in 20 SLE patients without overt central
nervous system disease. However, our results are
in accordance with a recent study in which the
presence of cognitive dysfunction and psychiatric
abnormalities in a sample of 24 patients with
NPSLE correlated with cerebral atrophy (18). This
study used a new sensitive MRI technique, volu-
metric magnetic transfer imaging (MTI). Contrary
to our findings, the results did not indicate a
relationship between the duration of SLE and
cerebral atrophy.
Table 4. Correlations of MRI volumes with various clinical features in 43 SLE patients.
MRI parameter Age Duration of SLE Cumulative dose of steroid ECLAM score NP-SLICC score
Relative intracranial
CSF space volume
0.22 0.39* 0.38* 0.040 0.69**
T1-weighted volume 0.17 0.11 0.40* 20.23 0.52**
T2-weighted volume 0.031* 0.19 0.22 20.024 0.69**
MRI, magnetic resonance imaging; SLE, systemic lupus erythematosus; ECLAM, European Consensus Lupus Activity Measurement; NP-
SLICC, Neuropsychiatric Systemic Lupus International Collaborating Clinics. Statistical values were determined by Spearman’s rank order
correlation test: *pv0.05, **pv0.01.
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In our study, the volumes of both T1- and T2-
weighted lesions were significantly higher in SLE
patients than in controls. Similarly, NPSLE patients
had increased volumes of both lesion types in
comparison with non-NPSLE patients. T1-weighted
lesions include gliotic infarcts and gliotic demyelinat-
ing lesions, whereas T2-weighted lesions also include
microinfarcts, ischaemic lesions, and non-gliotic
demyelinating lesions. It is generally known that
T2-weighted images of the brain reveal, in many
SLE patients, small punctate lesions localized mainly
in the periventricular and subcortical white matter.
These lesions may represent small-vessel vasculopa-
thy, which has been suggested to be a pathogenetic
mechanism in those SLE patients who have cognitive
disorder as a sole NP manifestation (19). Our
results support this hypothesis, as volumes of T2-
weighted lesions were statistically significantly higher
in SLE patients with cognitive dysfunction
than in those without. On the other hand, the
volumes of T1-weighted lesions representing gross
infarcts did not have an association with cognitive
impairment.
The SLE activity index ECLAM score did not
correlate with any of the MRI parameters. In two
previous studies, such a correlation has been noted
(20,21). These opposite findings may be due to
considerably low ECLAM scores in our patients, as
most of them were in good health at the time of the
assessment. Instead, the NP SLICC damage index
score correlated positively with all the measured MRI
parameters. This is in accordance with the results of
Sanna et al, who demonstrated the presence of
significantly higher SLICC scores in patients with
abnormal brain MRI (22). With regard to other
clinical features, we found that age correlated
positively with the volumes of T2-weighted lesions
both in the patients and the controls.
This is one of the few studies on NPSLE with
a population-based sample and a sex- and age-
stratified reference group. Most of the other studies
have been performed on patients from tertiary
referral centres, thus causing a possible bias in
the results. Our study confirms in a population-based
sample that both brain atrophy and the
occurrence of gliotic infarcts, microinfarcts, other
ischaemic lesions, and demyelinating lesions were
significantly more common in patients with SLE
than in the general population. Previous studies
have not been able to show any relationship between
cerebral MRI abnormalities and specific NP dys-
functions. In our study, cerebral atrophy cor-
related with cognitive dysfunction, cerebrovascular
disease, and seizure disorder. Contrary to other
findings, a clear correlation was also detected
between cerebral atrophy and the cumulative use of
corticosteroids.
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